,variant,drugs,EvidenceLevel,ClinicalSignificance,Disease,TherapyRegimen
0,P124S,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Resistance,Melanoma,Selumetinib
1,Q56P,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Resistance,Melanoma,Selumetinib
2,Q61,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Vemurafenib
3,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
4,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
5,S214C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
6,R882,"[{'id': 7, 'name': 'Idarubicin', 'ncit_id': 'C562', 'aliases': []}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Idarubicin
7,V617F,[],B,Sensitivity/Response,Polycythemia Vera,
8,V617F,"[{'id': 9, 'name': 'Fedratinib', 'ncit_id': 'C88293', 'aliases': ['TG101348', 'SAR302503', 'Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-']}]",D,Sensitivity/Response,Polycythemia Vera,Fedratinib
9,G13D,"[{'id': 10, 'name': 'Tanespimycin', 'ncit_id': 'C37899', 'aliases': []}]",C,Sensitivity/Response,Melanoma,Tanespimycin
10,Q61L,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",C,Sensitivity/Response,Melanoma,Temozolomide
11,Q61R,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",C,Sensitivity/Response,Melanoma,Temozolomide
12,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Inflammatory Myofibroblastic Tumor,Crizotinib
13,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
14,L576P,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Melanoma,Nilotinib+Imatinib+Sorafenib
15,G12/G13,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
16,Q61,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
17,F1174L,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Sensitivity/Response,Neuroblastoma,Alectinib
18,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Neuroblastoma,Crizotinib
19,R1275Q,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,TAE684
20,S214C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
21,S214C,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
22,L576P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Melanoma,Dasatinib
23,D842I,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
24,D842V,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
25,D842Y,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
26,I843DEL,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
27,D842_I843delinsVM,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
28,R1275Q,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Resistance,Neuroblastoma,TAE684
29,Exon 11 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Melanoma,Imatinib
30,V600E and V600M,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Sensitivity/Response,Melanoma,Dabrafenib
31,C634W,"[{'id': 23, 'name': 'Motesanib', 'ncit_id': 'C71896', 'aliases': []}]",D,Resistance,Thyroid Gland Medullary Carcinoma,Motesanib
32,M918T,"[{'id': 23, 'name': 'Motesanib', 'ncit_id': 'C71896', 'aliases': []}]",D,Resistance,Thyroid Gland Medullary Carcinoma,Motesanib
33,M918T,"[{'id': 24, 'name': 'JAK2 Inhibitor AZD1480', 'ncit_id': 'C91394', 'aliases': ['AZD1480']}]",D,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,JAK2 Inhibitor AZD1480
34,V600,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab
35,V600E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Sorafenib
36,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
37,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Dabrafenib
38,V600E and Amplification,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",E,Resistance,Colorectal Cancer,Selumetinib
39,V600,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
40,V600D,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Dabrafenib
41,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
42,V600E,"[{'id': 477, 'name': 'Pictilisib Bismesylate', 'ncit_id': 'C82380', 'aliases': ['Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)-, Methanesulfonate (1:2)', 'Pictilisib Dimesylate', 'GDC-0941 Dimesylate', 'GDC-0941 Bismesylate', '2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- Ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, Bimesylate Salt']}, {'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Pictilisib Bismesylate+PLX4720
43,V600E,"[{'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}, {'id': 31, 'name': 'Nutlin-3', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,PLX4720+Nutlin-3
44,V600E,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Colorectal Cancer,Bevacizumab+Capecitabine+Vemurafenib
45,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Colorectal Cancer,Vemurafenib
46,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Neuroblastoma,Crizotinib
47,V600E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
48,ITD,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Resistance,Acute Myeloid Leukemia,Tretinoin
49,ITD,"[{'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Acute Myeloid Leukemia,Daunorubicin
50,ITD,"[{'id': 35, 'name': 'SU5614', 'ncit_id': None, 'aliases': []}]",D,Resistance,Acute Myeloid Leukemia,SU5614
51,G12/G13,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
52,G12/G13,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
53,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
54,EXON 12 MUTATION,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Resistance,Acute Myeloid Leukemia,Tretinoin
55,Exon 21 Mutation,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
56,EXON 7 MUTATION,"[{'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}, {'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}]",B,Resistance,Acute Myeloid Leukemia,Daunorubicin+Cytarabine
57,EML4-ALK L1196M,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
58,F1174L,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,TAE684
59,R1275Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Neuroblastoma,Crizotinib
60,FGFR3-BAIAP2L1,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Bladder Carcinoma,PD173074
61,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab
62,EXON 12 MUTATION,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Tretinoin
63,EXON 12 MUTATION,"[{'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin
64,EXON 12 MUTATION,"[{'id': 37, 'name': 'Valproic Acid', 'ncit_id': 'C29536', 'aliases': ['Valproate', 'Stavzor', 'Di-n-propylacetic Acid', 'Depakene', '2-Propylvaleric Acid', '2-Propylpentanoic Acid']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Valproic Acid
65,EXON 12 MUTATION,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}, {'id': 38, 'name': 'NSC348884', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Tretinoin+NSC348884
66,EXON 12 MUTATION,"[{'id': 268, 'name': 'Anti-CD33', 'ncit_id': None, 'aliases': []}, {'id': 269, 'name': 'Anti-CD123', 'ncit_id': None, 'aliases': []}]",E,Sensitivity/Response,Acute Myeloid Leukemia,Anti-CD33+Anti-CD123
67,EXON 12 MUTATION,"[{'id': 268, 'name': 'Anti-CD33', 'ncit_id': None, 'aliases': []}]",E,Sensitivity/Response,Acute Myeloid Leukemia,Anti-CD33
68,W288FS,"[{'id': 38, 'name': 'NSC348884', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,NSC348884
69,W288FS,"[{'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}, {'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}, {'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}]",E,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin+Cytarabine+Etoposide
70,FRAMESHIFT TRUNCATION,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
71,Loss-of-function,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Bladder Carcinoma,Everolimus
72,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Olaparib
73,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Olaparib
74,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
75,BCR-ABL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Acute Myeloid Leukemia,Imatinib
76,BCR-ABL E255K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
77,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Chronic Myeloid Leukemia,Imatinib
78,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
79,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
80,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
81,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",A,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
82,T790M,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
83,T790M,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",B,Resistance,Lung Non-small Cell Carcinoma,Dacomitinib
84,L755S,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
85,L536Q,"[{'id': 46, 'name': 'Hormone Therapy', 'ncit_id': 'C15445', 'aliases': ['Hormone Treatment', 'Hormonal Therapy', 'Endocrine Therapy', 'Chemotherapy-Hormones/Steroids']}]",D,Resistance,Breast Cancer,Hormone Therapy
86,D538G,"[{'id': 46, 'name': 'Hormone Therapy', 'ncit_id': 'C15445', 'aliases': ['Hormone Treatment', 'Hormonal Therapy', 'Endocrine Therapy', 'Chemotherapy-Hormones/Steroids']}]",D,Resistance,Breast Cancer,Hormone Therapy
87,Y537C,"[{'id': 46, 'name': 'Hormone Therapy', 'ncit_id': 'C15445', 'aliases': ['Hormone Treatment', 'Hormonal Therapy', 'Endocrine Therapy', 'Chemotherapy-Hormones/Steroids']}]",D,Resistance,Breast Cancer,Hormone Therapy
88,Y537N,"[{'id': 46, 'name': 'Hormone Therapy', 'ncit_id': 'C15445', 'aliases': ['Hormone Treatment', 'Hormonal Therapy', 'Endocrine Therapy', 'Chemotherapy-Hormones/Steroids']}]",D,Resistance,Breast Cancer,Hormone Therapy
89,Y537S,"[{'id': 46, 'name': 'Hormone Therapy', 'ncit_id': 'C15445', 'aliases': ['Hormone Treatment', 'Hormonal Therapy', 'Endocrine Therapy', 'Chemotherapy-Hormones/Steroids']}]",D,Resistance,Breast Cancer,Hormone Therapy
90,TKD MUTATION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Acute Myeloid Leukemia,Sorafenib
91,TKD MUTATION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Acute Myeloid Leukemia,Sorafenib
92,V654A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
93,Exon 2 Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
94,G12A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
95,E542K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
96,BCR-ABL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",A,Sensitivity/Response,Acute Myeloid Leukemia,Imatinib
97,BCR-ABL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",A,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
98,BCR-ABL,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",A,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib+Nilotinib
99,EML4-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
100,LOSS,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,T-cell Lymphoblastic Leukemia/lymphoma,Palbociclib
101,EXPRESSION,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Alpelisib
102,G253C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
103,G505S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
104,G774V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
105,I638F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
106,L239R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
107,L63V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
108,S768R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Dasatinib
109,Exon 19 Deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
110,G719S,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
111,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
112,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
113,T790M,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed+Erlotinib
114,T790M,"[{'id': 51, 'name': 'Staurosporine', 'ncit_id': 'C1237', 'aliases': []}]",E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Staurosporine
115,D769H,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib+Neratinib
116,D769Y,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
117,L755_T759del,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
118,G309A,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
119,L755S,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
120,L755W,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
121,P780INS,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
122,R678Q,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Breast Cancer,Neratinib+Lapatinib
123,R896C,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
124,V777L,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
125,V842I,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Breast Cancer,Neratinib
126,L536Q,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
127,D538G,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
128,Y537C,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}, {'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",D,Sensitivity/Response,Breast Cancer,Tamoxifen+Fulvestrant
129,Y537N,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}, {'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",D,Sensitivity/Response,Breast Cancer,Tamoxifen+Fulvestrant
130,Y537S,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
131,FGFR2-MGEA5,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",C,Sensitivity/Response,Cholangiocarcinoma,Ponatinib
132,FGFR2-TACC3,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Cholangiocarcinoma,Ponatinib+Pazopanib
133,ITD,"[{'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib
134,ITD,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
135,ITD,"[{'id': 58, 'name': 'Tyrphostin AG 1296', 'ncit_id': 'C1731', 'aliases': ['AG 1296']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Tyrphostin AG 1296
136,EXPRESSION,"[{'id': 60, 'name': 'Fasudil', 'ncit_id': 'C65624', 'aliases': ['Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine', 'HA1077', 'AT 877', '1-(5-Isoquinolinesulfonyl)homopiperazine']}, {'id': 59, 'name': 'Bortezomib', 'ncit_id': 'C1851', 'aliases': ['Velcade', 'PS341', 'PS-341', 'MLN341', 'LDP 341', '[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Fasudil+Bortezomib
137,Internal Duplication,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Malignant Anus Melanoma,Imatinib
138,L576P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib+Imatinib+Nilotinib
139,V654A,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
140,G12D,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dactolisib+Selumetinib
141,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
142,Promoter Methylation,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",A,Sensitivity/Response,Glioblastoma,Temozolomide
143,Promoter Methylation,"[{'id': 64, 'name': 'Carmustine', 'ncit_id': 'C349', 'aliases': ['WR-139021', 'SRI 1720', 'SK 27702', 'Nitrumon', 'Nitrourean', ""N,N'-Bis(2-chloroethyl)-N-nitrosourea"", 'FDA 0345', 'Carmustinum', 'Carmustin', 'Carmubris', 'Bis-Chloronitrosourea', 'Bis(chloroethyl) Nitrosourea', 'BiCNU', 'Becenun', 'Becenum', 'BCNU', '1,3-Bis(beta-chloroethyl)-1-nitrosourea', '1,3-Bis(2-chloroethyl)-1-nitrosourea']}]",B,Sensitivity/Response,Glioblastoma,Carmustine
144,Promoter Methylation,"[{'id': 65, 'name': 'O6-Benzylguanine', 'ncit_id': 'C1306', 'aliases': ['O6-BG', 'O-6-Benzylguanine', 'O(6)-Benzylguanine', '6-O-BENZYLGUANINE', '2-amino-6-(phenylmethoxy)-9h-purine', '2-amino-6-(benzyloxy)purine']}]",E,Sensitivity/Response,Glioblastoma,O6-Benzylguanine
145,E542K,"[{'id': 66, 'name': 'PI3K-alpha Inhibitor MEN1611', 'ncit_id': 'C158603', 'aliases': ['PI3Kalpha Inhibitor MEN1611', 'PA799', 'PA-799', 'PA 799', 'MEN1611', 'MEN-1611', 'MEN 1611', 'CH5132799', 'CH-5132799', 'CH 5132799', 'Alpha-selective PI3K Inhibitor MEN1611', '5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine']}]",D,Sensitivity/Response,Breast Cancer,PI3K-alpha Inhibitor MEN1611
146,E542K,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Sirolimus
147,H1047R,"[{'id': 66, 'name': 'PI3K-alpha Inhibitor MEN1611', 'ncit_id': 'C158603', 'aliases': ['PI3Kalpha Inhibitor MEN1611', 'PA799', 'PA-799', 'PA 799', 'MEN1611', 'MEN-1611', 'MEN 1611', 'CH5132799', 'CH-5132799', 'CH 5132799', 'Alpha-selective PI3K Inhibitor MEN1611', '5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine']}]",D,Sensitivity/Response,Breast Cancer,PI3K-alpha Inhibitor MEN1611
148,PML-RARA,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Sensitivity/Response,Acute Promyelocytic Leukemia,Tretinoin
149,R233*,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,MTOR Inhibitor
150,R175H,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Sensitivity/Response,Breast Cancer,Doxorubicin
151,FRAMESHIFT TRUNCATION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Invasive Bladder Transitional Cell Carcinoma,Everolimus
152,BCR-ABL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",A,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
153,EXPRESSION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Palbociclib
154,E545K,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
155,H1047R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
156,R249,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",B,Sensitivity/Response,Breast Cancer,Doxorubicin
157,MEF2D-CSF1R,"[{'id': 70, 'name': 'GW-2580', 'ncit_id': None, 'aliases': []}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Acute Lymphoblastic Leukemia,GW-2580+Imatinib
158,Mutation,"[{'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}]",B,Resistance,Acute Myeloid Leukemia,Cytarabine
159,Exon 19 Deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
160,Overexpression,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 74, 'name': 'Cabazitaxel', 'ncit_id': 'C66937', 'aliases': ['XRP-6258', 'Taxoid XRP6258', 'RPR-116258A', 'Jevtana', '1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]']}, {'id': 430, 'name': 'Linsitinib', 'ncit_id': 'C70982', 'aliases': ['OSI-906AA', 'OSI-906', 'IGF-1R Inhibitor OSI-906', 'Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, Cis-', 'Cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol']}]",D,Sensitivity/Response,Prostate Cancer,Docetaxel+Cabazitaxel+Linsitinib
161,C481S,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",B,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
162,Q79K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
163,EML4-ALK and Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
164,ALK Fusion G1202R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
165,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
166,EML4-ALK S1206Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
167,EML4-ALK T1151INST,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
168,MUTATION,"[{'id': 75, 'name': 'JW55', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colon Carcinoma,JW55
169,MUTATION,"[{'id': 76, 'name': 'G007-LK', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,G007-LK
170,F877L,"[{'id': 364, 'name': 'Apalutamide', 'ncit_id': 'C92574', 'aliases': ['JNJ-56021927', 'JNJ 56021927', 'Erleada', 'ARN509', 'ARN-509', 'ARN 509', '4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide']}, {'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}]",D,Resistance,Prostate Cancer,Apalutamide+Enzalutamide
171,W742,"[{'id': 78, 'name': 'Bicalutamide', 'ncit_id': 'C1599', 'aliases': ['N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide', 'ICI 176334', 'ICI 176,334', 'Cosudex', 'Casodex', '4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline', ""4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide"", '(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide']}]",D,Resistance,Prostate Carcinoma,Bicalutamide
172,Mutation,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",D,Sensitivity/Response,Glioblastoma,Temozolomide
173,Mutation,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",D,Sensitivity/Response,Melanoma,Temozolomide
174,Underexpression,"[{'id': 406, 'name': 'NU7441', 'ncit_id': None, 'aliases': []}, {'id': 405, 'name': 'KU-0060648', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cancer,NU7441+KU-0060648
175,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Hematologic Cancer,Olaparib
176,AMPLIFICATION,"[{'id': 363, 'name': 'Alisertib', 'ncit_id': 'C71717', 'aliases': ['MLN8237', 'MLN-8237', 'Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy-', 'Aurora A Kinase Inhibitor MLN8237']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",E,Sensitivity/Response,Esophagus Adenocarcinoma,Alisertib+Cisplatin
177,Overexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Cervical Adenocarcinoma,Paclitaxel
178,V560DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Thymic Carcinoma,Imatinib
179,Loss,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
180,Loss,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Prostate Cancer,Temsirolimus
181,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
182,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
183,G12/G13,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Resistance,Pancreatic Adenocarcinoma,Trametinib+Gemcitabine
184,LOSS-OF-FUNCTION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
185,R367Q,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
186,K359Q,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
187,D407A,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
188,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",B,Resistance,Chronic Myeloid Leukemia,Dasatinib
189,BCR-ABL F317L,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
190,BCR-ABL F317L,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
191,T790M,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}]",D,Resistance,Lung Cancer,Gefitinib+Multikinase Inhibitor AEE788
192,Loss,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Resistance,Bladder Carcinoma,Everolimus
193,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Breast Cancer,Trastuzumab
194,T790M,"[{'id': 91, 'name': 'Rociletinib', 'ncit_id': 'C99905', 'aliases': ['N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide', 'CO-1686']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib
195,S2289*,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",C,Sensitivity/Response,Prostate Cancer,Olaparib
196,N2875H,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",C,Sensitivity/Response,Prostate Cancer,Olaparib
197,Y177fs,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",C,Resistance,Peritoneal Mesothelioma,Carboplatin+Cisplatin
198,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
199,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
200,V561A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
201,Exon 11 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
202,R194W,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 96, 'name': 'Vinorelbine', 'ncit_id': 'C1275', 'aliases': [""Nor-5'-Anhydrovinblastine"", 'Dihydroxydeoxynorvinkaleukoblastine', ""5'-Nor-Anhydrovinblastine"", ""3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine""]}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Vinorelbine+Docetaxel
203,DELETION,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Sensitivity/Response,Ovarian Carcinoma,Carboplatin+Cisplatin+Paclitaxel
204,AMPLIFICATION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Colon Cancer,Cisplatin
205,Exon 4 Deletion,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Epithelial Ovarian Cancer,Cisplatin
206,3' UTR MUTATION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Resistance,Ovarian Cancer,Paclitaxel+Carboplatin
207,RS61764370,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Resistance,Epithelial Ovarian Cancer,Paclitaxel+Carboplatin
208,A222V,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Sensitivity/Response,Stomach Cancer,Fluorouracil
209,I105V,"[{'id': 579, 'name': 'FOLFOX Regimen', 'ncit_id': 'C11197', 'aliases': ['FOLFOX', 'Fluorouracil/Leucovorin Calcium/Oxaliplatin', 'CF/5-FU/L-OHP']}]",B,Sensitivity/Response,Colorectal Cancer,FOLFOX Regimen
210,Q399R,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Sensitivity/Response,Cervical Cancer,Cisplatin+Carboplatin
211,S893T,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Sensitivity/Response,Ovarian Cancer,Paclitaxel
212,I1145I,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Carboplatin+Cisplatin
213,K751Q,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Osteosarcoma,Cisplatin
214,K751Q,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Carboplatin
215,5' TANDEM REPEAT,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Resistance,Colorectal Cancer,Irinotecan+Fluorouracil
216,EXON 12-22 DELETION,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Ovarian Cancer,Doxorubicin
217,Amplification,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Squamous Cell Carcinoma,PD173074
218,Expression,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Lung Cancer,Ponatinib
219,Amplification,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PD173074
220,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
221,Amplification,"[{'id': 121, 'name': 'Onartuzumab', 'ncit_id': 'C82348', 'aliases': ['PRO 143966', 'OA-5D5', 'MetMAb', 'Anti-MET Monoclonal Antibody MetMAb']}]",C,Sensitivity/Response,Gastric Adenocarcinoma,Onartuzumab
222,Overexpression,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
223,p16 Expression,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Panitumumab
224,KIF5B-RET,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib
225,G13D,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",C,Resistance,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
226,MUTATION,"[{'id': 124, 'name': 'MTOR Kinase Inhibitor AZD8055', 'ncit_id': 'C78856', 'aliases': ['AZD8055']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}, {'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Cancer,MTOR Kinase Inhibitor AZD8055+Everolimus+Mirdametinib+Binimetinib+Selumetinib
227,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Melanoma,Nivolumab+Pembrolizumab
228,MUTATION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Bladder Carcinoma,Everolimus+Pazopanib
229,EXPRESSION,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Trastuzumab
230,E17K,"[{'id': 111, 'name': 'Uprosertib', 'ncit_id': 'C84870', 'aliases': ['Oral Akt Inhibitor GSK2141795', 'GSK2141795', '2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-']}]",D,Sensitivity/Response,Melanoma,Uprosertib
231,Loss,"[{'id': 111, 'name': 'Uprosertib', 'ncit_id': 'C84870', 'aliases': ['Oral Akt Inhibitor GSK2141795', 'GSK2141795', '2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-']}]",D,Sensitivity/Response,Melanoma,Uprosertib
232,E17K,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",C,Sensitivity/Response,Breast Cancer,Capivasertib
233,E545K,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}, {'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}]",D,Sensitivity/Response,Breast Cancer,Pictilisib+Akt Inhibitor MK2206
234,Loss,"[{'id': 114, 'name': 'PI3Kbeta Inhibitor AZD8186', 'ncit_id': 'C107684', 'aliases': ['AZD8186', 'AZD-8186']}]",D,Sensitivity/Response,Breast Cancer,PI3Kbeta Inhibitor AZD8186
235,H1968Y,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}, {'id': 115, 'name': 'PI3K/BET Inhibitor LY294002', 'ncit_id': 'C148229', 'aliases': ['LY294002', 'LY-294002', 'LY 294002', '4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-', '2-Morpholin-4-yl-8-phenylchromen-4-one', '2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one']}]",D,Sensitivity/Response,Melanoma,Capivasertib+PI3K/BET Inhibitor LY294002
236,Loss,"[{'id': 116, 'name': 'Buparlisib', 'ncit_id': 'C90565', 'aliases': ['PI3K Inhibitor BKM120', 'BKM120']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Sensitivity/Response,Cancer,Buparlisib+Carboplatin+Paclitaxel
237,K159fs,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",C,Sensitivity/Response,Breast Cancer,Temsirolimus
238,Loss,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Resistance,Breast Cancer,Alpelisib
239,S492R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
240,MUTATION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
241,MUTATION,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
242,UNDEREXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
243,H1968Y,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Melanoma,Capivasertib
244,P2213S,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}, {'id': 115, 'name': 'PI3K/BET Inhibitor LY294002', 'ncit_id': 'C148229', 'aliases': ['LY294002', 'LY-294002', 'LY 294002', '4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-', '2-Morpholin-4-yl-8-phenylchromen-4-one', '2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one']}]",D,Sensitivity/Response,Melanoma,Capivasertib+PI3K/BET Inhibitor LY294002
245,AGK-BRAF,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Melanoma,Sorafenib
246,AGK-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
247,PAPSS1-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
248,PAPSS1-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Melanoma,Trametinib
249,TRIM24-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Melanoma,Trametinib
250,L597R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
251,Overexpression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
252,OVEREXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
253,R132C,"[{'id': 195, 'name': 'GSK321', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,GSK321
254,Amplification,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
255,OVEREXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Breast Cancer,Paclitaxel
256,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
257,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
258,Overexpression,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
259,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
260,P471L,"[{'id': 120, 'name': 'Idelalisib', 'ncit_id': 'C78825', 'aliases': ['Zydelig', 'Phosphoinositide-3 Kinase Delta Inhibitor CAL-101', 'GS-1101', 'GS 1101', 'CAL-101', '5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- Quinazolin-4-one']}]",C,Sensitivity/Response,Merkel Cell Carcinoma,Idelalisib
261,Overexpression,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",D,Sensitivity/Response,Breast Cancer,Vandetanib
262,MUTATION,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Pictilisib+Selumetinib
263,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Pembrolizumab
264,Amplification,"[{'id': 193, 'name': 'FACT Complex-targeting Curaxin CBL0137', 'ncit_id': 'C107239', 'aliases': ['CBL0137']}]",D,Sensitivity/Response,Neuroblastoma,FACT Complex-targeting Curaxin CBL0137
265,D473H,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Medulloblastoma,Vismodegib
266,Mutation,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",B,Resistance,Basal Cell Carcinoma,Vismodegib
267,Mutation,"[{'id': 271, 'name': 'PSI', 'ncit_id': None, 'aliases': []}, {'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}]",D,Sensitivity/Response,Basal Cell Carcinoma,PSI+Arsenic Trioxide
268,MUTATION,"[{'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}]",B,Sensitivity/Response,Medulloblastoma,Sonidegib
269,LOH,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",B,Sensitivity/Response,Medulloblastoma,Vismodegib
270,UNDEREXPRESSION,"[{'id': 133, 'name': 'SB202190', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Prostate Cancer,SB202190
271,OVEREXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Ovarian Cancer,Paclitaxel
272,p16 Expression,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Panitumumab
273,D473H,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
274,Amplification,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Epithelial Ovarian Cancer,Pictilisib
275,V600E,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Melanoma,Pictilisib
276,Amplification,"[{'id': 169, 'name': 'AKTi-1/2', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,AKTi-1/2
277,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
278,T790M,"[{'id': 91, 'name': 'Rociletinib', 'ncit_id': 'C99905', 'aliases': ['N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide', 'CO-1686']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib
279,EML4-ALK L1152R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
280,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
281,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
282,EML4-ALK and Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
283,EML4-ALK and Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
284,AUTOCRINE ACTIVATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
285,AUTOCRINE ACTIVATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
286,MUTATION,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Melanoma,Lapatinib
287,Mutation,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Colorectal Cancer,Cabozantinib
288,VIII,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
289,VIII,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Glioblastoma,Afatinib
290,Expression,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
291,Expression,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",D,Sensitivity/Response,Glioblastoma,Dacomitinib
292,Expression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Lapatinib
293,Expression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
294,Expression,"[{'id': 652, 'name': 'Seribantumab', 'ncit_id': 'C78859', 'aliases': ['SAR 256212', 'MM-121']}]",D,Sensitivity/Response,Ovarian Cancer,Seribantumab
295,Expression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Paclitaxel+Cisplatin+Carboplatin
296,Expression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
297,Expression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
298,G724S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab
299,G719S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab
300,Expression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
301,EXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
302,EXPRESSION,[],B,Sensitivity/Response,Colorectal Cancer,
303,E322K,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
304,AMPLIFICATION,"[{'id': 147, 'name': 'WZ4002', 'ncit_id': None, 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,WZ4002
305,A146V,"[{'id': 148, 'name': 'Abemaciclib', 'ncit_id': 'C97660', 'aliases': ['Verzenio', 'LY2835219', 'LY-2835219', '2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Abemaciclib
306,G12V,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Palbociclib
307,Mutation,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}]",B,Sensitivity/Response,Papillary Renal Cell Carcinoma,Foretinib
308,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
309,Expression,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Infigratinib
310,Expression,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Infigratinib
311,Expression,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}, {'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",D,Sensitivity/Response,Bladder Carcinoma,PD173074+Dovitinib
312,Expression,[],D,Sensitivity/Response,Bladder Carcinoma,
313,Overexpression,"[{'id': 153, 'name': 'Tyrosine Kinase Inhibitor SU5402', 'ncit_id': 'C1725', 'aliases': ['SU 5402', '3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone']}, {'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}, {'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",D,Sensitivity/Response,Bladder Carcinoma,Tyrosine Kinase Inhibitor SU5402+PD173074+Dovitinib
314,EXPRESSION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Resistance,Cancer,Olaparib
315,MUTATION,"[{'id': 154, 'name': 'JSI-124', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Head And Neck Carcinoma,JSI-124
316,EXPRESSION,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Prostate Cancer,Docetaxel
317,AMPLIFICATION,"[{'id': 683, 'name': 'NOTCH1 Antibody (PF-06293622)', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,NOTCH1 Antibody (PF-06293622)
318,Expression,"[{'id': 262, 'name': 'Patritumab', 'ncit_id': 'C78853', 'aliases': ['U3-1287', 'AMG 888']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Patritumab
319,RS3910384,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Platinum Compound+Gemcitabine
320,RS11623866,"[{'id': 270, 'name': 'Lonafarnib', 'ncit_id': 'C1829', 'aliases': ['SCH66336', 'SCH-66336', 'SCH 66336', 'Sarasar', '4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide', '4-[2-[4-(3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide']}]",B,Resistance,Ovarian Cancer,Lonafarnib
321,PROMOTER HYPERMETHYLATION,"[{'id': 231, 'name': 'Stattic', 'ncit_id': None, 'aliases': []}, {'id': 154, 'name': 'JSI-124', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Stattic+JSI-124
322,Decreased Peri-therapeutic Expression,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 215, 'name': 'Levoleucovorin', 'ncit_id': 'C1559', 'aliases': ['Levofolinic Acid', 'Levofolinate', 'L-Leucovorin', 'L-5-Formyltetrahydrofolate', 'Isovorin', 'Elvorine, Isovorin, Levofolene, Levorin', 'CL-307,782']}, {'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Colorectal Cancer,Fluorouracil+Irinotecan+Levoleucovorin+Bevacizumab
323,EXPRESSION,"[{'id': 155, 'name': 'Decitabine', 'ncit_id': 'C981', 'aliases': ['Dezocitidine', 'Deoxyazacytidine', 'Decitabine For Injection', 'Dacogen', '5-Azadeoxycytidine', '5-Aza-2-deoxycytidine', ""5-Aza-2'deoxycytidine"", ""5-Aza-2'-deoxycytidine"", '4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one', ""2'-Deoxy-5-azacytidine""]}]",D,Sensitivity/Response,Ovarian Cancer,Decitabine
324,Mutation,"[{'id': 155, 'name': 'Decitabine', 'ncit_id': 'C981', 'aliases': ['Dezocitidine', 'Deoxyazacytidine', 'Decitabine For Injection', 'Dacogen', '5-Azadeoxycytidine', '5-Aza-2-deoxycytidine', ""5-Aza-2'deoxycytidine"", ""5-Aza-2'-deoxycytidine"", '4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one', ""2'-Deoxy-5-azacytidine""]}]",D,Sensitivity/Response,Ovarian Cancer,Decitabine
325,EXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Sensitivity/Response,Lung Cancer,Paclitaxel
326,RS16906252,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Glioblastoma,Temozolomide
327,EXPRESSION,"[{'id': 235, 'name': 'Aminoglutethimide', 'ncit_id': 'C233', 'aliases': ['Rodazol', 'Orimetene', 'Orimeten', 'Orimenten', 'Mamomit', 'Elipten', 'Cytadren', 'BA-16038', 'Aminoblastin', 'Alpha-(4-Aminophenyl)-alpha-ethylglutarimide', '3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine', '3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione', '2-(p-Aminophenyl)-2-ethylglutarimide']}, {'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Sensitivity/Response,Breast Cancer,Aminoglutethimide+Tamoxifen
328,NUCLEAR EXPRESSION,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 215, 'name': 'Levoleucovorin', 'ncit_id': 'C1559', 'aliases': ['Levofolinic Acid', 'Levofolinate', 'L-Leucovorin', 'L-5-Formyltetrahydrofolate', 'Isovorin', 'Elvorine, Isovorin, Levofolene, Levorin', 'CL-307,782']}]",B,Resistance,Colorectal Cancer,Oxaliplatin+Fluorouracil+Irinotecan+Levoleucovorin
329,CD44s Expression,"[{'id': 240, 'name': 'RG7356', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cancer,RG7356
330,EXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
331,EXPRESSION,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Malignant Pleural Mesothelioma,Pemetrexed+Cisplatin
332,EXPRESSION,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Renal Cell Carcinoma,Sunitinib+Sorafenib
333,Overexpression,"[{'id': 158, 'name': 'Conatumumab', 'ncit_id': 'C71015', 'aliases': []}]",D,Sensitivity/Response,Ewing Sarcoma Of Bone,Conatumumab
334,Overexpression,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Resistance,Lung Non-small Cell Carcinoma,Pemetrexed
335,OVEREXPRESSION,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
336,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
337,UNDEREXPRESSION,"[{'id': 96, 'name': 'Vinorelbine', 'ncit_id': 'C1275', 'aliases': [""Nor-5'-Anhydrovinblastine"", 'Dihydroxydeoxynorvinkaleukoblastine', ""5'-Nor-Anhydrovinblastine"", ""3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vinorelbine+Cisplatin
338,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}, {'id': 160, 'name': 'Luminespib', 'ncit_id': 'C71467', 'aliases': ['NVP-AUY 922', 'NVP AUY 922', 'Hsp90 Inhibitor AUY922', 'AUY922']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib+Ceritinib+Luminespib
339,EML4-ALK C1156Y,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
340,EML4::ALK C1156Y-L1198F,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Lorlatinib
341,EML4::ALK C1156Y-L1198F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
342,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",C,Sensitivity/Response,Prostate Cancer,Olaparib
343,Expression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab+Docetaxel
344,Expression,[],B,Resistance,Head And Neck Squamous Cell Carcinoma,
345,VIII,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Docetaxel+Cetuximab
346,Mutation,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Sensitivity/Response,Gastric Adenocarcinoma,Chemotherapy
347,Mutation,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Sensitivity/Response,Breast Cancer,Doxorubicin
348,EXPRESSION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Resistance,Colorectal Cancer,Fluorouracil
349,EXPRESSION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Resistance,Colorectal Cancer,Fluorouracil
350,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
351,EXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Resistance,Endometrial Carcinoma,Paclitaxel
352,Overexpression,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Resistance,Estrogen-receptor Positive Breast Cancer,Tamoxifen
353,AMPLIFICATION,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Resistance,Breast Cancer,Tamoxifen
354,OVEREXPRESSION,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Breast Cancer,Dactolisib
355,CYTOPLASMIC MISLOCALIZATION,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
356,Expression,"[{'id': 225, 'name': 'Anti-ErbB3 Monoclonal Antibody AV-203', 'ncit_id': 'C102535', 'aliases': ['CAN-017', 'AV203', 'AV 203', 'AV-203', 'Anti-ErbB3 MoAb AV-203']}]",D,Sensitivity/Response,Cancer,Anti-ErbB3 Monoclonal Antibody AV-203
357,V7 EXPRESSION,"[{'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}, {'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}]",B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
358,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Resistance,Gastric Adenocarcinoma,Trastuzumab+Lapatinib
359,EXPRESSION,"[{'id': 248, 'name': '9F7-F11', 'ncit_id': None, 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,9F7-F11+Pertuzumab
360,EXPRESSION,"[{'id': 165, 'name': 'Ganetespib', 'ncit_id': 'C77872', 'aliases': ['STA-9090', 'Hsp90 Inhibitor STA-9090', '5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)-', '3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one']}]",D,Resistance,Colorectal Cancer,Ganetespib
361,NUCLEAR TRANSLOCATION,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Breast Cancer,Trastuzumab
362,EXPRESSION,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Breast Cancer,Trastuzumab
363,EXPRESSION,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
364,EXPRESSION,"[{'id': 166, 'name': '7-Ethyl-10-Hydroxycamptothecin', 'ncit_id': 'C61618', 'aliases': ['SN-38', 'SN 38', '7-Ethyl-10-hydroxy-20(S)-camptothecin']}]",D,Sensitivity/Response,Colorectal Cancer,7-Ethyl-10-Hydroxycamptothecin
365,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
366,RS61764370,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Cisplatin
367,P29S,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Dabrafenib+Vemurafenib
368,NUCLEAR EXPRESSION,"[{'id': 167, 'name': 'Taxane Compound', 'ncit_id': 'C1490', 'aliases': []}, {'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Taxane Compound+Platinum Compound
369,Wildtype,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Oxaliplatin+Capecitabine
370,LOSS,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",D,Sensitivity/Response,Endometrial Cancer,Talazoparib
371,LOSS,[],C,Sensitivity/Response,Prostate Cancer,
372,Underexpression,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Olaparib
373,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
374,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
375,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
376,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
377,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
378,Exon 19 Deletion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
379,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
380,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Uterine Corpus Endometrial Carcinoma,Afatinib
381,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab+Afatinib
382,AMPLIFICATION,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Sensitivity/Response,Colorectal Cancer,Irinotecan
383,EXPRESSION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Fluorouracil+Cisplatin
384,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Squamous Cell Carcinoma,Crizotinib
385,EXPRESSION,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Resistance,Breast Cancer,Tamoxifen
386,Expression,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",D,Sensitivity/Response,Colorectal Cancer,Infigratinib
387,PROMOTER HYPERMETHYLATION,"[{'id': 172, 'name': 'GNE-617', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cancer,GNE-617
388,Exon 18 Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Bevacizumab+Erlotinib
389,Expression,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}, {'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Resistance,Mantle Cell Lymphoma,Doxorubicin+Cytarabine+Gemcitabine
390,Expression,"[{'id': 174, 'name': 'Salinomycin', 'ncit_id': 'C76430', 'aliases': ['(alphaR,2R,5S,6R)-alpha-ethyl-6-[(1S,2S,3S,5R)-5-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxydispiro[4.1.5.3]-pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxoheptyl]-tetrahydro-5-methyl-2H-pyran-2-acetic Acid']}, {'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Sensitivity/Response,Mantle Cell Lymphoma,Salinomycin+Doxorubicin
391,OVEREXPRESSION,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",D,Resistance,Breast Cancer,Fulvestrant
392,OVEREXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab
393,Amplification,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Resistance,Lung Adenocarcinoma,Pemetrexed
394,EXPRESSION,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
395,EXPRESSION,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Resistance,Colorectal Cancer,Bevacizumab
396,Wildtype,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Sensitivity/Response,Esophageal Carcinoma,Chemotherapy
397,Underexpression,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed
398,Underexpression,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",C,Sensitivity/Response,Prostate Cancer,Pemetrexed
399,EXPRESSION,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",B,Sensitivity/Response,Breast Cancer,Doxorubicin
400,EXPRESSION,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 250, 'name': 'Cyclophosphamide', 'ncit_id': 'C405', 'aliases': ['WR- 138719', 'Syklofosfamid', 'Revimmune', 'Neosar', ""N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric Acid Ester Diamide Monohydrate"", ""N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric Acid Ester Diamide Monohydrate"", ""N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric Acid Ester Diamide Monohydrate"", 'N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide Monohydrate', ""N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic Acid Intramolecular Ester Monohydrate"", ""N,N-bis(2-chloroethyl)-N',O-propylenephosphoric Acid Ester Diamide Monohydrate"", 'Mitoxan', 'Ledoxina', 'Genuxal', 'Genoxal', 'Fosfaseron', 'Cytoxan', 'Cytophosphane', 'Cytophosphan', 'Cyclostine', 'Cyclostin', 'Cyclophosphanum', 'Cyclophosphane', 'Cyclophosphan', 'Cyclophosphamidum', 'Cyclophosphamide Monohydrate', 'Cyclophosphamid Monohydrate', 'Cyclophospham', 'Cycloblastine', 'Cycloblastin', 'CYCLO-cell', 'CTX', 'CP Monohydrate', 'Claphene', 'Clafen', 'Cicloxal', 'Ciclofosfamide', 'Ciclofosfamida', 'Carloxan', 'Bis(2-chloroethyl)phosphoramide Cyclic Propanolamide Ester Monohydrate', 'Bis(2-chloroethyl)phosphamide Cyclic Propanolamide Ester Monohydrate', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, Monohydrate', '2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide Monohydrate', '2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide Monohydrate', '2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide Monohydrate', '1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin Monohydrate', '(-)-Cyclophosphamide']}, {'id': 175, 'name': 'Topotecan', 'ncit_id': 'C1413', 'aliases': ['Topotecan Lactone', 'Hycamptamine', '9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin', ""(s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione""]}]",B,Sensitivity/Response,Ovarian Cancer,Carboplatin+Cyclophosphamide+Topotecan
401,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
402,EXPRESSION,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Sensitivity/Response,Colorectal Cancer,Irinotecan
403,T172 PHOSPHORYLATION,"[{'id': 255, 'name': 'ACLY SiRNA', 'ncit_id': None, 'aliases': []}]",E,Sensitivity/Response,Cancer,ACLY SiRNA
404,EXPRESSION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Sensitivity/Response,Colorectal Cancer,Fluorouracil
405,Mutation,"[{'id': 252, 'name': 'Anti-EGFR Monoclonal Antibody', 'ncit_id': 'C133878', 'aliases': []}]",B,Resistance,Colorectal Cancer,Anti-EGFR Monoclonal Antibody
406,PHOSPHORYLATION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Everolimus
407,MUTATION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Pictilisib
408,EXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Cancer,Paclitaxel
409,EXPRESSION,"[{'id': 167, 'name': 'Taxane Compound', 'ncit_id': 'C1490', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Taxane Compound
410,Overexpression,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Resistance,Lung Non-small Cell Carcinoma,Pemetrexed
411,Y1092 PHOSPHORYLATION,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
412,NUCLEAR EXPRESSION,"[{'id': 253, 'name': 'IGF1R Monoclonal Antibody', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Sarcoma,IGF1R Monoclonal Antibody
413,EXPRESSION,"[{'id': 78, 'name': 'Bicalutamide', 'ncit_id': 'C1599', 'aliases': ['N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide', 'ICI 176334', 'ICI 176,334', 'Cosudex', 'Casodex', '4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline', ""4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide"", '(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide']}]",D,Resistance,Prostate Cancer,Bicalutamide
414,EXPRESSION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Hepatocellular Carcinoma,Sorafenib
415,OVEREXPRESSION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Resistance,Breast Cancer,Paclitaxel
416,EXPRESSION,"[{'id': 257, 'name': 'Epirubicin', 'ncit_id': 'C62028', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Epirubicin
417,Overexpression,"[{'id': 176, 'name': 'Raltitrexed', 'ncit_id': 'C1804', 'aliases': ['ZD1694', 'Tomudex', 'N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid', 'N-(5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic Acid', 'ICI D1694', 'D1694']}]",B,Resistance,Gastric Adenocarcinoma,Raltitrexed
418,PHOSPHORYLATION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Everolimus
419,OVEREXPRESSION,"[{'id': 177, 'name': 'Enzastaurin', 'ncit_id': 'C77392', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Enzastaurin
420,PHOSPHORYLATION,"[{'id': 179, 'name': 'MTOR Kinase Inhibitor PP242', 'ncit_id': 'C128632', 'aliases': ['PP242', 'PP-242', '2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 256, 'name': 'WYE354', 'ncit_id': None, 'aliases': []}]",D,Resistance,Colorectal Cancer,MTOR Kinase Inhibitor PP242+Dactolisib+WYE354
421,Expression,"[{'id': 96, 'name': 'Vinorelbine', 'ncit_id': 'C1275', 'aliases': [""Nor-5'-Anhydrovinblastine"", 'Dihydroxydeoxynorvinkaleukoblastine', ""5'-Nor-Anhydrovinblastine"", ""3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine""]}]",D,Sensitivity/Response,Malignant Mesothelioma,Vinorelbine
422,EXPRESSION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Cancer,Trametinib
423,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Cancer,Trametinib
424,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Cancer,Trametinib
425,G12D,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}]",C,Sensitivity/Response,Pancreatic Carcinoma,Akt Inhibitor MK2206
426,Loss,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}]",C,Sensitivity/Response,Pancreatic Carcinoma,Akt Inhibitor MK2206
427,EXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Gemcitabine
428,EXPRESSION,"[{'id': 181, 'name': 'Amrubicin', 'ncit_id': 'C80089', 'aliases': []}]",D,Resistance,Lung Cancer,Amrubicin
429,P187S,"[{'id': 181, 'name': 'Amrubicin', 'ncit_id': 'C80089', 'aliases': []}]",D,Sensitivity/Response,Lung Cancer,Amrubicin
430,Underexpression,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}, {'id': 167, 'name': 'Taxane Compound', 'ncit_id': 'C1490', 'aliases': []}]",B,Sensitivity/Response,Ovarian Cancer,Platinum Compound+Taxane Compound
431,Mutation,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}, {'id': 182, 'name': 'Immunomodulatory Oligonucleotide', 'ncit_id': None, 'aliases': ['Wellcovorin', 'Tonofolin', 'Rescuvolin', 'Rescufolin', 'N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid', 'N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid, Calcium Salt (1:1)', 'Leucovorin', 'Leucosar', 'Lederfolin', 'Lederfolat', 'Imo', 'Folix', 'Foliplus', 'Folinvit', 'Folinoral', 'Folinic Acid Calcium Salt Pentahydrate', 'Folinic Acid', 'Folinate Calcium', 'Folinac', 'Folidar', 'Folidan', 'Foliben', 'FOLI-cell', 'Folaxin', 'Folaren', 'Flynoken A', 'Factor, Citrovorum', 'Emovis', 'Ecofol', 'Divical', 'Disintox', 'Dalisol', 'Cromatonbic Folinico', 'Citrovorum Factor', 'Citrec', 'Citofolin', 'Cehafolin', 'Calinat', 'Calfolex', 'Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1)', 'Calcium Leucovorin', 'Calcium Folinate', 'Calcium (6S)-Folinate', 'Calcifolin', 'Adinepar', '5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid', '5-Formyl-5,6,7,8-tetrahydrofolic Acid', '5-Formyl Tetrahydrofolate']}]",D,Sensitivity/Response,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Immunomodulatory Oligonucleotide
432,Overexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Paclitaxel
433,Fusion,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed
434,EXPRESSION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Gastric Adenocarcinoma,Cisplatin
435,Mutation,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Dasatinib+Cetuximab
436,Amplification,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
437,EXPRESSION,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Resistance,Gastric Adenocarcinoma,Docetaxel
438,EXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Resistance,Bile Duct Adenocarcinoma,Gemcitabine
439,AMPLIFICATION,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 183, 'name': 'Monomethyl Auristatin E', 'ncit_id': 'C122637', 'aliases': ['N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- Phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide', 'Monomethylauristatin E', 'MMAE', 'L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- Methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- Methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-', '(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide']}]",D,Resistance,Breast Cancer,Paclitaxel+Monomethyl Auristatin E
440,Overexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Paclitaxel
441,AMPLIFICATION,"[{'id': 258, 'name': 'Asparaginase', 'ncit_id': 'C286', 'aliases': ['Spectrila', 'Serasa', 'Re-82-TAD-15', 'Paronal', 'MK-965', 'Leunase', 'Leucogen', 'Lcf-ASP', 'Laspar', 'L-Asparagine Amidohydrolase', 'L-Asparaginase', 'L-ASP', 'L-Asnase', 'Kidrolase', 'Elspar', 'Colaspase', 'Asparaginase-E.Coli', 'Asparaginase II', 'ASP-1']}]",D,Resistance,Ovarian Cancer,Asparaginase
442,Overexpression,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
443,Expression,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Trastuzumab
444,EXPRESSION,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",D,Resistance,Colon Cancer,Oxaliplatin
445,Kinase Domain Mutation,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
446,Y772_A775DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib+Sirolimus
447,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
448,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Pancreatic Adenocarcinoma,Afatinib
449,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
450,C797S,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Resistance,Lung Non-small Cell Carcinoma,Osimertinib
451,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
452,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
453,T790M,"[{'id': 91, 'name': 'Rociletinib', 'ncit_id': 'C99905', 'aliases': ['N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide', 'CO-1686']}, {'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib+Osimertinib
454,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
455,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
456,VIII,"[{'id': 204, 'name': 'Rindopepimut', 'ncit_id': 'C69076', 'aliases': ['PF-04948568', 'L-Cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-(1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)-, Complex With Hemocyanin (Megathura Crenulata)', 'CDX-110', 'Anti-EGFRvIII Vaccine CDX-110']}]",B,Sensitivity/Response,Glioblastoma,Rindopepimut
457,SERUM LEVELS,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Breast Cancer,Lapatinib
458,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",D,Sensitivity/Response,Colorectal Cancer,Larotrectinib
459,R132H,"[{'id': 473, 'name': 'AGI-5198', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Oligodendroglioma,AGI-5198
460,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
461,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
462,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
463,EXPRESSION,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Skin Melanoma,Nivolumab+Pembrolizumab+Atezolizumab
464,L265P,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",B,Sensitivity/Response,Waldenstroem's Macroglobulinemia,Ibrutinib
465,Mutation,"[{'id': 233, 'name': 'B-Raf/VEGFR-2 Inhibitor RAF265', 'ncit_id': 'C61311', 'aliases': ['RAF265', 'RAF-265', 'CHIR-265']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib
466,Mutation,"[{'id': 233, 'name': 'B-Raf/VEGFR-2 Inhibitor RAF265', 'ncit_id': 'C61311', 'aliases': ['RAF265', 'RAF-265', 'CHIR-265']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib
467,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Colorectal Cancer,Trametinib+Afatinib
468,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Afatinib
469,Exon 2 Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",A,Resistance,Colorectal Cancer,Cetuximab
470,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
471,V600,"[{'id': 394, 'name': 'Refametinib', 'ncit_id': 'C74059', 'aliases': ['RDEA119', 'MEK Inhibitor RDEA119', 'BAY86-9766', 'BAY 869766']}]",C,Resistance,Melanoma,Refametinib
472,Q61K,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",D,Sensitivity/Response,Neuroblastoma,Everolimus+Binimetinib
473,Mutation,"[{'id': 114, 'name': 'PI3Kbeta Inhibitor AZD8186', 'ncit_id': 'C107684', 'aliases': ['AZD8186', 'AZD-8186']}, {'id': 245, 'name': 'SCH772984', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Pancreatic Adenocarcinoma,PI3Kbeta Inhibitor AZD8186+SCH772984
474,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 246, 'name': 'Teprotumumab', 'ncit_id': 'C95797', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Teprotumumab
475,V600E,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Melanoma,Dactolisib+Selumetinib
476,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Lapatinib+Trastuzumab
477,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Lapatinib
478,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
479,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
480,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
481,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib+Trastuzumab
482,FRAMESHIFT MUTATION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
483,VIII,"[{'id': 188, 'name': 'Nimotuzumab', 'ncit_id': 'C2733', 'aliases': []}]",D,Sensitivity/Response,Brain Glioma,Nimotuzumab
484,Fusion,"[{'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Lestaurtinib+Crizotinib+Larotrectinib
485,Expression,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Panitumumab
486,EXPRESSION,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Panitumumab
487,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Gastric Adenocarcinoma,Trastuzumab
488,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Gastric Adenocarcinoma,Lapatinib
489,EXPRESSION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Endometrial Cancer,Imatinib
490,EXPRESSION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Endometrial Cancer,Imatinib
491,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
492,LOSS,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Renal Carcinoma,Temsirolimus
493,D835,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Resistance,Acute Myeloid Leukemia,Ponatinib+Quizartinib
494,D835,"[{'id': 35, 'name': 'SU5614', 'ncit_id': None, 'aliases': []}]",D,Resistance,Acute Myeloid Leukemia,SU5614
495,D835,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Acute Myeloid Leukemia,Quizartinib+Sorafenib
496,D835,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Resistance,Acute Myeloid Leukemia,Sorafenib
497,ITD,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
498,Kinase Domain Mutation,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Trastuzumab
499,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Sensitivity/Response,Lung Small Cell Carcinoma,Trastuzumab+Irinotecan
500,Y772_A775DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
501,Y772_A775DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Lung Carcinoma,Afatinib+Sirolimus
502,Y772_A775DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Carcinoma,Afatinib
503,P780INS,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Dacomitinib
504,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trastuzumab Emtansine
505,Mutation,"[{'id': 273, 'name': 'Futuximab/Modotuximab Mixture', 'ncit_id': 'C91381', 'aliases': ['Sym004', 'Futuximab/Zatuximab', 'Futuximab/Modotuximab', 'Anti-EGFR Monoclonal Antibody Mixture Sym004']}]",D,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture
506,G465R,"[{'id': 273, 'name': 'Futuximab/Modotuximab Mixture', 'ncit_id': 'C91381', 'aliases': ['Sym004', 'Futuximab/Zatuximab', 'Futuximab/Modotuximab', 'Anti-EGFR Monoclonal Antibody Mixture Sym004']}]",C,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture
507,G465R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
508,RS461155,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Cisplatin
509,Amplification,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pertuzumab+Docetaxel+Trastuzumab
510,S492R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Sensitivity/Response,Colorectal Cancer,Panitumumab
511,S492R,"[{'id': 273, 'name': 'Futuximab/Modotuximab Mixture', 'ncit_id': 'C91381', 'aliases': ['Sym004', 'Futuximab/Zatuximab', 'Futuximab/Modotuximab', 'Anti-EGFR Monoclonal Antibody Mixture Sym004']}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture+Panitumumab
512,S492R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
513,R451C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 273, 'name': 'Futuximab/Modotuximab Mixture', 'ncit_id': 'C91381', 'aliases': ['Sym004', 'Futuximab/Zatuximab', 'Futuximab/Modotuximab', 'Anti-EGFR Monoclonal Antibody Mixture Sym004']}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab+Futuximab/Modotuximab Mixture
514,K467T,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 273, 'name': 'Futuximab/Modotuximab Mixture', 'ncit_id': 'C91381', 'aliases': ['Sym004', 'Futuximab/Zatuximab', 'Futuximab/Modotuximab', 'Anti-EGFR Monoclonal Antibody Mixture Sym004']}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Futuximab/Modotuximab Mixture
515,K467T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
516,P753S,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Sensitivity/Response,Skin Squamous Cell Carcinoma,Sirolimus+Cetuximab
517,PML-RARA,"[{'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}, {'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",A,Sensitivity/Response,Acute Promyelocytic Leukemia,Arsenic Trioxide+Tretinoin
518,B2 DOMAIN MUTATION,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Resistance,Acute Promyelocytic Leukemia,Tretinoin
519,PML-RARA A216V,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",C,Resistance,Acute Promyelocytic Leukemia,Tretinoin
520,PML-RARA L218P,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",C,Resistance,Acute Promyelocytic Leukemia,Tretinoin
521,EXON 14 MUTATION and AMPLIFICATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
522,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Sensitivity/Response,Endometrial Serous Adenocarcinoma,Trastuzumab
523,D473H,"[{'id': 274, 'name': 'Patidegib', 'ncit_id': 'C80063', 'aliases': ['Smoothened Antagonist IPI-926', 'Saridegib', 'IPI-926 Free Base', 'IPI-926', 'IP9 Free Base', 'FIN-5']}]",D,Sensitivity/Response,Medulloblastoma,Patidegib
524,CD74-ROS1 G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
525,CD74-ROS1 G2032R,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
526,N-TERMINAL FRAME SHIFT,"[{'id': 275, 'name': 'OICR-9429', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,OICR-9429
527,ZNF198-FGFR1,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",C,Sensitivity/Response,Myeloproliferative Neoplasm,Midostaurin
528,Amplification,"[{'id': 277, 'name': 'Afimoxifene', 'ncit_id': 'C975', 'aliases': ['4-OHT', '4-Hydroxytamoxifen', '4-Hydroxy-Tamoxifen', '4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol']}]",D,Resistance,Breast Cancer,Afimoxifene
529,A1065T,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Angiosarcoma,Sunitinib+Sorafenib
530,D717V,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Angiosarcoma,Sorafenib+Sunitinib
531,Q1178*,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Thyroid Gland Carcinoma,Everolimus
532,F2108L,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Resistance,Thyroid Gland Carcinoma,Everolimus
533,ITD,"[{'id': 278, 'name': 'Anthracycline Antineoplastic Antibiotic', 'ncit_id': 'C1594', 'aliases': []}, {'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",B,Resistance,Acute Promyelocytic Leukemia,Anthracycline Antineoplastic Antibiotic+Tretinoin
534,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Trastuzumab
535,Underexpression,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Tretinoin
536,UNDEREXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Gemcitabine
537,EML4-ALK,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Acinar Adenocarcinoma,Erlotinib
538,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
539,Y772_A775DUP,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Trastuzumab Emtansine
540,VIII,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Glioblastoma,Erlotinib+Gefitinib
541,Expression,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Glioblastoma,Erlotinib+Gefitinib
542,Q22*,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colon Mucinous Adenocarcinoma,Panitumumab
543,Amplification,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capecitabine+Lapatinib
544,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Capecitabine
545,P904L,"[{'id': 155, 'name': 'Decitabine', 'ncit_id': 'C981', 'aliases': ['Dezocitidine', 'Deoxyazacytidine', 'Decitabine For Injection', 'Dacogen', '5-Azadeoxycytidine', '5-Aza-2-deoxycytidine', ""5-Aza-2'deoxycytidine"", ""5-Aza-2'-deoxycytidine"", '4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one', ""2'-Deoxy-5-azacytidine""]}, {'id': 282, 'name': '5-Fluoro-2-Deoxycytidine', 'ncit_id': 'C62785', 'aliases': ['Ro 5-1090', 'FdCyd', ""Cytidine, 2'-deoxy-5-fluoro-"", ""5-FLUORO-2'-DEOXYCYTIDINE""]}, {'id': 281, 'name': 'Guadecitabine', 'ncit_id': 'C95209', 'aliases': ['SGI-110', 'S110', 'DNMT Inhibitor SGI-110']}, {'id': 280, 'name': 'Azacitidine', 'ncit_id': 'C288', 'aliases': ['Onureg', 'Vidaza', 'U-18496', 'Mylosar', 'Ladakamycin', 'Azacytidine, 5-', 'Azacytidine', '5-AZC', '5-Azacytidine', '5-Aza-cytidine', '5-AC', '5 AZC', '4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one']}]",E,Sensitivity/Response,Myelodysplastic Syndrome,Decitabine+5-Fluoro-2-Deoxycytidine+Guadecitabine+Azacitidine
546,OVEREXPRESSION,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Resistance,Uveal Melanoma,Selumetinib+Trametinib+Mirdametinib
547,RS3733542,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Selumetinib
548,ITD,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Resistance,Acute Myeloid Leukemia,Selumetinib
549,OVEREXPRESSION,"[{'id': 283, 'name': 'AZ909', 'ncit_id': None, 'aliases': []}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Melanoma,AZ909+Selumetinib
550,Mutation,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Colorectal Cancer,Bevacizumab+Chemotherapy
551,Mutation,"[{'id': 285, 'name': 'G-573', 'ncit_id': None, 'aliases': []}, {'id': 284, 'name': 'MEK Inhibitor GDC-0623', 'ncit_id': 'C95738', 'aliases': ['GDC-0623']}]",D,Sensitivity/Response,Cancer,G-573+MEK Inhibitor GDC-0623
552,V600E,"[{'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",D,Sensitivity/Response,Cancer,Cobimetinib
553,G12C,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
554,G12V,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Docetaxel+Selumetinib
555,LOSS,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Resistance,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
556,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
557,Mutation,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Resistance,Lung Non-small Cell Carcinoma,Docetaxel
558,Wildtype,"[{'id': 288, 'name': 'Adjuvant Chemotherapy', 'ncit_id': 'C15360', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Adjuvant Chemotherapy
559,OVEREXPRESSION,"[{'id': 289, 'name': 'PD1 Inhibitor', 'ncit_id': 'C124946', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,PD1 Inhibitor
560,OVEREXPRESSION,"[{'id': 290, 'name': 'Anti-TIM-3 Monoclonal Antibody', 'ncit_id': 'C141146', 'aliases': []}, {'id': 289, 'name': 'PD1 Inhibitor', 'ncit_id': 'C124946', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Anti-TIM-3 Monoclonal Antibody+PD1 Inhibitor
561,Overexpression,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Cancer,Selumetinib+Afatinib
562,Overexpression,"[{'id': 291, 'name': 'HER2 Inhibitor CP-724,714', 'ncit_id': 'C26648', 'aliases': ['CP-724714', 'CP724714', 'CP-724-714', 'CP-724,714', 'CP 724714']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Cancer,"HER2 Inhibitor CP-724,714+Selumetinib+Gefitinib"
563,p16 Expression,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Afatinib
564,SERUM LEVELS,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Inflammatory Breast Carcinoma,Bevacizumab
565,SERUM LEVELS,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Resistance,Inflammatory Breast Carcinoma,Bevacizumab
566,SERUM LEVELS,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Brain Glioma,Bevacizumab
567,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
568,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
569,NUCLEAR EXPRESSION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Cisplatin+Fluorouracil
570,T17 DELETION,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Sensitivity/Response,Colorectal Cancer,Oxaliplatin+Fluorouracil
571,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 296, 'name': 'Avelumab', 'ncit_id': 'C116870', 'aliases': []}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Pembrolizumab+Avelumab+Atezolizumab
572,Deleterious Mutation,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",B,Sensitivity/Response,Sarcoma,Pazopanib
573,E545K,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Adenocarcinoma,Gefitinib
574,Expression,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
575,G12C,"[{'id': 297, 'name': 'ARS-853', 'ncit_id': None, 'aliases': []}, {'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",D,Sensitivity/Response,Cancer,ARS-853+Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
576,V842I,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Colon Cancer,Trastuzumab+Lapatinib+Neratinib
577,Fusion,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
578,L755S,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Colon Cancer,Lapatinib+Neratinib+Trastuzumab
579,V777L,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Colon Cancer,Trastuzumab+Lapatinib+Neratinib
580,L866M,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Colon Cancer,Trastuzumab+Neratinib+Lapatinib
581,S310F/Y,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Colon Cancer,Neratinib+Trastuzumab+Lapatinib
582,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
583,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
584,Mutation,"[{'id': 298, 'name': 'Ixazomib', 'ncit_id': 'C97940', 'aliases': ['{(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid', 'MLN2238', 'MLN-2238']}]",D,Resistance,Colorectal Cancer,Ixazomib
585,Mutation,"[{'id': 299, 'name': 'AZD5438', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cancer,AZD5438
586,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
587,EXON 14 SKIPPING MUTATION,"[{'id': 300, 'name': 'Capmatinib', 'ncit_id': 'C90564', 'aliases': ['INCB28060', 'INCB028060', 'INCB 28060', 'INC280', 'INC-280', '2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Capmatinib
588,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
589,EML4-ALK,"[{'id': 301, 'name': 'WHI-P154', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,WHI-P154
590,EML4::ALK e20-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
591,EML4::ALK e2-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
592,R961W,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Sensitivity/Response,Colorectal Adenocarcinoma,Regorafenib
593,EML4::ALK e6-e20,"[{'id': 302, 'name': '2,4-pyrimidinediamine', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,"2,4-pyrimidinediamine"
594,EML4::ALK e6-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
595,EML4::ALK e6-e20,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
596,EML4::ALK e20-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
597,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
598,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
599,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
600,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
601,Fusion,"[{'id': 303, 'name': 'Retaspimycin Hydrochloride', 'ncit_id': 'C48401', 'aliases': ['IPI-504', 'Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, Monohydrochloride', '17-Allylamino-17-demethoxygeldanamycin Hydroquinone Hydrochloride']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Retaspimycin Hydrochloride
602,EML4-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 303, 'name': 'Retaspimycin Hydrochloride', 'ncit_id': 'C48401', 'aliases': ['IPI-504', 'Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, Monohydrochloride', '17-Allylamino-17-demethoxygeldanamycin Hydroquinone Hydrochloride']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib+Retaspimycin Hydrochloride
603,EML4::ALK e20-e20,"[{'id': 304, 'name': 'Alvespimycin', 'ncit_id': 'C38142', 'aliases': ['Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-', '17-DMAG', '17-dimethylaminoethylamino-17-demethoxygeldanamycin', '17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alvespimycin+Crizotinib
604,EML4-ALK,"[{'id': 304, 'name': 'Alvespimycin', 'ncit_id': 'C38142', 'aliases': ['Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-', '17-DMAG', '17-dimethylaminoethylamino-17-demethoxygeldanamycin', '17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alvespimycin+Crizotinib
605,EML4-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
606,Exon 2 Mutation,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Resistance,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
607,P47S,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",E,Resistance,Cancer,Cisplatin
608,MUTATION,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Uveal Melanoma,JQ1
609,MUTATION,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Uveal Melanoma,JQ1
610,K706FS*19,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",C,Sensitivity/Response,Glioblastoma,Nivolumab
611,G12C,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Colorectal Cancer,Gefitinib+Erlotinib
612,Exon 2 Mutation,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Pancreatic Cancer,Gemcitabine+Erlotinib
613,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
614,Exon 9 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
615,MUTATION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Melanoma,Imatinib
616,Exon 9 Mutation,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
617,Exon 11 Mutation,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Melanoma,Sunitinib
618,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Skin Melanoma,Trametinib+Docetaxel
619,Q61,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",B,Sensitivity/Response,Skin Melanoma,Binimetinib
620,MUTATION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Uveal Melanoma,Trametinib
621,MUTATION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Uveal Melanoma,Trametinib
622,Mutation,"[{'id': 308, 'name': 'Metformin', 'ncit_id': 'C61612', 'aliases': ['N,N-Dimethylimidodicarbonimidic Diamide', 'N,N-dimethylbiguanide', '1,1-Dimethylbiguanide']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Cancer,Metformin+Trametinib
623,Deletion,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Prostate Cancer,Everolimus
624,Q209,"[{'id': 394, 'name': 'Refametinib', 'ncit_id': 'C74059', 'aliases': ['RDEA119', 'MEK Inhibitor RDEA119', 'BAY86-9766', 'BAY 869766']}]",C,Sensitivity/Response,Uveal Melanoma,Refametinib
625,Mutation,"[{'id': 679, 'name': 'Trichostatin A', 'ncit_id': 'C1261', 'aliases': []}, {'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}, {'id': 37, 'name': 'Valproic Acid', 'ncit_id': 'C29536', 'aliases': ['Valproate', 'Stavzor', 'Di-n-propylacetic Acid', 'Depakene', '2-Propylvaleric Acid', '2-Propylpentanoic Acid']}, {'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,Uveal Melanoma,Trichostatin A+Vorinostat+Valproic Acid+Panobinostat
626,Mutation,"[{'id': 316, 'name': 'MC1568', 'ncit_id': None, 'aliases': []}, {'id': 315, 'name': 'Mocetinostat', 'ncit_id': 'C62521', 'aliases': ['N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide', 'MGCD0103', 'MG-0103', 'Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-']}, {'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}]",E,Sensitivity/Response,Malignant Mesothelioma,MC1568+Mocetinostat+Vorinostat
627,Mutation,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Endometrial Cancer,Ponatinib
628,Mutation,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
629,NPM-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
630,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
631,NPM-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
632,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
633,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
634,RANBP2-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
635,EML4::ALK e20-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Cancer,Crizotinib
636,N546K,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",E,Sensitivity/Response,Ewing Sarcoma Of Bone,Ponatinib
637,Amplification,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Ewing Sarcoma Of Bone,Ponatinib
638,REARRANGEMENT,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Ceritinib
639,CD74-ROS1 G2032R,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}, {'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib+Cabozantinib
640,CD74-ROS1 G2032R,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 319, 'name': 'AZD3463', 'ncit_id': None, 'aliases': []}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib+Crizotinib+AZD3463+Brigatinib
641,CD74-ROS1 G2032R,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
642,CD74-ROS1 L2026M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
643,CD74-ROS1 L2026M,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
644,CD74-ROS1 G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
645,CD74-ROS1 G2032R,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
646,CD74-ROS1 L2155S,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Foretinib+Crizotinib+TAE684
647,CD74-ROS1 L2026M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
648,CD74-ROS1 L2026M,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
649,CD74-ROS1 G2101A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
650,CD74-ROS1 G2101A,"[{'id': 150, 'name': 'Foretinib', 'ncit_id': 'C80058', 'aliases': ['XL880', ""N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"", 'Multitargeted Tyrosine Kinase Inhibitor GSK1363089', 'MET/VEGFR-2 Inhibitor GSK1363089', 'GSK1363089']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
651,CLTC-ALK,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Diffuse Large B-cell Lymphoma,TAE684
652,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Crizotinib
653,CLTC-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Crizotinib
654,EML4::ALK e2-e20,[],E,Sensitivity/Response,Renal Cell Carcinoma,
655,DEL 485-490,"[{'id': 320, 'name': 'Pan-RAF Inhibitor LY3009120', 'ncit_id': 'C116861', 'aliases': ['LY3009120', 'LY-3009120', 'DP-4978']}]",D,Sensitivity/Response,Cancer,Pan-RAF Inhibitor LY3009120
656,NPM-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
657,R1275Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Neuroblastoma,Crizotinib
658,R1275Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Neuroblastoma,Crizotinib
659,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
660,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
661,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
662,DELETION POLYMORPHISM,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Chronic Myeloid Leukemia,Imatinib
663,DELETION POLYMORPHISM,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
664,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
665,ALK Fusion I1171,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Alectinib
666,ALK Fusion I1171,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
667,ALK Fusion I1171,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
668,EML4-ALK  V1180L,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Alectinib
669,ALK Fusion I1171,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
670,EML4-ALK  V1180L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
671,EML4-ALK  V1180L,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
672,EML4-ALK  V1180L,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
673,EML4-ALK  V1180L,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
674,OVEREXPRESSION,"[{'id': 324, 'name': 'Niacinamide', 'ncit_id': 'C2327', 'aliases': []}]",D,Resistance,Pancreatic Cancer,Niacinamide
675,TKD MUTATION,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
676,Mutation,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Everolimus
677,Loss,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Everolimus
678,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",E,Sensitivity/Response,Colorectal Adenocarcinoma,Crizotinib
679,Biallelic Inactivation,"[{'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}]",C,Sensitivity/Response,Pancreatic Cancer,Mitomycin
680,LOSS-OF-FUNCTION,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 327, 'name': 'Chlorambucil', 'ncit_id': 'C362', 'aliases': ['WR-139013', 'Phenylbutyric Acid Nitrogen Mustard', 'P-N, N-di-(beta-chloroethyl)aminophenyl Butyric Acid', 'P-N, N-Di-(.beta.-chloroethyl)aminophenyl Butyric Acid', 'P-(N, N-Di-2-chloroethyl)aminophenyl Butyric Acid', 'N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric Acid', 'N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric Acid', 'Lympholysin', 'Linfolysin', 'Linfolizin', 'Leukoran', 'Leukersan', 'Leukeran', 'Gamma-[p-di(2-chloroethyl)aminophenyl]butyric Acid', 'Gamma-(p-bis(2-chloroethyl)aminophenyl)butyric Acid', 'Elcoril', 'Ecloril', 'Chlorobutine', 'Chlorobutin', 'Chloroambucil', 'Chlorbutinum', 'Chlorbutine', 'Chlorbutin', 'Chloraminophene', 'Chloraminophen', 'Chlorambucilum', 'CHL', 'CB-1348', 'CB 1348', 'Butyric Acid, 4-(p-bis(2-chloroethyl)aminophenyl)-', 'Butyric Acid, 4-(p-bis(2-chloroethyl)aminophenyl)', 'Butyric Acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-', 'Benzenebutanoic Acid, 4-[bis(2-chloroethyl)amino]- (9CI)', 'Aminochlorambucil', 'Amboclorin', 'Ambochlorin', 'Alti-chlorambucil', '4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric Acid', '4-[Bis(2-chloroethyl)amino]benzenebutanoic Acid', '.gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric Acid', '.gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric Acid', '.gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric Acid']}]",D,Sensitivity/Response,Pancreatic Cancer,Melphalan+Gemcitabine+Mitomycin+Cisplatin+Chlorambucil
681,Loss-of-function,"[{'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}]",D,Sensitivity/Response,Pancreatic Cancer,Mitomycin
682,I843DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
683,EBF1-PDGFRB,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
684,SNP,"[{'id': 329, 'name': 'Abiraterone Acetate', 'ncit_id': 'C68845', 'aliases': ['JNJ-212082', 'BR9004-1', 'BR9004', 'Zytiga', 'Yonsa', 'CB7630', 'Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-', '17-(3-Pyridyl)-5,16-androstadien-3beta-acetate']}]",B,Resistance,Prostate Cancer,Abiraterone Acetate
685,METHYLATION,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",B,Resistance,Stomach Carcinoma,Oxaliplatin
686,T227M,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Adverse Response,Renal Cell Carcinoma,Sunitinib
687,S2215Y,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Endometrial Adenocarcinoma,Sirolimus
688,C1483Y,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Sirolimus
689,E1799K,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Sirolimus
690,N550K,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Endometrial Cancer,PD173074
691,Fusion,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
692,OVEREXPRESSION,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}]",D,Resistance,Pancreatic Adenocarcinoma,Doxorubicin+Gemcitabine+Fluorouracil+Mitomycin
693,RS557806,"[{'id': 332, 'name': 'FOLFIRI Regimen', 'ncit_id': 'C63593', 'aliases': ['Folinic Acid/Fluorouracil/Irinotecan Regimen', 'Fluorouracil/Folinic Acid/Irinotecan', 'Fluorouracil-Folinic Acid-Irinotecan', 'Folinic Acid-Fluorouracil-Irinotecan Regimen', 'FOLFIRI']}, {'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Colorectal Cancer,FOLFIRI Regimen+Bevacizumab
694,Exon 2 Mutation,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Selumetinib
695,F1174L,"[{'id': 319, 'name': 'AZD3463', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,AZD3463
696,F1174L,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Neuroblastoma,Lorlatinib
697,F1245C,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Neuroblastoma,Lorlatinib
698,R1275Q,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Neuroblastoma,Lorlatinib
699,EML4-ALK,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
700,F1245C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Neuroblastoma,Crizotinib
701,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",E,Sensitivity/Response,Colorectal Adenocarcinoma,Crizotinib
702,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",E,Sensitivity/Response,Breast Cancer,Crizotinib
703,Exon 4-11 Deletion,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Neuroblastoma,Brigatinib
704,ALK Fusion F1245C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Cancer,Crizotinib
705,ALK Fusion F1245C,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
706,ALK Fusion F1245C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
707,EML4::ALK e6-e20,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
708,EML4-ALK L1196M,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
709,ALK Fusion G1269A,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
710,EML4-ALK S1206Y,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Cancer,Ceritinib
711,ALK Fusion I1171,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
712,ALK Fusion G1202R,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib
713,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
714,EML4-ALK T1151INST,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Alectinib
715,EML4-ALK T1151INST,"[{'id': 18, 'name': 'TAE684', 'ncit_id': None, 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,TAE684
716,EML4-ALK T1151INST,"[{'id': 10, 'name': 'Tanespimycin', 'ncit_id': 'C37899', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tanespimycin
717,ALK Fusion G1202R,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Resistance,Cancer,Alectinib
718,ALK Fusion G1202R,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Resistance,Cancer,Brigatinib
719,ALK Fusion G1202R,"[{'id': 10, 'name': 'Tanespimycin', 'ncit_id': 'C37899', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tanespimycin
720,ALK Fusion G1269A,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Cancer,Brigatinib
721,ALK Fusion G1269A,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Resistance,Cancer,Alectinib
722,ALK Fusion G1269A,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Cancer,Ceritinib
723,NPM-ALK,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
724,ALK Fusion G1202R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
725,Mutation,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
726,H1047R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
727,H1047R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
728,H1047R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Head And Neck Cancer,Dactolisib+Cetuximab
729,M918T,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Sorafenib
730,AMPLIFICATION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Liposarcoma,Palbociclib
731,ALK Fusion I1171,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Alectinib
732,ALK Fusion I1171,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
733,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Cancer,Olaparib
734,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Cancer,Olaparib
735,Loss,"[{'id': 335, 'name': 'Alvocidib', 'ncit_id': 'C74940', 'aliases': ['Flavopiridol', 'Alvocidib Freebase', '(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one']}]",D,Sensitivity/Response,Skin Melanoma,Alvocidib
736,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Renal Cell Carcinoma,Palbociclib
737,LOSS,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Renal Cell Carcinoma,Palbociclib
738,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Skin Melanoma,Palbociclib
739,R24C,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Skin Melanoma,Palbociclib
740,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Ovarian Cancer,Palbociclib
741,Amplification,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
742,Amplification,"[{'id': 337, 'name': 'A66', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,A66
743,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
744,Mutation,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
745,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
746,BCR-ABL T315I,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
747,T790M,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
748,Amplification,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
749,Amplification,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Adenocarcinoma,Erlotinib+Gefitinib
750,S768I,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
751,S768I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
752,C797S,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Resistance,Lung Adenocarcinoma,Osimertinib
753,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
754,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
755,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
756,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
757,H1047R,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Sensitivity/Response,Head And Neck Cancer,Alpelisib
758,Mutation,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Sensitivity/Response,Cancer,Alpelisib
759,Amplification,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Sensitivity/Response,Stomach Carcinoma,Alpelisib
760,V600,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Dabrafenib
761,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Colorectal Cancer,Vemurafenib+Cetuximab+Gefitinib
762,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",A,Sensitivity/Response,Skin Melanoma,Vemurafenib
763,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Skin Melanoma,Vemurafenib
764,V600,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",A,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
765,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
766,V600,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Colorectal Cancer,Trametinib+Dabrafenib
767,TRIM24-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
768,K700E,"[{'id': 341, 'name': 'Spliceostatin A', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Spliceostatin A
769,K666N,"[{'id': 341, 'name': 'Spliceostatin A', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Spliceostatin A
770,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
771,V600E,"[{'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Cobimetinib+Vemurafenib
772,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",B,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
773,M541L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Chronic Leukemia,Imatinib
774,Exon 9 Mutation,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
775,V600E,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 344, 'name': 'GDC-0879', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib+GDC-0879
776,Mutation,"[{'id': 346, 'name': 'Omipalisib', 'ncit_id': 'C88270', 'aliases': ['GSK2126458', 'Benzenesulfonamide, 2,4-Difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Melanoma,Omipalisib+Trametinib
777,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Gastrointestinal Neuroendocrine Tumor,Dabrafenib+Vemurafenib+Trametinib
778,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
779,Amplification,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Docetaxel+Pertuzumab+Trastuzumab
780,E2014K and E2419K,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Everolimus+Pazopanib
781,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
782,AMPLIFICATION,"[{'id': 435, 'name': 'Sapanisertib', 'ncit_id': 'C90548', 'aliases': ['TAK-228', 'MLN0128', 'MLN-0128', 'INK128', 'INK-128']}, {'id': 347, 'name': 'Onatasertib', 'ncit_id': 'C92575', 'aliases': ['WHO 11237', 'ATG-008', 'TORKi', 'CC-223']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Sapanisertib+Onatasertib
783,FIP1L1-PDGFRA,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
784,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
785,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,Crizotinib
786,TFG-ROS1,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
787,FIP1L1-PDGFRA,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",A,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
788,FIP1L1-PDGFRA T674I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
789,H1047R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Dactolisib
790,Amplification,"[{'id': 680, 'name': 'Pilaralisib', 'ncit_id': 'C71705', 'aliases': ['XL147', 'XL-147', 'XL 147', 'SAR245408', '2-Amino-N-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pilaralisib+Trastuzumab
791,OVEREXPRESSION,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
792,E545K,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
793,D594A,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",E,Sensitivity/Response,Skin Melanoma,Sorafenib+Mitogen-Activated Protein Kinase Kinase Inhibitor
794,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 115, 'name': 'PI3K/BET Inhibitor LY294002', 'ncit_id': 'C148229', 'aliases': ['LY294002', 'LY-294002', 'LY 294002', '4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-', '2-Morpholin-4-yl-8-phenylchromen-4-one', '2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+PI3K/BET Inhibitor LY294002
795,D594V,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",E,Sensitivity/Response,Skin Melanoma,Sorafenib+Trametinib
796,K483M,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",E,Sensitivity/Response,Skin Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+Sorafenib
797,L597R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
798,L597S,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
799,L597S,"[{'id': 350, 'name': 'MEK Inhibitor TAK-733', 'ncit_id': 'C84858', 'aliases': ['TAK-733']}]",C,Sensitivity/Response,Skin Melanoma,MEK Inhibitor TAK-733
800,L597Q,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Skin Melanoma,Trametinib+Vemurafenib
801,K601E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
802,L597V,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Skin Melanoma,Trametinib
803,Amplification,"[{'id': 660, 'name': 'Taselisib', 'ncit_id': 'C116876', 'aliases': ['RO5537381', 'GDC-0032']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Taselisib
804,H1047R,"[{'id': 660, 'name': 'Taselisib', 'ncit_id': 'C116876', 'aliases': ['RO5537381', 'GDC-0032']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Taselisib
805,Amplification,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Mucosal Melanoma,Imatinib
806,Mutation,"[{'id': 660, 'name': 'Taselisib', 'ncit_id': 'C116876', 'aliases': ['RO5537381', 'GDC-0032']}]",D,Resistance,Head And Neck Squamous Cell Carcinoma,Taselisib
807,Mutation,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
808,Mutation,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}, {'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Skin Melanoma,Sirolimus+Mirdametinib
809,Mutation,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Melanoma,Vemurafenib
810,Mutation,"[{'id': 354, 'name': 'AZ628', 'ncit_id': None, 'aliases': []}, {'id': 353, 'name': 'VTX-11e', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Skin Melanoma,AZ628+VTX-11e
811,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",B,Sensitivity/Response,Skin Melanoma,Binimetinib
812,Q61,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Skin Melanoma,Selumetinib
813,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
814,Q61K,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Skin Melanoma,Selumetinib
815,Mutation,"[{'id': 384, 'name': 'Amuvatinib', 'ncit_id': 'C71750', 'aliases': ['Receptor Tyrosine Kinase Inhibitor MP470', 'MP470', 'HPK56']}]",D,Sensitivity/Response,Skin Melanoma,Amuvatinib
816,Mutation,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}, {'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}]",B,Resistance,Basal Cell Carcinoma,Vismodegib+Sonidegib
817,Mutation,"[{'id': 358, 'name': 'Alemtuzumab', 'ncit_id': 'C1681', 'aliases': []}]",B,Sensitivity/Response,Chronic Lymphocytic Leukemia,Alemtuzumab
818,EXON 9 FRAMESHIFT,"[{'id': 8, 'name': 'Peginterferon Alfa-2a', 'ncit_id': 'C33987', 'aliases': []}]",B,Sensitivity/Response,Myeloproliferative Neoplasm,Peginterferon Alfa-2a
819,HIP1-ALK I1171N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib+Alectinib
820,EML4-ALK I1171S,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Alectinib+Crizotinib
821,Mutation,"[{'id': 360, 'name': 'Radiation Therapy', 'ncit_id': 'C15313', 'aliases': ['ENERGY_TYPE', 'Radiation Therapy, NOS', 'Therapy, Radiation', 'RT', 'RADIOTHERAPY', 'Radiotherapeutics', 'RADIATION', 'Irradiation', 'Irradiated', 'Irradiate', 'Cancer Radiotherapy']}, {'id': 660, 'name': 'Taselisib', 'ncit_id': 'C116876', 'aliases': ['RO5537381', 'GDC-0032']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Radiation Therapy+Taselisib
822,Mutation,"[{'id': 361, 'name': 'Ipatasertib', 'ncit_id': 'C91072', 'aliases': ['RG-7440', 'GDC-0068', '(2S)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one']}]",D,Sensitivity/Response,Cancer,Ipatasertib
823,Loss,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Ovarian Cancer,Cisplatin
824,Loss,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Stomach Carcinoma,Chemotherapy
825,Y646,"[{'id': 362, 'name': 'GSK126', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Skin Melanoma,GSK126
826,Amplification,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Skin Melanoma,Carboplatin+Paclitaxel+Sorafenib
827,AMPLIFICATION,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Skin Melanoma,Carboplatin+Paclitaxel+Sorafenib
828,Amplification,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Skin Melanoma,Carboplatin+Docetaxel+Sorafenib
829,Fusion,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",A,Sensitivity/Response,Myeloproliferative Neoplasm,Imatinib
830,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",A,Sensitivity/Response,Gastric Adenocarcinoma,Trastuzumab
831,Loss,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Stomach Cancer,Docetaxel+Capivasertib
832,Mutation,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Stomach Cancer,Capivasertib
833,Loss,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Cancer,Capivasertib
834,Mutation,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Cancer,Capivasertib
835,Mutation,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capivasertib
836,H1047R,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Capivasertib
837,H1047R,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capivasertib+Lapatinib
838,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",D,Sensitivity/Response,Melanoma,Binimetinib
839,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Sensitivity/Response,Cancer,Nivolumab
840,Overexpression,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Papillary Adenocarcinoma,Sunitinib
841,PML-RARA,"[{'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",C,Sensitivity/Response,Acute Promyelocytic Leukemia,Tretinoin
842,CTLA4-CD28,"[{'id': 365, 'name': 'Ipilimumab', 'ncit_id': 'C2654', 'aliases': []}]",C,Sensitivity/Response,Sezary's Disease,Ipilimumab
843,MUTATION,"[{'id': 366, 'name': 'Flutamide', 'ncit_id': 'C509', 'aliases': ['Testotard', 'Tecnoflut', 'Tafenil', 'SCH 13521', 'Prostogenat', 'Prostica', 'Prostadirex', 'Prostacur', 'Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-', 'Profamid', 'Oncosal', 'Niftolide', 'Grisetin', 'Fugerel', 'Flutaplex', 'Flutan', 'Flutamin', 'Flutamex', 'Flutacan', 'Flutabene', 'Fluta-Gry', 'FLUT', 'Flulem', 'Fluken', 'Flugerel', 'Flucinome', 'Flucinom', 'Eulexine', 'Eulexin', 'Euflex', 'Drogenil', 'Cytomid', 'Chimax', 'Cebatrol', 'Apimid', ""Alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide"", ""4'-Nitro-3'-trifluoromethylisobutyranilide"", '2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide']}, {'id': 367, 'name': 'Cyproterone Acetate', 'ncit_id': 'C1059', 'aliases': ['SH-714', 'SH 714', 'Dianette', 'Diane', 'Cyproteroni Acetas', 'Cyproteronazetat', 'Cyprostat', 'Cyprone', 'CyPat', 'Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate', 'Androcur', 'Andro-Diane', ""6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate"", ""3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-""]}, {'id': 78, 'name': 'Bicalutamide', 'ncit_id': 'C1599', 'aliases': ['N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide', 'ICI 176334', 'ICI 176,334', 'Cosudex', 'Casodex', '4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline', ""4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide"", '(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide']}, {'id': 368, 'name': 'Nilutamide', 'ncit_id': 'C1173', 'aliases': ['RU-23908', 'Nilandron', 'Anandron', '5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione', ""1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione""]}]",B,Resistance,Prostate Cancer,Flutamide+Cyproterone Acetate+Bicalutamide+Nilutamide
844,Mutation,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}, {'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}, {'id': 114, 'name': 'PI3Kbeta Inhibitor AZD8186', 'ncit_id': 'C107684', 'aliases': ['AZD8186', 'AZD-8186']}]",D,Sensitivity/Response,Prostate Cancer,Alpelisib+Enzalutamide+PI3Kbeta Inhibitor AZD8186
845,LOSS-OF-FUNCTION,"[{'id': 370, 'name': 'Porcupine Inhibitor WNT974', 'ncit_id': 'C116860', 'aliases': ['WNT974', 'PORCN Inhibitor LGK974', 'LGK974', '2-(2,3-Dimethyl-[2,4-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Porcupine Inhibitor WNT974
846,OVEREXPRESSION,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",B,Resistance,Estrogen-receptor Positive Breast Cancer,Fulvestrant
847,OVEREXPRESSION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Palbociclib+Fulvestrant
848,Overexpression,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,Sunitinib
849,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
850,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
851,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
852,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
853,Q209P,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Melanoma,Vemurafenib
854,V317FS,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}, {'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",D,Sensitivity/Response,Skin Melanoma,Akt Inhibitor MK2206+MEK Inhibitor CI-1040
855,LOSS-OF-FUNCTION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Breast Cancer,Palbociclib
856,Q209P,"[{'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}]",D,Resistance,Skin Melanoma,PLX4720
857,Overexpression,"[{'id': 375, 'name': 'Letrozole', 'ncit_id': 'C1527', 'aliases': ['Femara', 'CGS 20267', ""4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile""]}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Breast Cancer,Letrozole+Palbociclib
858,F2108L,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Resistance,Breast Cancer,Sirolimus
859,M2327I,"[{'id': 124, 'name': 'MTOR Kinase Inhibitor AZD8055', 'ncit_id': 'C78856', 'aliases': ['AZD8055']}]",D,Resistance,Breast Cancer,MTOR Kinase Inhibitor AZD8055
860,M2327I,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Resistance,Breast Cancer,Sirolimus
861,A2034V,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Resistance,Breast Cancer,Sirolimus
862,E542K,"[{'id': 377, 'name': 'Apitolisib', 'ncit_id': 'C91731', 'aliases': ['RG 7422', 'GNE 390', 'GDC-0980', 'GDC 0980']}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Apitolisib
863,E545K,"[{'id': 377, 'name': 'Apitolisib', 'ncit_id': 'C91731', 'aliases': ['RG 7422', 'GNE 390', 'GDC-0980', 'GDC 0980']}]",C,Sensitivity/Response,Cancer,Apitolisib
864,ITD,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
865,D835H,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Resistance,Acute Myeloid Leukemia,Sorafenib
866,D835H/Y,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
867,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Glioblastoma,Palbociclib
868,Amplification,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Palbociclib+Trastuzumab
869,Amplification,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Breast Cancer,Palbociclib
870,Overexpression,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Mantle Cell Lymphoma,Palbociclib
871,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Glioblastoma,Crizotinib
872,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
873,Q503*,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Skin Melanoma,Pembrolizumab
874,c.1641+1dup,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Skin Melanoma,Pembrolizumab
875,S14FS,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Skin Melanoma,Pembrolizumab
876,PPFIBP2-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Skin Melanoma,Trametinib
877,KIAA1549-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Skin Melanoma,Trametinib
878,Expression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
879,OVEREXPRESSION,"[{'id': 379, 'name': 'Aspirin', 'ncit_id': 'C287', 'aliases': ['Measurin', 'Extren', 'Entericin', 'Empirin', 'Ecotrin', 'Aspergum', 'ASA', 'Acetylsalicylic Acid', '2-(Acetyloxy)benzoic Acid']}]",B,Sensitivity/Response,Colorectal Cancer,Aspirin
880,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
881,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Langerhans-cell Histiocytosis,Vemurafenib
882,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Colorectal Cancer,Vemurafenib
883,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
884,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
885,G12D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Hairy Cell Leukemia,Vemurafenib
886,Overexpression,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Skin Melanoma,Vemurafenib
887,Overexpression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",E,Sensitivity/Response,Uveal Melanoma,Crizotinib
888,Overexpression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Uveal Melanoma,Crizotinib
889,Mutation,"[{'id': 155, 'name': 'Decitabine', 'ncit_id': 'C981', 'aliases': ['Dezocitidine', 'Deoxyazacytidine', 'Decitabine For Injection', 'Dacogen', '5-Azadeoxycytidine', '5-Aza-2-deoxycytidine', ""5-Aza-2'deoxycytidine"", ""5-Aza-2'-deoxycytidine"", '4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one', ""2'-Deoxy-5-azacytidine""]}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Decitabine
890,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Colorectal Cancer,Crizotinib+Vemurafenib
891,V600E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Colorectal Cancer,Panitumumab+Vemurafenib
892,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
893,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
894,LOSS-OF-FUNCTION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Glioblastoma,Palbociclib
895,EXPRESSION,"[{'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}]",D,Sensitivity/Response,Sarcoma,Vorinostat
896,Mutation,"[{'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}, {'id': 382, 'name': 'Phosphatidylinositide 3-Kinase Inhibitor', 'ncit_id': 'C2152', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Ribociclib+Phosphatidylinositide 3-Kinase Inhibitor
897,CCDC6-RET,"[{'id': 383, 'name': 'Nintedanib', 'ncit_id': 'C62765', 'aliases': ['Vargatef', 'Tyrosine Kinase Inhibitor BIBF 1120', 'Multitargeted Tyrosine Kinase Inhibitor BIBF 1120', 'Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate', 'Intedanib', 'BIBF-1120', 'BIBF 1120']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nintedanib
898,C121S,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
899,S249C,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Pazopanib
900,Amplification,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Dovitinib
901,Amplification,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Dovitinib
902,AMPLIFICATION,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Dovitinib
903,Mutation,"[{'id': 382, 'name': 'Phosphatidylinositide 3-Kinase Inhibitor', 'ncit_id': 'C2152', 'aliases': []}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Breast Cancer,Phosphatidylinositide 3-Kinase Inhibitor+Palbociclib
904,R200W (c.598C>T),"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,Chuvash Polycythemia,Ruxolitinib
905,PHOSPHORYLATION,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",B,Resistance,Breast Cancer,Alpelisib
906,Mutation,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 179, 'name': 'MTOR Kinase Inhibitor PP242', 'ncit_id': 'C128632', 'aliases': ['PP242', 'PP-242', '2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol']}]",D,Sensitivity/Response,Breast Cancer,Everolimus+MTOR Kinase Inhibitor PP242
907,MUTATION,"[{'id': 179, 'name': 'MTOR Kinase Inhibitor PP242', 'ncit_id': 'C128632', 'aliases': ['PP242', 'PP-242', '2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol']}]",D,Sensitivity/Response,Breast Cancer,MTOR Kinase Inhibitor PP242
908,Amplification,"[{'id': 179, 'name': 'MTOR Kinase Inhibitor PP242', 'ncit_id': 'C128632', 'aliases': ['PP242', 'PP-242', '2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol']}]",D,Sensitivity/Response,Breast Cancer,MTOR Kinase Inhibitor PP242
909,Loss,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Endometrial Cancer,Temsirolimus
910,Mutation,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Endometrial Cancer,Pictilisib
911,D194E,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Pancreatic Cancer,Everolimus
912,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Peutz-Jeghers Syndrome,Sirolimus
913,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Peutz-Jeghers Syndrome,Sirolimus
914,Amplification,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib+Everolimus
915,KIF5B-RET,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib+Everolimus
916,H1047R,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Fulvestrant+Everolimus
917,Expression,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Resistance,Her2-receptor Positive Breast Cancer,Fulvestrant+Everolimus
918,H1047R,"[{'id': 389, 'name': 'Perifosine', 'ncit_id': 'C1727', 'aliases': ['Octadecylphosphopiperidine', 'Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate', 'D21266', '4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt']}, {'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Perifosine+Temsirolimus
919,E542K,"[{'id': 389, 'name': 'Perifosine', 'ncit_id': 'C1727', 'aliases': ['Octadecylphosphopiperidine', 'Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate', 'D21266', '4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt']}, {'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Perifosine+Temsirolimus
920,R130*,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}, {'id': 389, 'name': 'Perifosine', 'ncit_id': 'C1727', 'aliases': ['Octadecylphosphopiperidine', 'Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate', 'D21266', '4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Temsirolimus+Perifosine
921,LOSS-OF-FUNCTION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",E,Sensitivity/Response,Renal Cell Carcinoma,Everolimus
922,Amplification,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Estrogen-receptor Positive Breast Cancer,Palbociclib
923,M695FS*26,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Estrogen-receptor Positive Breast Cancer,Palbociclib
924,MUTATION,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",B,Sensitivity/Response,Cancer,MTOR Inhibitor
925,LOSS-OF-FUNCTION,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Cancer,Sirolimus
926,OVEREXPRESSION,"[{'id': 390, 'name': 'Irbesartan', 'ncit_id': 'C29130', 'aliases': ['Avapro']}]",C,Sensitivity/Response,Colorectal Adenocarcinoma,Irbesartan
927,OVEREXPRESSION,"[{'id': 390, 'name': 'Irbesartan', 'ncit_id': 'C29130', 'aliases': ['Avapro']}]",C,Sensitivity/Response,Colon Adenocarcinoma,Irbesartan
928,L265P,"[{'id': 393, 'name': 'IRAK-1/4 Inhibitor', 'ncit_id': None, 'aliases': []}, {'id': 536, 'name': 'IMG-2005-5', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Waldenstroem's Macroglobulinemia,IRAK-1/4 Inhibitor+IMG-2005-5
929,Mutation,"[{'id': 394, 'name': 'Refametinib', 'ncit_id': 'C74059', 'aliases': ['RDEA119', 'MEK Inhibitor RDEA119', 'BAY86-9766', 'BAY 869766']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Hepatocellular Carcinoma,Refametinib+Sorafenib
930,Deletion,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Resistance,Colorectal Cancer,Fluorouracil
931,Underexpression,"[{'id': 9809, 'name': 'PCV Regimen', 'ncit_id': 'C63491', 'aliases': ['POC', 'Procarbazine-Lomustine-Vincristine Regimen', 'PCV', 'Matulane-CCNU-Oncovin Regimen']}, {'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Malignant Astrocytoma,PCV Regimen+Temozolomide
932,Overexpression,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Resistance,Ovarian Serous Carcinoma,Platinum Compound
933,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
934,D1228N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
935,EXPRESSION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 360, 'name': 'Radiation Therapy', 'ncit_id': 'C15313', 'aliases': ['ENERGY_TYPE', 'Radiation Therapy, NOS', 'Therapy, Radiation', 'RT', 'RADIOTHERAPY', 'Radiotherapeutics', 'RADIATION', 'Irradiation', 'Irradiated', 'Irradiate', 'Cancer Radiotherapy']}]",B,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Fluorouracil+Cisplatin+Radiation Therapy
936,EXPRESSION,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Resistance,Prostate Cancer,Docetaxel
937,UNDEREXPRESSION,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
938,UNDEREXPRESSION,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
939,Q56_V60del,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Ovarian Serous Carcinoma,Selumetinib
940,BRAF-CUL1,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",C,Sensitivity/Response,Ovarian Serous Carcinoma,Mitogen-Activated Protein Kinase Kinase Inhibitor
941,ZKSCAN1-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Melanoma,Trametinib
942,KIAA1549-BRAF,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Spindle Cell Sarcoma,Bevacizumab+Temsirolimus+Sorafenib
943,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
944,Exon 19 Deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
945,T790M,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
946,L505H,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
947,L505H,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Vemurafenib
948,E545K,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
949,Mutation,"[{'id': 400, 'name': 'Cediranib', 'ncit_id': 'C80867', 'aliases': ['AZD2171', '4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Cediranib+Olaparib
950,Mutation,"[{'id': 400, 'name': 'Cediranib', 'ncit_id': 'C80867', 'aliases': ['AZD2171', '4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Cediranib+Olaparib
951,Mutation,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Cisplatin+Carboplatin
952,Mutation,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Carboplatin+Cisplatin
953,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
954,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
955,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
956,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Colorectal Cancer,Trastuzumab+Lapatinib
957,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
958,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
959,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
960,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Sensitivity/Response,Scrotum Paget's Disease,Trastuzumab
961,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",C,Sensitivity/Response,Bladder Carcinoma,Platinum Compound
962,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Multiple Myeloma,Vemurafenib
963,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Multiple Myeloma,Vemurafenib
964,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
965,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
966,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
967,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
968,EXPRESSION,"[{'id': 402, 'name': 'I-BET151', 'ncit_id': None, 'aliases': []}, {'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Multiple Myeloma,I-BET151+JQ1
969,EXPRESSION,"[{'id': 403, 'name': 'MET Tyrosine Kinase Inhibitor SGX523', 'ncit_id': 'C74062', 'aliases': ['SGX523']}]",D,Sensitivity/Response,Glioblastoma,MET Tyrosine Kinase Inhibitor SGX523
970,Expression,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Panitumumab
971,Expression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab
972,LOSS,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
973,EXPRESSION,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Resistance,Acute Myeloid Leukemia,Quizartinib
974,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
975,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Cancer,Crizotinib
976,E384*,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Cholangiocarcinoma,Erlotinib
977,D816V,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",B,Sensitivity/Response,Systemic Mastocytosis,Midostaurin
978,S463P,"[{'id': 407, 'name': 'Aromatase Inhibitor', 'ncit_id': 'C1740', 'aliases': []}]",D,Resistance,Estrogen-receptor Positive Breast Cancer,Aromatase Inhibitor
979,Mutation,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
980,Overexpression,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Resistance,Breast Cancer,Alpelisib
981,Overexpression,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",B,Resistance,Breast Cancer,Alpelisib
982,Overexpression,"[{'id': 408, 'name': 'SGK1-Inh', 'ncit_id': None, 'aliases': []}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Sensitivity/Response,Breast Cancer,SGK1-Inh+Alpelisib
983,Expression,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
984,Overexpression,"[{'id': 412, 'name': 'CDK Inhibitor SNS-032', 'ncit_id': 'C62523', 'aliases': ['SNS-032', 'BMS-387032']}]",D,Sensitivity/Response,Ovarian Cancer,CDK Inhibitor SNS-032
985,Amplification,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}, {'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Sensitivity/Response,Ovarian Serous Cystadenocarcinoma,Akt Inhibitor MK2206+Dinaciclib
986,G719S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
987,G596C,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
988,UNDEREXPRESSION,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",D,Sensitivity/Response,Synovial Sarcoma,Tazemetostat
989,DELETION,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",D,Sensitivity/Response,Rhabdoid Cancer,Tazemetostat
990,Loss,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Thyroid Gland Carcinoma,Selumetinib
991,Loss,"[{'id': 414, 'name': 'JQ1 Compound', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,JQ1 Compound
992,V104M,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
993,R103G,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
994,G284R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
995,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
996,V600,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Trametinib
997,A222V,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",B,Sensitivity/Response,Rectum Cancer,Fluorouracil
998,D761Y,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
999,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
1000,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 375, 'name': 'Letrozole', 'ncit_id': 'C1527', 'aliases': ['Femara', 'CGS 20267', ""4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile""]}]",C,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Palbociclib+Letrozole
1001,MUTATION,"[{'id': 417, 'name': 'Pomalidomide', 'ncit_id': 'C72560', 'aliases': ['Pomalyst', 'Imnovid', 'CC-4047', 'Actimid', '4-Aminothalidomide', '4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione', '3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide']}, {'id': 416, 'name': 'Lenalidomide', 'ncit_id': 'C2668', 'aliases': ['Revlimid', 'CDC 501', 'CC5013', 'CC-5013', '3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione']}]",C,Resistance,Multiple Myeloma,Pomalidomide+Lenalidomide
1002,Amplification,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Ponatinib
1003,C481S,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",B,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
1004,Amplification,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sunitinib
1005,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Olaparib
1006,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Cancer,Olaparib
1007,FIP1L1-PDGFRA,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
1008,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Resistance,Triple-receptor Negative Breast Cancer,Olaparib
1009,FIP1L1-PDGFRA,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Ponatinib
1010,FIP1L1-PDGFRA T674I,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Ponatinib
1011,G719,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1012,BRD4-NUTM1,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,NUT Midline Carcinoma,JQ1
1013,S720,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
1014,K757R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1015,E746G,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1016,Exon 20 Insertion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
1017,UGT1A1*28,"[{'id': 419, 'name': 'Belinostat', 'ncit_id': 'C48812', 'aliases': ['PXD101', 'PXD 101', 'Beleodaq']}]",A,Adverse Response,Cancer,Belinostat
1018,UGT1A1*60,"[{'id': 419, 'name': 'Belinostat', 'ncit_id': 'C48812', 'aliases': ['PXD101', 'PXD 101', 'Beleodaq']}]",B,Adverse Response,Cancer,Belinostat
1019,V769_770insASV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1020,DPYD*2A HOMOZYGOSITY,"[{'id': 421, 'name': 'Tegafur', 'ncit_id': 'C513', 'aliases': ['WR-220066', 'Utefos', 'Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-', 'Tefsiel', 'Sunfural', 'Sinoflurol', 'Riol', 'Nitobanil', 'Neberk', ""N1-(2'-Furanidyl)-5-fluorouracil"", 'MJF-12264', 'Lifril', 'Lamar', 'Futraful', 'Furofutran', 'Furafluor', 'Fulfeel', 'Fulaid', 'Ftoralon', 'Ftoral', 'Ftorafur', 'FT-207', 'FT', 'Fluorofur', 'Florafur', 'Fental', 'Exonal', 'Coparogin', 'Citofur', '5-Fluoro-1-(tetrahydro-2-furyl)-uracil', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",A,Adverse Response,Cancer,Tegafur+Capecitabine+Fluorouracil
1021,DPYD*13 HOMOZYGOSITY,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 421, 'name': 'Tegafur', 'ncit_id': 'C513', 'aliases': ['WR-220066', 'Utefos', 'Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-', 'Tefsiel', 'Sunfural', 'Sinoflurol', 'Riol', 'Nitobanil', 'Neberk', ""N1-(2'-Furanidyl)-5-fluorouracil"", 'MJF-12264', 'Lifril', 'Lamar', 'Futraful', 'Furofutran', 'Furafluor', 'Fulfeel', 'Fulaid', 'Ftoralon', 'Ftoral', 'Ftorafur', 'FT-207', 'FT', 'Fluorofur', 'Florafur', 'Fental', 'Exonal', 'Coparogin', 'Citofur', '5-Fluoro-1-(tetrahydro-2-furyl)-uracil', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione']}]",A,Adverse Response,Cancer,Capecitabine+Fluorouracil+Tegafur
1022,RS67376798 HOMOZYGOSITY,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 421, 'name': 'Tegafur', 'ncit_id': 'C513', 'aliases': ['WR-220066', 'Utefos', 'Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-', 'Tefsiel', 'Sunfural', 'Sinoflurol', 'Riol', 'Nitobanil', 'Neberk', ""N1-(2'-Furanidyl)-5-fluorouracil"", 'MJF-12264', 'Lifril', 'Lamar', 'Futraful', 'Furofutran', 'Furafluor', 'Fulfeel', 'Fulaid', 'Ftoralon', 'Ftoral', 'Ftorafur', 'FT-207', 'FT', 'Fluorofur', 'Florafur', 'Fental', 'Exonal', 'Coparogin', 'Citofur', '5-Fluoro-1-(tetrahydro-2-furyl)-uracil', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione', '5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",A,Adverse Response,Cancer,Capecitabine+Tegafur+Fluorouracil
1023,Exon 20 Insertion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Resistance,Lung Adenocarcinoma,Afatinib
1024,TNKS2-PDGFRA,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
1025,RS4149056,"[{'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}]",B,Adverse Response,Cancer,Methotrexate
1026,N130D,"[{'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}]",B,Adverse Response,Cancer,Methotrexate
1027,RS34743033,"[{'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}]",B,Adverse Response,Cancer,Methotrexate
1028,V855A,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib+Pertuzumab
1029,FGFR2-BICC1,"[{'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}, {'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",D,Sensitivity/Response,Cholangiocarcinoma,PD173074+Infigratinib
1030,FGFR2-AHCYL1,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}, {'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cholangiocarcinoma,Infigratinib+PD173074
1031,V253I,"[{'id': 423, 'name': 'Cixutumumab', 'ncit_id': 'C79828', 'aliases': []}, {'id': 246, 'name': 'Teprotumumab', 'ncit_id': 'C95797', 'aliases': []}]",C,Sensitivity/Response,Ewing Sarcoma Of Bone,Cixutumumab+Teprotumumab
1032,Overexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Resistance,Pancreatic Cancer,Gemcitabine
1033,OVEREXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Resistance,Pancreatic Cancer,Gemcitabine
1034,MUTATION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Glioblastoma,Pembrolizumab
1035,MUTATION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Endometrial Cancer,Pembrolizumab
1036,T790M,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Resistance,Lung Non-small Cell Carcinoma,Afatinib
1037,D1228V,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
1038,D1228V,"[{'id': 425, 'name': 'Savolitinib', 'ncit_id': 'C104732', 'aliases': ['Volitinib', 'HMPL-504', 'AZD6094', 'AZD 6094']}]",C,Resistance,Lung Non-small Cell Carcinoma,Savolitinib
1039,MUTATION,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Sensitivity/Response,Lung Small Cell Carcinoma,Chemotherapy
1040,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
1041,SQSTM1-NTRK1,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1042,ETV6-NTRK3,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,Entrectinib
1043,ETV6-NTRK3 G623R,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Resistance,Mammary Analogue Secretory Carcinoma,Entrectinib
1044,LOSS,"[{'id': 428, 'name': 'Anti-PD-1 Monoclonal Antibody MEDI0680', 'ncit_id': 'C113332', 'aliases': []}, {'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab
1045,LOSS,"[{'id': 428, 'name': 'Anti-PD-1 Monoclonal Antibody MEDI0680', 'ncit_id': 'C113332', 'aliases': []}, {'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab
1046,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 430, 'name': 'Linsitinib', 'ncit_id': 'C70982', 'aliases': ['OSI-906AA', 'OSI-906', 'IGF-1R Inhibitor OSI-906', 'Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, Cis-', 'Cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol']}]",D,Sensitivity/Response,Ewing Sarcoma,Palbociclib+Linsitinib
1047,LOSS,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 430, 'name': 'Linsitinib', 'ncit_id': 'C70982', 'aliases': ['OSI-906AA', 'OSI-906', 'IGF-1R Inhibitor OSI-906', 'Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, Cis-', 'Cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol']}]",D,Sensitivity/Response,Ewing Sarcoma,Palbociclib+Linsitinib
1048,Loss,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Palbociclib
1049,Y772_A775DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1050,G776L,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1051,G778_P780DUP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1052,G778_P780DUP,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1053,M774DELINSWLV,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1054,Loss-of-function,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 6473, 'name': 'Vatalanib', 'ncit_id': 'C1868', 'aliases': ['ZK-232934', 'PTK787/ZK 222584', 'PTK787', 'N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine', 'CGP-79787', 'CGP 79787']}]",D,Sensitivity/Response,Angiosarcoma,Sunitinib+Vatalanib
1055,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Ovarian Cancer,Rucaparib
1056,G12D,"[{'id': 685, 'name': 'Therapeutic Tumor Infiltrating Lymphocytes', 'ncit_id': 'C28699', 'aliases': ['Tumor Infiltrating Lymphocytes', 'Tumor Infiltrating Lymphocyte Therapy']}]",C,Sensitivity/Response,Colorectal Cancer,Therapeutic Tumor Infiltrating Lymphocytes
1057,COPY-NEUTRAL LOSS OF HETEROZYGOSITY,"[{'id': 685, 'name': 'Therapeutic Tumor Infiltrating Lymphocytes', 'ncit_id': 'C28699', 'aliases': ['Tumor Infiltrating Lymphocytes', 'Tumor Infiltrating Lymphocyte Therapy']}]",C,Resistance,Colorectal Cancer,Therapeutic Tumor Infiltrating Lymphocytes
1058,S703I,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",D,Sensitivity/Response,Hepatocellular Carcinoma,Ruxolitinib
1059,V600E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
1060,C121S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Vemurafenib+Irinotecan
1061,K57T,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Vemurafenib+Cetuximab+Irinotecan
1062,S490T,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Vemurafenib+Cetuximab+Irinotecan
1063,R201C,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
1064,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Mantle Cell Lymphoma,Olaparib
1065,Amplification,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Infigratinib
1066,Mutation,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Bladder Carcinoma,Infigratinib
1067,Mutation,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
1068,Fusion,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
1069,AMPLIFICATION,"[{'id': 434, 'name': 'Vistusertib', 'ncit_id': 'C88329', 'aliases': ['Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-', 'AZD2014', 'AZD-2014', 'AZD 2014']}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Vistusertib
1070,AMPLIFICATION,"[{'id': 435, 'name': 'Sapanisertib', 'ncit_id': 'C90548', 'aliases': ['TAK-228', 'MLN0128', 'MLN-0128', 'INK128', 'INK-128']}, {'id': 434, 'name': 'Vistusertib', 'ncit_id': 'C88329', 'aliases': ['Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-', 'AZD2014', 'AZD-2014', 'AZD 2014']}, {'id': 124, 'name': 'MTOR Kinase Inhibitor AZD8055', 'ncit_id': 'C78856', 'aliases': ['AZD8055']}]",D,Sensitivity/Response,Lung Small Cell Carcinoma,Sapanisertib+Vistusertib+MTOR Kinase Inhibitor AZD8055
1071,FGFR2-BICC1,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
1072,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",B,Sensitivity/Response,Cancer,Erdafitinib
1073,FGFR3-TACC3,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",B,Sensitivity/Response,Cancer,Erdafitinib
1074,FGFR2-BICC1,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",C,Sensitivity/Response,Endometrial Cancer,Erdafitinib
1075,OVEREXPRESSION,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}]",D,Resistance,Breast Cancer,Akt Inhibitor MK2206
1076,OVEREXPRESSION,"[{'id': 438, 'name': 'Pan-AKT Kinase Inhibitor GSK690693', 'ncit_id': 'C71711', 'aliases': ['GSK690693']}]",E,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Pan-AKT Kinase Inhibitor GSK690693
1077,Loss-of-function,"[{'id': 439, 'name': 'Pidnarulex', 'ncit_id': 'C126798', 'aliases': ['Pol I Inhibitor CX5461', 'RNA Pol I Inhibitor CX5461', 'CX5461', 'CX-5461', '5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-', '2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide', '2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide']}, {'id': 440, 'name': 'Quarfloxin', 'ncit_id': 'C71726', 'aliases': ['Quarfloxacin', 'CX-3543', '5-Fluoro-N-(2-((2S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-(3-(pyrazin-2- Yl)pyrrolidin-1-yl)-3H-benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide', '3H-Benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide, 5-fluoro-N-(2-((2S)- 1-methyl-2-pyrrolidinyl)ethyl)-3-oxo-6-(3-pyrazinyl-1-pyrrolidinyl)-']}]",D,Sensitivity/Response,Breast Cancer,Pidnarulex+Quarfloxin
1078,Loss-of-function,"[{'id': 439, 'name': 'Pidnarulex', 'ncit_id': 'C126798', 'aliases': ['Pol I Inhibitor CX5461', 'RNA Pol I Inhibitor CX5461', 'CX5461', 'CX-5461', '5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-', '2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide', '2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide']}, {'id': 440, 'name': 'Quarfloxin', 'ncit_id': 'C71726', 'aliases': ['Quarfloxacin', 'CX-3543', '5-Fluoro-N-(2-((2S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-(3-(pyrazin-2- Yl)pyrrolidin-1-yl)-3H-benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide', '3H-Benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide, 5-fluoro-N-(2-((2S)- 1-methyl-2-pyrrolidinyl)ethyl)-3-oxo-6-(3-pyrazinyl-1-pyrrolidinyl)-']}]",D,Sensitivity/Response,Breast Cancer,Pidnarulex+Quarfloxin
1079,Alternative Transcript (ATI),"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Skin Melanoma,Crizotinib
1080,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1081,G469R,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
1082,G469V,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
1083,MUTATION,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}, {'id': 441, 'name': 'Sotrastaurin Acetate', 'ncit_id': 'C80631', 'aliases': ['AEB071', 'AEB 071', '3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4- Yl)-1H-pyrrole-2,5-dione Acetate']}]",D,Sensitivity/Response,Uveal Melanoma,Mirdametinib+Sotrastaurin Acetate
1084,MUTATION,"[{'id': 441, 'name': 'Sotrastaurin Acetate', 'ncit_id': 'C80631', 'aliases': ['AEB071', 'AEB 071', '3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4- Yl)-1H-pyrrole-2,5-dione Acetate']}, {'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Uveal Melanoma,Sotrastaurin Acetate+Mirdametinib
1085,LOSS,"[{'id': 442, 'name': 'GPI-15427', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Head And Neck Cancer,GPI-15427
1086,Q61L,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Everolimus+Selumetinib
1087,Loss,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",D,Sensitivity/Response,Neuroblastoma,Binimetinib
1088,Loss,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Resistance,Melanoma,Dabrafenib
1089,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Plexiform Neurofibroma,Selumetinib
1090,EXPRESSION,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",D,Resistance,Estrogen-receptor Positive Breast Cancer,Tamoxifen
1091,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",C,Sensitivity/Response,Prostate Cancer,Olaparib
1092,D419del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1093,Biallelic Inactivation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",C,Sensitivity/Response,Prostate Cancer,Olaparib
1094,DELETION,"[{'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,Rhabdoid Cancer,Panobinostat
1095,DELETION,"[{'id': 446, 'name': 'C646', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,C646
1096,AMPLIFICATION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Hepatocellular Carcinoma,Sorafenib
1097,Expression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
1098,OVEREXPRESSION,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",B,Sensitivity/Response,Tenosynovial Giant Cell Tumor,Pexidartinib
1099,Overexpression,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Glioblastoma,Gefitinib
1100,Amplification,"[{'id': 252, 'name': 'Anti-EGFR Monoclonal Antibody', 'ncit_id': 'C133878', 'aliases': []}]",D,Resistance,Colorectal Cancer,Anti-EGFR Monoclonal Antibody
1101,P577S,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Melanoma,Imatinib+Crenolanib
1102,R841K,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Melanoma,Crenolanib+Imatinib
1103,H845Y,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Melanoma,Imatinib+Crenolanib
1104,G853D,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Melanoma,Crenolanib+Imatinib
1105,OVEREXPRESSION,"[{'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Resistance,Melanoma,PLX4720+Selumetinib
1106,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Crizotinib
1107,Underexpression,"[{'id': 450, 'name': 'Pyrimidine Antagonist', 'ncit_id': 'C1557', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pyrimidine Antagonist
1108,UNDEREXPRESSION,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Ovarian Cancer,Cetuximab
1109,OVEREXPRESSION,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",D,Resistance,Esophageal Cancer,Docetaxel+Fluorouracil
1110,OVEREXPRESSION,"[{'id': 451, 'name': 'Verteporfin', 'ncit_id': 'C1014', 'aliases': []}]",D,Sensitivity/Response,Esophageal Cancer,Verteporfin
1111,Expression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Chordoma,Lapatinib
1112,T316A,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",C,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
1113,T862A,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Stomach Carcinoma,Lapatinib
1114,V773A,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib
1115,N857S,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib
1116,H878Y,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Hepatocellular Carcinoma,Lapatinib
1117,Amplification,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",B,Sensitivity/Response,Stomach Carcinoma,FGFR Inhibitor AZD4547
1118,Amplification,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",C,Sensitivity/Response,Breast Cancer,FGFR Inhibitor AZD4547
1119,Overexpression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Lapatinib
1120,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1121,c.393T>C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1122,G12D,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1123,G12D,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1124,G12V,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1125,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1126,G12D,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1127,G12/G13,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab
1128,G12A,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1129,G12A,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1130,G12A,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1131,G12A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1132,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1133,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1134,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1135,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1136,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1137,G12A,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1138,R132L,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1139,R132L,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1140,R132L,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1141,R132,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,High Grade Glioma,Bevacizumab+Sunitinib
1142,R132L,"[{'id': 454, 'name': 'Ivosidenib', 'ncit_id': 'C114383', 'aliases': ['Tibsovo', 'AG-120']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1143,E542K,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1144,E542K,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pictilisib
1145,E545K,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pictilisib
1146,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
1147,E545K,"[{'id': 456, 'name': 'PI103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PI103
1148,G13D,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Resistance,Breast Cancer,Pictilisib
1149,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Breast Cancer,Trastuzumab
1150,Loss,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1151,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1152,E542K,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
1153,E545K,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1154,Amplification,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pictilisib
1155,Mutation,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Resistance,Breast Cancer,Trastuzumab
1156,C420R,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1157,K111N,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1158,Mutation,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Breast Cancer,Trastuzumab
1159,H1047L,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pictilisib
1160,H1047R,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1161,Mutation,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
1162,H1047R,"[{'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Pictilisib
1163,H1047R,"[{'id': 456, 'name': 'PI103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PI103
1164,V600E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
1165,V600E,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",B,Resistance,Colorectal Cancer,Oxaliplatin
1166,V600E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Resistance,Colorectal Cancer,Irinotecan
1167,V600E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Irinotecan
1168,V600E,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Resistance,Colorectal Cancer,Capecitabine+Oxaliplatin+Bevacizumab
1169,V600E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Melanoma,Sorafenib
1170,V600E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Melanoma,Sorafenib
1171,V600E,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Melanoma,Mirdametinib
1172,V600E,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Melanoma,Mirdametinib
1173,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Dabrafenib
1174,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Melanoma,Dabrafenib
1175,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Melanoma,Dabrafenib
1176,V600E,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Melanoma,Selumetinib
1177,V600E,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Melanoma,Selumetinib
1178,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Melanoma,Trametinib
1179,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Melanoma,Dabrafenib
1180,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Melanoma,Dabrafenib
1181,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Melanoma,Trametinib
1182,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Trametinib
1183,V600E,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",D,Sensitivity/Response,Thyroid Gland Cancer,MEK Inhibitor CI-1040
1184,V600E,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",B,Sensitivity/Response,Thyroid Gland Cancer,MEK Inhibitor CI-1040
1185,V600E,"[{'id': 463, 'name': 'RDEA 119', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1186,V600E,"[{'id': 463, 'name': 'RDEA 119', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1187,V600E,"[{'id': 463, 'name': 'RDEA 119', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1188,V600E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Sorafenib
1189,V600E,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Mirdametinib
1190,V600E,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,High Grade Glioma,Selumetinib
1191,V600E,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,High Grade Glioma,Selumetinib
1192,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1193,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1194,L747_S752del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1195,L747_S752del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1196,L747_S752del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1197,L747_S752del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1198,Mutation,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1199,L747_S752del,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1200,Ex19 del L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1201,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
1202,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1203,T790M,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1204,T790M,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Lung Non-small Cell Carcinoma,Lapatinib
1205,T790M,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1206,T790M,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
1207,T790M,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1208,T790M,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1209,T790M,"[{'id': 465, 'name': 'Canertinib', 'ncit_id': 'C77588', 'aliases': ['N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide', '2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Canertinib
1210,T790M,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
1211,BCR-ABL F359V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1212,BCR-ABL F359V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1213,BCR-ABL F359V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1214,BCR-ABL F359V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1215,Q61H,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1216,Q61H,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1217,Q61H,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1218,Q61H,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1219,Q61H,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1220,Q61H,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1221,Q61L,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1222,G13D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1223,Q61L,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1224,Q61L,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1225,Q61L,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
1226,Q61L,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1227,G13D,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1228,Q61R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1229,Q61R,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1230,Q61R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1231,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1232,Q61R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1233,Q61K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1234,Q61K,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1235,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
1236,Q61K,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1237,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1238,Q61K,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",B,Sensitivity/Response,Colorectal Cancer,Dactolisib
1239,Q61K,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1240,Q61K,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1241,G13C,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1242,G13C,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1243,G13C,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1244,G13C,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1245,G13R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1246,G13R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1247,G13R,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1248,A146T,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1249,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1250,G13R,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1251,A146V,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1252,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1253,G12C,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1254,G12C,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1255,G12C,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1256,G12S,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1257,G12S,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1258,G12D,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1259,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1260,G12S,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1261,T2666A,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1262,Mutation,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1263,R3008C,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1264,c.902-1G>T,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1265,A146P,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1266,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1267,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1268,Q61L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1269,Q61R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1270,Q61K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1271,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1272,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1273,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1274,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1275,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1276,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1277,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1278,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1279,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1280,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1281,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1282,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1283,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1284,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1285,G12D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Cancer,Gefitinib
1286,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1287,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1288,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1289,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1290,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1291,G12D,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1292,G12C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1293,G12C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1294,G12C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1295,G12C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1296,G12C,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1297,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1298,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1299,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1300,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1301,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1302,G12C,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1303,G12R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1304,G12R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1305,G12R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1306,G12R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1307,G12V,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Cancer,Gefitinib
1308,G12S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1309,G12S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1310,G12S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1311,G12S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1312,G12S,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1313,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1314,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1315,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",B,Resistance,Multiple Myeloma,Melphalan
1316,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1317,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1318,G12S,"[{'id': 328, 'name': 'Melphalan', 'ncit_id': 'C633', 'aliases': ['WR-19813', 'Sarkolysin', 'Sarcoclorin', 'Phenylalanine Nitrogen Mustard', 'Phenylalanine Mustard', 'P-di(chloroethyl)amino-L-phenylalanine', 'Melphalanum', 'L-Sarcolysine', 'L-Sarcolysin Phenylalanine Mustard', 'L-Sarcolysin', 'L-Phenylalanine Mustard', 'L-PAM', 'CB-3025', 'Alanine Nitrogen Mustard', '4-[bis(2-chloroethyl)amino]-L-phenylalanine']}]",D,Resistance,Multiple Myeloma,Melphalan
1319,R273L,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",C,Resistance,Ovarian Cancer,Cisplatin+Carboplatin
1320,Y220C,"[{'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}]",C,Sensitivity/Response,Stomach Carcinoma,Etoposide+Cisplatin+Mitomycin
1321,R175H,"[{'id': 468, 'name': 'EAP Protocol', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1322,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1323,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1324,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1325,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1326,LOSS,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1327,LOSS,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1328,LOSS,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1329,LOSS,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1330,LOSS,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1331,LOSS,"[{'id': 462, 'name': 'MEK Inhibitor CI-1040', 'ncit_id': 'C2670', 'aliases': ['PD-184352', 'PD 184352/CI-1040', 'CI-1040', '2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1332,R132H,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1333,R132H,"[{'id': 659, 'name': 'BPTES', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Brain Glioma,BPTES
1334,R132H,"[{'id': 472, 'name': 'Pan-Mutant-IDH1 Inhibitor Bay-1436032', 'ncit_id': 'C131690', 'aliases': ['BAY1436032', 'BAY-1436032', 'BAY 1436032', '3-(2-((4-(Trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic Acid']}]",D,Sensitivity/Response,Glioblastoma,Pan-Mutant-IDH1 Inhibitor Bay-1436032
1335,R132C,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1336,R132C,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1337,R132C,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1338,R132C,"[{'id': 473, 'name': 'AGI-5198', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,AGI-5198
1339,R132,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,High Grade Glioma,Bevacizumab
1340,R132C,"[{'id': 454, 'name': 'Ivosidenib', 'ncit_id': 'C114383', 'aliases': ['Tibsovo', 'AG-120']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1341,R132C,"[{'id': 659, 'name': 'BPTES', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,BPTES
1342,R132G,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1343,R132G,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1344,R132G,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1345,R132S,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1346,R132S,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1347,R132S,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Brain Glioma,Temozolomide
1348,R132S,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,High Grade Glioma,Bevacizumab
1349,R132S,"[{'id': 454, 'name': 'Ivosidenib', 'ncit_id': 'C114383', 'aliases': ['Tibsovo', 'AG-120']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1350,R1275Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Neuroblastoma,Crizotinib
1351,R1275Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Neuroblastoma,Crizotinib
1352,EML4-ALK L1196M,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
1353,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Resistance,Neuroblastoma,Crizotinib
1354,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Resistance,Neuroblastoma,Crizotinib
1355,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1356,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
1357,Y503_F504insAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1358,K550_W557del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1359,K550_K558del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1360,P551L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1361,M552_W557DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1362,Y553D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1363,Y553_K558DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1364,DEL 554-558,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1365,E554D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1366,T417_D419delinsY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1367,V555_Q556DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1368,V555_P573DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1369,W557R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1370,W557G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1371,W557T,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1372,W557_K558del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1373,W557_E561del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1374,K558Q,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1375,K558_V559del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1376,K558R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1377,V559DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1378,D816V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
1379,V559_V560DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1380,V559A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1381,V559G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1382,V560DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1383,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
1384,V560D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1385,K484_G487DEL,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1386,Exon 9 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1387,V560G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1388,V560G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1389,Exon 11 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1390,T574A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1391,V561D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1392,Exon 13 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1393,Q575L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1394,Exon 9 Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Imatinib
1395,D842V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1396,L576P,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1397,EXPRESSION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1398,P577L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1399,D579del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1400,Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1401,EXPRESSION,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1402,T661I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1403,T661I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1404,T661I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1405,T661I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1406,S692L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1407,S692L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1408,S692L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1409,S692L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1410,S692L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1411,Q694K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1412,Q694K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1413,Q694K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1414,Q694K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1415,Q694K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1416,V600E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Thyroid Gland Cancer,Sorafenib
1417,V600K,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Dabrafenib
1418,V600K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Trametinib
1419,V600K,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Dabrafenib
1420,G719A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1421,E746_A750del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1422,E746_A750del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1423,Wildtype,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1424,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,Erlotinib
1425,E746_A750del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1426,E746_A750del,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1427,E746_A750del,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1428,E746_A750del,"[{'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Durvalumab
1429,Exon 19 Deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1430,E746_T751>I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1431,E746_T751>I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1432,E746_T751>I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1433,E746_T751>I,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1434,E746_T751>I,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1435,E746_T751delinsA,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1436,E746_T751delinsA,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1437,E746_T751delinsA,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1438,E746V,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1439,E746V,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1440,E746V,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1441,E746V,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1442,E746V,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1443,L747_A750>P,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1444,L747_A750>P,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1445,L747_A750>P,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1446,L747_A750>P,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1447,L747_A750>P,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1448,L747_T751delLREAT,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1449,L747_T751>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1450,L747_T751>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1451,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1452,L747_T751>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1453,L747_T751>Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1454,L747_T751>Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1455,E746_S752>D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1456,E746_S752>D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1457,E746_S752>D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1458,E746_S752>D,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1459,E746_S752>D,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1460,L747_T751delinsP,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1461,L747_T751delinsP,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1462,L747_T751delinsP,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1463,L747_T751delinsP,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1464,L747_T751delinsP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1465,L747_T751delinsP,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1466,L747_T751delLREAT,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1467,L747_T751delLREAT,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1468,L747_T751delLREAT,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1469,L747_P753>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1470,L747_P753>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1471,L747_P753>Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1472,L747_P753>Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1473,L747_P753>Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1474,L747_T751delLREAT,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1475,L747_P753delinsS,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1476,L747_P753delinsS,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1477,L747_P753delinsS,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1478,L747_P753delinsS,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1479,L747_P753delinsS,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1480,S768I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1481,S768I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1482,S768I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1483,G719S,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1484,R831H,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1485,R831H,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1486,R831H,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1487,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1488,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1489,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1490,E746_A750del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1491,L858R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lapatinib
1492,L858R,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1493,L858R,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
1494,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1495,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1496,L858R,"[{'id': 465, 'name': 'Canertinib', 'ncit_id': 'C77588', 'aliases': ['N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide', '2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Canertinib
1497,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1498,L858R,"[{'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Durvalumab
1499,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1500,BCR-ABL M244V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1501,BCR-ABL M244V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Cancer,Imatinib
1502,BCR-ABL M244V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1503,BCR-ABL L248V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1504,BCR-ABL L248V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1505,BCR-ABL L248V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1506,BCR-ABL L248V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate+Nilotinib
1507,BCR-ABL G250E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1508,BCR-ABL G250E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1509,BCR-ABL G250E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1510,BCR-ABL G250E,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1511,BCR-ABL Q252H,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1512,BCR-ABL Q252H,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1513,BCR-ABL Q252H,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1514,BCR-ABL Y253H,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
1515,BCR-ABL Y253F,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1516,BCR-ABL E255V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1517,BCR-ABL Y253F,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1518,BCR-ABL E255K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1519,BCR-ABL E255K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1520,BCR-ABL E255K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1521,BCR-ABL E255K,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1522,BCR-ABL D276G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1523,BCR-ABL D276G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1524,BCR-ABL D276G,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1525,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1526,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1527,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1528,BCR-ABL T315I,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1529,BCR-ABL T315I,"[{'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Cancer,Bafetinib+Nilotinib+Imatinib+Dasatinib
1530,BCR-ABL T315I,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
1531,BCR-ABL T315I,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Lymphoblastic Leukemia,Ponatinib
1532,BCR-ABL F317L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1533,BCR-ABL F317L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1534,BCR-ABL F317L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1535,BCR-ABL F317L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1536,BCR-ABL S417Y,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1537,BCR-ABL F317L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1538,Overexpression,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Bafetinib
1539,BCR-ABL M351T,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1540,BCR-ABL M351T,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1541,BCR-ABL M351T,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1542,BCR-ABL M351T,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1543,BCR-ABL H396R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
1544,BCR-ABL H396R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1545,BCR-ABL H396R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
1546,L1600P,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1547,L1574P,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1548,Mutation,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1549,Mutation,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1550,Y234C,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",C,Resistance,Ovarian Cancer,Carboplatin+Cisplatin
1551,ALTERATION,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Ovarian Cancer,Carboplatin+Cisplatin
1552,DNA Binding Domain Mutation,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Resistance,Breast Cancer,Tamoxifen
1553,Mutation,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",C,Resistance,Breast Cancer,Tamoxifen
1554,Overexpression,"[{'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 325, 'name': 'Mitomycin', 'ncit_id': 'C1820', 'aliases': []}]",B,Sensitivity/Response,Stomach Cancer,Etoposide+Cisplatin+Mitomycin
1555,Q61P,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1556,Q61P,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Resistance,Colorectal Cancer,Irinotecan
1557,Q61E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1558,Q61E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Resistance,Colorectal Cancer,Irinotecan
1559,Q61FS,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1560,G464V,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Breast Cancer,Sorafenib
1561,K601E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1562,D594N,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1563,D594N,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1564,D594N,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1565,D594N,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1566,D594N,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1567,R282L,"[{'id': 468, 'name': 'EAP Protocol', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1568,R213P,"[{'id': 468, 'name': 'EAP Protocol', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1569,Mutation,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}]",C,Sensitivity/Response,Stomach Carcinoma,Doxorubicin+Cisplatin+Etoposide
1570,F1592S,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1571,L1600Q,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1572,L1585R,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1573,V1577A,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1574,V1577E,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1575,L1574Q,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1576,BCR-ABL F486S,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1577,c.7089+1del,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1578,c.7515+1_2del,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1579,K293*,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1580,R2459C,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1581,Q984E,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1582,F1025L,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1583,Q1084*,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1584,D1930V,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1585,R2034P,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1586,E2187*,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1587,L2427P,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1588,F2732V,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1589,R777FS,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1590,V1268FS,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1591,D1682H,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1592,A2062V,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1593,R1575H,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1594,A2274T,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1595,C2488Y,"[{'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1596,BCR-ABL E255V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1597,BCR-ABL E255V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1598,F1592C,"[{'id': 476, 'name': 'Prednisone', 'ncit_id': 'C770', 'aliases': ['Sterapred', 'SK-Prednisone', 'Servisone', 'Rayos', 'Promifen', 'Prednitone', 'Prednisonum', 'Prednisone Intensol', 'Predniment', 'Prednilonga', 'Prednidib', 'Prednicort', 'Prednicen-M', 'Predicorten', 'Predicor', 'Predeltin', 'PRED', 'Perrigo Prednisone', 'Paracort', 'Panasol-S', 'Panafcort', 'Orasone', 'Ofisolona', 'Meticorten', 'Metacortandracin', 'Meprosona-F', 'Lisacort', 'Liquid Pred', 'Econosone', 'Deltra', 'Deltison', 'Deltasone', 'Deltadehydrocortisone', 'Deltacortisone', 'Deltacortene', 'Delta-Dome', 'Delta 1-Cortisone', 'Decorton', 'Decortisyl', 'DeCortin', 'Dacortin', 'Cortancyl', 'Adasone', '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione', '1,2-Dehydrocortisone', '1, 2-Dehydrocortisone', '.delta.1-Cortisone']}]",C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1599,BCR-ABL E292V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1600,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1601,S501_A502INSAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1602,S501_A502INSAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1603,S501_A502INSAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1604,S501_A502INSAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1605,E746_T751delinsVA,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1606,BCR-ABL L384M,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1607,BCR-ABL V299L,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1608,BCR-ABL L387F,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1609,BCR-ABL G398R,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1610,EML4-ALK S1206Y,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
1611,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Ovarian Cancer,Rucaparib
1612,Q1467*,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1613,M1R,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1614,M1I,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1615,V159M,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1616,V211L,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1617,V211I,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1618,R2336P,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1619,D820Y,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Melanoma,Imatinib
1620,D820Y,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Melanoma,Sunitinib
1621,K642E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Mucosal Melanoma,Imatinib
1622,V600E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Sorafenib+Cetuximab
1623,c.393T>C,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Esophageal Cancer,Fluorouracil+Cisplatin
1624,Underexpression,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Glioblastoma,Temozolomide
1625,OVEREXPRESSION,"[{'id': 478, 'name': 'UO126', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,UO126
1626,Underexpression,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,High Grade Glioma,Temozolomide
1627,Underexpression,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Oligodendroglioma,Temozolomide
1628,Underexpression,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Glioblastoma,Temozolomide
1629,Underexpression,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Sensitivity/Response,Neuroendocrine Tumor,Temozolomide
1630,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
1631,Q61K,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Trametinib
1632,Q61K,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Cancer,Selumetinib+Trametinib
1633,EXPRESSION,"[{'id': 479, 'name': 'Erlotinib Hydrochloride', 'ncit_id': 'C2693', 'aliases': ['Tarceva', 'OSI-774', 'N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride', 'CP-358,774']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib Hydrochloride
1634,OVEREXPRESSION,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
1635,EXPRESSION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
1636,Expression,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}, {'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}, {'id': 480, 'name': 'FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Sarcoma,"Infigratinib+FGFR Inhibitor AZD4547+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
1637,AMPLIFICATION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 365, 'name': 'Ipilimumab', 'ncit_id': 'C2654', 'aliases': []}]",B,Adverse Response,Cancer,Pembrolizumab+Nivolumab+Ipilimumab
1638,EXPRESSION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Adverse Response,Cancer,Atezolizumab+Pembrolizumab+Nivolumab
1639,N822K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1640,Y823D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1641,C809G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1642,D820A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1643,D820G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1644,D816H,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1645,T670I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1646,AMPLIFICATION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Adverse Response,Cancer,Atezolizumab+Nivolumab+Pembrolizumab
1647,Mutation,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Resistance,Cancer,Pembrolizumab+Nivolumab+Atezolizumab
1648,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}]",B,Resistance,Colorectal Cancer,Cetuximab+Encorafenib
1649,Amplification,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Dabrafenib+Panitumumab
1650,F53L,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Colorectal Cancer,Trametinib+Dabrafenib
1651,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",B,Sensitivity/Response,Skin Melanoma,Binimetinib+Ribociclib
1652,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Brain Glioma,Olaparib
1653,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Brain Glioma,Olaparib
1654,G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
1655,K57N,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Selumetinib
1656,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",B,Sensitivity/Response,Skin Melanoma,Binimetinib
1657,G12,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Resistance,Lung Cancer,Gefitinib
1658,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Cancer,Gefitinib
1659,Overexpression,"[{'id': 1958, 'name': 'Letetresgene Autoleucel', 'ncit_id': 'C121379', 'aliases': ['Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794', 'NY-ESO-1c259 T Cells GSK3377794', 'Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794', 'Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794', 'Autologous T-Cells Expressing Enhanced TCRs Specific For NY-ESO-1/LAGE-1a GSK3377794']}]",B,Sensitivity/Response,Multiple Myeloma,Letetresgene Autoleucel
1660,Overexpression,"[{'id': 1958, 'name': 'Letetresgene Autoleucel', 'ncit_id': 'C121379', 'aliases': ['Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794', 'NY-ESO-1c259 T Cells GSK3377794', 'Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794', 'Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794', 'Autologous T-Cells Expressing Enhanced TCRs Specific For NY-ESO-1/LAGE-1a GSK3377794']}]",B,Sensitivity/Response,Multiple Myeloma,Letetresgene Autoleucel
1661,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1662,A146T,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}]",D,Sensitivity/Response,Colorectal Cancer,Mirdametinib
1663,AMPLIFICATION,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1664,AMPLIFICATION,"[{'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sonidegib+Gefitinib
1665,Fusion,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1666,Fusion,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",B,Sensitivity/Response,Cancer,Entrectinib
1667,Fusion,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",B,Sensitivity/Response,Cancer,Entrectinib
1668,SQSTM1-NTRK1,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1669,REARRANGEMENT,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",B,Sensitivity/Response,Cancer,Entrectinib
1670,Fusion,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",B,Sensitivity/Response,Cancer,Entrectinib
1671,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Cancer,Larotrectinib
1672,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",B,Sensitivity/Response,Cancer,Larotrectinib
1673,LMNA::NTRK1 e2-e11,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
1674,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
1675,OVEREXPRESSION,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,JQ1
1676,LMNA::NTRK1 e11-e10,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Colorectal Adenocarcinoma,Entrectinib
1677,LMNA-NTRK1 G595R and G667C,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Resistance,Colorectal Adenocarcinoma,Entrectinib
1678,Wildtype,"[{'id': 488, 'name': 'Nutlin-3a', 'ncit_id': 'C74594', 'aliases': []}]",D,Sensitivity/Response,Cancer,Nutlin-3a
1679,Wildtype,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Sensitivity/Response,Cancer,MDM2 Inhibitor AMGMDS3
1680,Wildtype,"[{'id': 491, 'name': 'RG7112', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Leukemia,RG7112
1681,Deleterious Mutation,"[{'id': 491, 'name': 'RG7112', 'ncit_id': None, 'aliases': []}]",B,Resistance,Leukemia,RG7112
1682,Deleterious Mutation,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
1683,Deleterious Mutation,"[{'id': 488, 'name': 'Nutlin-3a', 'ncit_id': 'C74594', 'aliases': []}]",D,Resistance,Cancer,Nutlin-3a
1684,CYTOPLASMIC EXPRESSION,"[{'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 492, 'name': 'Eribulin', 'ncit_id': 'C96748', 'aliases': ['ER-086526', ""2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one""]}]",B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Carboplatin+Eribulin
1685,Q61H,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Colorectal Cancer,Panitumumab+Trametinib
1686,K57T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1687,M511I,"[{'id': 493, 'name': 'Tofacitinib', 'ncit_id': 'C95800', 'aliases': ['Tasocitinib', 'CP-690550', 'CP-690,550 Free Base', '3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile']}]",D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Tofacitinib
1688,V722I,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Atezolizumab
1689,S61C,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Atezolizumab
1690,P429S,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Melanoma,Pembrolizumab
1691,W690*,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Colon Carcinoma,Pembrolizumab
1692,LOSS-OF-FUNCTION,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
1693,LOSS-OF-FUNCTION,"[{'id': 362, 'name': 'GSK126', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,GSK126
1694,E545K,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 141, 'name': 'Pictilisib', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Cervix Carcinoma,Cisplatin+Pictilisib
1695,E545K,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Cervical Cancer,Cisplatin
1696,F1245V,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Neuroblastoma,Entrectinib
1697,Activating Mutation,"[{'id': 496, 'name': 'Anti-PD-L1 Monoclonal Antibody', 'ncit_id': 'C128057', 'aliases': []}, {'id': 495, 'name': 'Anti-CTLA-4 Monoclonal Antibody', 'ncit_id': 'C128036', 'aliases': []}]",D,Resistance,Melanoma,Anti-PD-L1 Monoclonal Antibody+Anti-CTLA-4 Monoclonal Antibody
1698,OVEREXPRESSION,"[{'id': 497, 'name': 'UNC1062', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Melanoma,UNC1062
1699,Overexpression,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",D,Sensitivity/Response,Estrogen-receptor Negative Breast Cancer,Vandetanib
1700,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1701,Exon 19 Deletion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1702,Exon 19 Deletion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1703,L858R,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1704,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",A,Resistance,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
1705,Expression,"[{'id': 360, 'name': 'Radiation Therapy', 'ncit_id': 'C15313', 'aliases': ['ENERGY_TYPE', 'Radiation Therapy, NOS', 'Therapy, Radiation', 'RT', 'RADIOTHERAPY', 'Radiotherapeutics', 'RADIATION', 'Irradiation', 'Irradiated', 'Irradiate', 'Cancer Radiotherapy']}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Radiation Therapy
1706,OVEREXPRESSION,"[{'id': 438, 'name': 'Pan-AKT Kinase Inhibitor GSK690693', 'ncit_id': 'C71711', 'aliases': ['GSK690693']}]",D,Resistance,Breast Cancer,Pan-AKT Kinase Inhibitor GSK690693
1707,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 502, 'name': 'Prexasertib', 'ncit_id': 'C91392', 'aliases': ['LY2606368', '2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)-']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Lung Small Cell Carcinoma,Cisplatin+Prexasertib+Olaparib
1708,L755S,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
1709,L755P,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
1710,T798M,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
1711,D835V,"[{'id': 503, 'name': 'Tandutinib', 'ncit_id': 'C48404', 'aliases': ['MLN518', 'MLN 518', 'CT53518', '1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Tandutinib
1712,D835V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib+Cytarabine
1713,D835V,"[{'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin+Sunitinib
1714,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}]",B,Resistance,Ovarian Cancer,Cisplatin+Carboplatin
1715,Amplification,"[{'id': 91, 'name': 'Rociletinib', 'ncit_id': 'C99905', 'aliases': ['N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide', 'CO-1686']}, {'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Rociletinib+Osimertinib
1716,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1717,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
1718,Q61L,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Selumetinib
1719,Q61R,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Selumetinib
1720,L768S,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Trastuzumab
1721,L638S,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib
1722,V773,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,Trastuzumab
1723,V773L,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib
1724,K753E,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
1725,L753E,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Breast Cancer,Trastuzumab
1726,K755S,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Resistance,Breast Cancer,Trastuzumab
1727,Amplification,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dovitinib
1728,V559D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1729,V559D,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 507, 'name': 'PD-180970', 'ncit_id': None, 'aliases': []}, {'id': 503, 'name': 'Tandutinib', 'ncit_id': 'C48404', 'aliases': ['MLN518', 'MLN 518', 'CT53518', '1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Cancer,Dasatinib+Sunitinib+PD-180970+Tandutinib+Imatinib
1730,V559,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Gastrointestinal System Cancer,Imatinib+Dasatinib
1731,D835V,"[{'id': 510, 'name': 'JQ-1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Myeloid Leukemia,JQ-1
1732,V559D,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Nilotinib+Sorafenib+Dasatinib+Imatinib
1733,D835V,"[{'id': 511, 'name': 'AS602868', 'ncit_id': None, 'aliases': []}, {'id': 58, 'name': 'Tyrphostin AG 1296', 'ncit_id': 'C1731', 'aliases': ['AG 1296']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,AS602868+Tyrphostin AG 1296
1734,G13V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
1735,L3 Domain Mutation,"[{'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Resistance,Breast Cancer,Tamoxifen
1736,Overexpression,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}, {'id': 657, 'name': 'C-Met Inhibitor', 'ncit_id': 'C143099', 'aliases': []}, {'id': 658, 'name': 'ERBB3 Inhibitor', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Uveal Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+C-Met Inhibitor+ERBB3 Inhibitor
1737,Overexpression,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Uveal Melanoma,Selumetinib+Trametinib
1738,E17K,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",B,Sensitivity/Response,Cancer,Capivasertib
1739,Mutation,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",B,Sensitivity/Response,Cancer,Capivasertib
1740,R248Q,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
1741,R201H,"[{'id': 516, 'name': 'Radioactive Iodine', 'ncit_id': 'C2462', 'aliases': []}]",C,Sensitivity/Response,Thyroid Gland Follicular Carcinoma,Radioactive Iodine
1742,MUTATION,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",B,Sensitivity/Response,Uveal Melanoma,Cabozantinib
1743,Overexpression,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Uveal Melanoma,Selumetinib+Trametinib
1744,EXPRESSION,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",D,Sensitivity/Response,Melanoma,Pertuzumab
1745,NON-AMPLIFICATION,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Lapatinib
1746,Overexpression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Breast Cancer,Lapatinib
1747,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1748,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1749,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1750,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1751,C634W,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Thyroid Gland Medullary Carcinoma,Axitinib
1752,C634W,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
1753,M918T,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Thyroid Gland Medullary Carcinoma,Axitinib
1754,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Head And Neck Cancer,Erlotinib
1755,G12D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1756,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1757,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1758,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1759,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1760,Mutation,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1761,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1762,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1763,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1764,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1765,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1766,G12A,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
1767,G12A,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
1768,G12A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Cancer,Erlotinib
1769,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 246, 'name': 'Teprotumumab', 'ncit_id': 'C95797', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Teprotumumab
1770,G12A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1771,G12A,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Regorafenib
1772,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
1773,R132,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,Cetuximab
1774,E545K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1775,E545G,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1776,H1047R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Colorectal Cancer,Vemurafenib
1777,W535L,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
1778,W535L,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
1779,V600E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1780,V600E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
1781,V600E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 538, 'name': 'FOLFOX-4 Regimen', 'ncit_id': 'C63590', 'aliases': ['Folinic Acid-Fluororuracil-Oxaliplatin-4 Regimen']}]",B,Resistance,Colorectal Cancer,Cetuximab+FOLFOX-4 Regimen
1782,V600E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1783,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Colorectal Cancer,Vemurafenib
1784,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Colorectal Cancer,Vemurafenib
1785,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 360, 'name': 'Radiation Therapy', 'ncit_id': 'C15313', 'aliases': ['ENERGY_TYPE', 'Radiation Therapy, NOS', 'Therapy, Radiation', 'RT', 'RADIOTHERAPY', 'Radiotherapeutics', 'RADIATION', 'Irradiation', 'Irradiated', 'Irradiate', 'Cancer Radiotherapy']}]",C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib+Radiation Therapy
1786,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib
1787,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1788,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1789,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1790,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1791,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
1792,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
1793,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1794,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1795,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1796,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
1797,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
1798,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
1799,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
1800,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
1801,V600E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Melanoma,Dasatinib
1802,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Vemurafenib
1803,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
1804,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,High Grade Glioma,Vemurafenib
1805,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1806,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1807,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1808,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1809,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1810,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1811,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1812,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1813,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Glioblastoma,Vemurafenib
1814,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Pilocytic Astrocytoma,Vemurafenib
1815,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
1816,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
1817,V600E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Dasatinib
1818,V600E,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Colon Cancer,Regorafenib
1819,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Vemurafenib
1820,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Ganglioglioma,Vemurafenib
1821,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Clear Cell Sarcoma,Vemurafenib
1822,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1823,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1824,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1825,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1826,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Thyroid Gland Carcinoma,Vemurafenib
1827,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Thyroid Gland Carcinoma,Vemurafenib
1828,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Pleomorphic Xanthoastrocytoma,Vemurafenib
1829,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Ovarian Serous Carcinoma,Vemurafenib
1830,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,Vemurafenib
1831,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Histiocytoma,Vemurafenib
1832,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Malignant Conjunctival Melanoma,Vemurafenib
1833,Ex19 del L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1834,E709_T710>D,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1835,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1836,L747_S752del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1837,Overexpression,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1838,L747_S752del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1839,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1840,L861Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1841,S752_I759delSPKANKEI,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1842,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
1843,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1844,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1845,T790M,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1846,T790M,"[{'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Cancer,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib
1847,L858R,"[{'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib
1848,E884K,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
1849,BCR-ABL F359V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
1850,BCR-ABL F359V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
1851,BCR-ABL F359V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
1852,BCR-ABL F359V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
1853,BCR-ABL F359V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
1854,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1855,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1856,Q61L,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1857,V600E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1858,Q61R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1859,Q61R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
1860,Q61R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
1861,Q61K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1862,Q61K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1863,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1864,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1865,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
1866,Q61K,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1867,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1868,H1047R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1869,G13R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab
1870,G13R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
1871,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1872,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1873,G1049R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1874,Q61L,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1875,Q61R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1876,Q61K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1877,G13D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1878,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1879,G13R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
1880,G12V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Head And Neck Cancer,Erlotinib
1881,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1882,A146P,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1883,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1884,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 538, 'name': 'FOLFOX-4 Regimen', 'ncit_id': 'C63590', 'aliases': ['Folinic Acid-Fluororuracil-Oxaliplatin-4 Regimen']}]",B,Resistance,Colorectal Cancer,Cetuximab+FOLFOX-4 Regimen
1885,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1886,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1887,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1888,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1889,Q61H,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1890,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Cancer,Erlotinib
1891,Q61H,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Vemurafenib
1892,Q61L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1893,Q61L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1894,Q61L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1895,Q61R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1896,Q61R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1897,Q61K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1898,Q61K,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1899,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1900,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1901,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1902,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1903,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1904,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1905,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1906,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1907,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1908,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1909,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1910,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1911,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1912,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1913,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1914,G13D,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
1915,G13D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
1916,G13D,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1917,G13D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1918,G13D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1919,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1920,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
1921,G13D,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Colon Cancer,Regorafenib
1922,G13C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1923,G13C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1924,G13C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1925,G13C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1926,G13R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1927,G13R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1928,G13S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1929,G13S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1930,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1931,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1932,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1933,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1934,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1935,Q61,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1936,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1937,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1938,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1939,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1940,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1941,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1942,G12V,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
1943,G12V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
1944,G12V,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1945,G12V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1946,G12V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1947,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
1948,G12V,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Colon Cancer,Regorafenib
1949,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1950,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1951,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1952,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1953,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
1954,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1955,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1956,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1957,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1958,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1959,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1960,G12D,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
1961,G12D,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Resistance,Colorectal Cancer,Regorafenib
1962,G12D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
1963,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Cancer,Erlotinib
1964,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Cancer,Erlotinib
1965,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Cancer,Erlotinib
1966,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Cancer,Erlotinib
1967,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Cancer,Erlotinib
1968,G12D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1969,G12D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
1970,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Ovarian Cancer,Cetuximab
1971,G12D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Pancreatic Cancer,Vemurafenib
1972,G12D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
1973,G12D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1974,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1975,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1976,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1977,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1978,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1979,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1980,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1981,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1982,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1983,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1984,G12C,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
1985,G12C,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
1986,G12C,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1987,G12C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1988,G12C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1989,G12C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
1990,G12C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
1991,G12C,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1992,G12C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
1993,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1994,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1995,G12R,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1996,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1997,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
1998,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
1999,G12R,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2000,G12R,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
2001,G12R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2002,G12R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2003,G12R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Thyroid Gland Cancer,Dasatinib
2004,G12R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colon Cancer,Cetuximab
2005,G12R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
2006,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2007,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2008,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2009,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2010,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2011,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2012,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2013,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2014,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2015,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2016,G12S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2017,G12S,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2018,G12S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2019,G12S,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Colorectal Cancer,Sunitinib
2020,G12S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2021,G12S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2022,G12S,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Vemurafenib
2023,G12S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Lung Squamous Cell Carcinoma,Dasatinib
2024,D835E,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2025,D835V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2026,D835V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2027,D835,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2028,D835,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2029,D835,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2030,D835H,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2031,D835H,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2032,E17K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2033,F57C,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2034,R132,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,Cetuximab
2035,R132S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,Cetuximab
2036,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2037,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2038,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2039,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2040,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2041,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Adenocarcinoma,Crizotinib
2042,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2043,F1174L,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2044,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2045,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2046,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2047,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2048,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2049,N345K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2050,K650E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Skin Melanoma,Vemurafenib
2051,D842V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Dasatinib
2052,D842V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2053,D842V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2054,D842V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Cancer,Sunitinib
2055,V560_L576DEL,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2056,K550_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2057,K550_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2058,Y553_K558DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2059,Y553_K558DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2060,Exon 11 Mutation,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2061,DEL 554-558,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2062,W557G,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2063,W557_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2064,W557_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2065,W557_K558del,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Ponatinib
2066,W557_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2067,W557_K558del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Regorafenib
2068,W557_E561del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2069,W557_E561del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2070,K558_V559del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2071,K558_V559del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2072,V559DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2073,Exon 9 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Regorafenib
2074,V559_V560DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2075,V559_V560DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2076,V559D,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Melanoma,Dasatinib
2077,V559D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2078,V559D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2079,V559D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2080,V559D,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Solid Tumor,Dasatinib
2081,V559G,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Thymus Squamous Cell Carcinoma,Sunitinib
2082,V560DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2083,V560DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2084,V560D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2085,V560D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2086,V560D,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2087,P551_E554delPMYE,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
2088,V560D,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Ponatinib+Regorafenib+Sunitinib
2089,V560G,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2090,V560G,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2091,V560G,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2092,V560G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2093,L576P,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2094,L576P,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2095,Exon 9 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Regorafenib
2096,L576P,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Cancer,Imatinib+Dasatinib
2097,D579del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2098,D579del,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2099,WILDTYPE,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2100,K642E,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2101,K642E,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2102,K642E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Melanoma,Dasatinib
2103,V654A,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2104,V654A,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2105,V654A,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2106,D816H,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2107,D816H,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2108,D816H,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2109,D816H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2110,D816Y,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2111,D816Y,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2112,D816G,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2113,D816G,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2114,D816V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Dasatinib
2115,D816V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2116,D816V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2117,D816V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2118,D816V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2119,D820A,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2120,D820G,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2121,N822K,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2122,N822K,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2123,N822K,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2124,V600R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2125,V600R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2126,V600R,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Skin Melanoma,Vemurafenib
2127,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2128,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2129,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2130,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2131,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
2132,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2133,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2134,V600K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Melanoma,Vemurafenib
2135,V600K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
2136,G469A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2137,G469A,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2138,G469A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2139,S768I,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2140,R108K,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2141,T263P,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2142,A289V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2143,G719,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2144,G719S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2145,G719S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2146,G719S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2147,G719A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2148,G719A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2149,G719A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2150,G719A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2151,V742A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2152,E746_A750del,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2153,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2154,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2155,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2156,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2157,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2158,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2159,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2160,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2161,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Hematologic Cancer,Erlotinib
2162,E746_T751>I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2163,G719D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2164,E746_T751>I,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2165,Expression,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2166,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2167,E746_A750del,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cetuximab
2168,E746_T751delinsA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2169,E746_T751delinsA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2170,V774A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2171,E746_S752>A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2172,E746V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2173,V834I,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2174,L838P,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2175,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Cancer,Erlotinib
2176,L747_P753delinsS,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2177,L747_P753delinsS,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2178,L747_P753delinsS,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2179,S768N,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2180,S768N,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2181,S768I,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2182,D770_N771insSVD,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2183,H773_V774insH,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2184,R831H,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2185,L838V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2186,P848L,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2187,T854A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2188,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2189,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Cancer,Erlotinib
2190,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2191,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2192,L858R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2193,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2194,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2195,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Small Cell Carcinoma,Erlotinib
2196,L858R,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
2197,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2198,A859T,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2199,A859T,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2200,L861,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2201,L861Q,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2202,L861R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2203,E868G,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2204,BCR-ABL M244V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2205,BCR-ABL M244V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2206,BCR-ABL L248V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2207,BCR-ABL L248V,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2208,BCR-ABL G250E,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2209,BCR-ABL G250E,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2210,BCR-ABL G250E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2211,BCR-ABL G250E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2212,BCR-ABL G250E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2213,BCR-ABL G250E,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2214,BCR-ABL G250E,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2215,BCR-ABL Q252H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2216,BCR-ABL Q252H,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2217,BCR-ABL Q252H,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2218,BCR-ABL Q252H,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2219,BCR-ABL Q252H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2220,BCR-ABL Q252H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2221,BCR-ABL Y253H,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2222,BCR-ABL Y253H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2223,BCR-ABL Y253H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2224,BCR-ABL Y253H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2225,BCR-ABL Y253F,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2226,BCR-ABL Y253F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2227,BCR-ABL Y253F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2228,BCR-ABL Y253F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2229,BCR-ABL Y253F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2230,BCR-ABL Y253F,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2231,BCR-ABL E255K,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2232,BCR-ABL E255K,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2233,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2234,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2235,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2236,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2237,BCR-ABL E255K,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2238,BCR-ABL D276G,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2239,BCR-ABL D276G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2240,BCR-ABL D276G,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2241,BCR-ABL T315I,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2242,BCR-ABL T315I,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2243,BCR-ABL T315I,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2244,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",B,Resistance,Chronic Myeloid Leukemia,Dasatinib
2245,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2246,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2247,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2248,BCR-ABL T315I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2249,BCR-ABL T315I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2250,BCR-ABL T315I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2251,BCR-ABL T315I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2252,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2253,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2254,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2255,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2256,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2257,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2258,BCR-ABL F317L,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2259,BCR-ABL F317L,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2260,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2261,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2262,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2263,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2264,BCR-ABL M244V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2265,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2266,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2267,BCR-ABL F317L,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2268,BCR-ABL F317L,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2269,BCR-ABL M351T,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2270,BCR-ABL M351T,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2271,BCR-ABL M351T,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2272,BCR-ABL M351T,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2273,BCR-ABL M351T,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2274,BCR-ABL M351T,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2275,BCR-ABL E355G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2276,BCR-ABL E355G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2277,BCR-ABL L387M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2278,BCR-ABL H396R,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2279,BCR-ABL H396R,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2280,BCR-ABL H396R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2281,BCR-ABL H396R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2282,BCR-ABL H396R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2283,BCR-ABL H396R,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2284,G13V,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
2285,P278S,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
2286,FIP1L1-PDGFRA T674I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Dasatinib
2287,Q61P,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2288,Q61E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2289,Q61FS,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2290,K117N,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Clear Cell Sarcoma,Vemurafenib
2291,F595L,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Histiocytoma,Vemurafenib
2292,D473H,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Medulloblastoma,Vismodegib
2293,Y772_A775DUP,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Bosutinib
2294,G12A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2295,F1174C,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2296,T1151M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2297,H1047L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2298,S438C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2299,BCR-ABL,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Acute Lymphoblastic Leukemia,Dasatinib
2300,E450G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2301,BCR-ABL F486S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2302,BCR-ABL F486S,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2303,BCR-ABL E255V,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2304,BCR-ABL E255V,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2305,BCR-ABL E255V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2306,BCR-ABL E255V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2307,BCR-ABL E255V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2308,BCR-ABL E255V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2309,BCR-ABL E255V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2310,V777L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2311,P551_E554delPMYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2312,P551_E554delPMYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2313,P551_E554delPMYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2314,V559D,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib+Regorafenib+Imatinib
2315,W557_V559insC,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2316,W557_V559insC,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2317,S158L,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2318,G12V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2319,R93W,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Oxaliplatin+Fluorouracil+Cetuximab
2320,R776C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2321,S784F,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2322,R505C,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2323,R505H,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2324,D594G,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2325,F1174V,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2326,BCR-ABL E292V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2327,L298V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2328,BCR-ABL F311I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2329,BCR-ABL F311I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2330,BCR-ABL F359C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2331,BCR-ABL L364I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2332,Q456*,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
2333,V600D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2334,V600D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2335,S768_D770dup,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2336,D770_N771insNPG,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Hematologic Cancer,Erlotinib
2337,D770_N771insNPG,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Hematologic Cancer,Cetuximab
2338,H773_V774insNPH,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2339,D770_N771insGL,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2340,A864T,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2341,N826S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2342,A763_Y764insFQEA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2343,Q79K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2344,G466A,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
2345,VIII,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,High Grade Glioma,Erlotinib
2346,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2347,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2348,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2349,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2350,A502_Y503insAY,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
2351,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2352,S501_A502INSAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2353,G13V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2354,T670I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Solid Tumor,Dasatinib
2355,T670I,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2356,D842_M844del,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Dasatinib
2357,L861Q,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2358,S310F/Y,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2359,L755S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2360,V842I,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2361,E17K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2362,Q2223K,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Temsirolimus
2363,W110*,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Melanoma,Palbociclib
2364,A20P,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Melanoma,Palbociclib
2365,BCR-ABL L384M,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2366,BCR-ABL L384M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2367,BCR-ABL L384M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2368,BCR-ABL M343T,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2369,BCR-ABL F317V,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
2370,BCR-ABL F317V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2371,BCR-ABL V299L,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2372,BCR-ABL V299L,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2373,BCR-ABL V299L,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2374,BCR-ABL V299L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2375,BCR-ABL V299L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2376,BCR-ABL E279K,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2377,BCR-ABL E279K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2378,BCR-ABL F311L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2379,BCR-ABL F311L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2380,BCR-ABL N331S,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2381,BCR-ABL L387F,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2382,BCR-ABL L387F,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2383,BCR-ABL H396P,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2384,BCR-ABL H396P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2385,BCR-ABL H396P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2386,BCR-ABL H396P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2387,BCR-ABL G398R,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2388,BCR-ABL G398R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2389,BCR-ABL I432T,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2390,BCR-ABL E450V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2391,BCR-ABL E453K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2392,F486Y,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2393,F486Y,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2394,BCR-ABL F486S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2395,F486Y,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2396,W559_R560DELWR,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2397,L579M,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2398,Q556_I571DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2399,Y553_W557DELYEVQW,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2400,V555_I571DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2401,E611_F612INS25,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2402,E611_F612INS25,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2403,K550_W557del,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib+Ponatinib+Imatinib+Sunitinib
2404,T417_D419DELTYDINSI,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2405,D579_H580insIDPTQLPYD,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2406,Y570_L576DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2407,Y570_L576DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2408,D820Y,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2409,K558NP,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2410,K558NP,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Regorafenib+Ponatinib+Imatinib
2411,N822K,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2412,D842V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2413,V560_L576DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2414,Exon 11 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2415,V569_L576DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2416,V569_L576DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2417,Exon 15 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",C,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2418,E278E,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
2419,EML4-ALK T1151INST,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2420,L1196Q,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2421,ALK Fusion I1171,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2422,ALK Fusion I1171,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2423,ALK Fusion I1171,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2424,L1152P,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2425,G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2426,G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2427,G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2428,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2429,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2430,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2431,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2432,EML4-ALK G1269A,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2433,EML4-ALK S1206Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2434,W1815X,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Endometrioid Ovary Carcinoma,Olaparib
2435,ALK Fusion G1202R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2436,ALK Fusion G1202R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2437,L1198P,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2438,G776INSV_G/C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2439,Exon 9 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2440,Exon 11 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2441,D816E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib+Sunitinib
2442,HIP1-ALK I1171N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2443,HIP1-ALK I1171N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2444,D473G,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2445,D473Y,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2446,S278I,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2447,W281C,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2448,W281C,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2449,Q477E,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2450,D770_N771insSVD,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2451,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2452,D770_N771insGT,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2453,V774_C775insHV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2454,Exon 20 Insertion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Adenocarcinoma,Gefitinib
2455,A763_Y764insFQEA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2456,A763_Y764insFQEA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2457,V769_770insASV,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Resistance,Lung Adenocarcinoma,Gefitinib
2458,Exon 20 Insertion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2459,D770_N771insNPG,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2460,L412F,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2461,L412F,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2462,L412F,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2463,W731L,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2464,E734Q,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2465,T785A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2466,C797Y,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2467,Y801H,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2468,V321M,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2469,V321M,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2470,V321M,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2471,E709_T710>D,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2472,V769A,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2473,A767_V769dupASV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2474,A767_V769dupASV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2475,L747_S752delinsQ,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2476,L861R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2477,N771>GY,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2478,P546S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Cetuximab
2479,L866M,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
2480,W281L,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2481,G497W,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Resistance,Basal Cell Carcinoma,Vismodegib
2482,I408V,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2483,C469Y,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2484,T241M,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2485,A459V,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2486,S533N,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",D,Resistance,Basal Cell Carcinoma,Vismodegib
2487,W170X,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2488,W712X,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2489,Q787X,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2490,Q17X,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2491,Exon 11 Mutation,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Melanoma,Dasatinib
2492,H201L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2493,Y232S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2494,M237V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2495,I242T,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2496,G250V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2497,BCR-ABL Q252R,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2498,E258D,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2499,L273M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2500,E281K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2501,V289I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2502,Y342H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2503,D363Y,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2504,BCR-ABL A365V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2505,BCR-ABL A366G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2506,BCR-ABL V379I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2507,BCR-ABL V379I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2508,BCR-ABL,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2509,M388L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2510,Y393C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2511,BCR-ABL A397P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2512,BCR-ABL S417Y,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2513,BCR-ABL S417Y,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2514,I418V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2515,I418S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2516,P441L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2517,E450K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2518,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2519,E450A,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2520,E453V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2521,E459G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2522,E459G,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2523,M472I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2524,P480L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2525,G514S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2526,BCR-ABL F317I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2527,Q56P,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
2528,E203K,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
2529,R163X,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
2530,Y591_V592INSVDFREYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2531,Y591_V592INSVDFREYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2532,Y591_V592INSVDFREYE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2533,Y591_V592INSVDFREYE,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2534,E588_Y589INSKYFYVDFRE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2535,E588_Y589INSKYFYVDFRE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2536,E588_Y589INSKYFYVDFRE,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2537,E588_Y589INSKYFYVDFRE,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2538,V592_D593INSDFREY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2539,V592_D593INSDFREY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2540,V592_D593INSDFREY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2541,V592_D593INSDFREY,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2542,E746_A750>IP,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2543,RARE Exon 18-21 Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2544,Ex19 del L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2545,K745_E749delKELRE,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2546,Exon 19 Deletion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2547,D2033N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Adenocarcinoma,Crizotinib
2548,Y956N,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2549,Q225X,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2550,P1460T,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2551,Y1520X,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2552,A59E,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2553,C284Y,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2554,E374K,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2555,D1010Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2556,G596V,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
2557,D1010N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2558,D1010N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Squamous Cell Carcinoma,Crizotinib
2559,L1198F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
2560,N561D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2561,D350G,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2562,Q179X,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2563,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2564,R351W,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
2565,G340L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib+Imatinib Mesylate
2566,V600_K601DELINSD,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Skin Melanoma,Vemurafenib
2567,V600_K601DELINSD,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Melanoma,Vemurafenib
2568,S628N,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Cancer,Dasatinib+Imatinib
2569,D1010H,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2570,D1010H,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2571,EML4-ALK I1171S,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2572,R1192P,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2573,N771DELinsVH,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2574,E322K,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
2575,DELNVTAP,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Pancreatic Cancer,Vemurafenib
2576,M766_A767insAI,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2577,Y764_V765insHH,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2578,D770delinsGY,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Adenocarcinoma,Erlotinib
2579,P772_H773insYNP,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2580,Y508F,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2581,Y508F,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2582,S1986Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2583,S1986F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2584,Y69FS*11,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Esophagus Squamous Cell Carcinoma,Erlotinib
2585,G1109C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Head And Neck Squamous Cell Carcinoma,Erlotinib
2586,E380Q,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2587,L536R,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2588,Y537C,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2589,D538G,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2590,S463P,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2591,Y537N,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2592,Y537N,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Breast Cancer,Palbociclib
2593,Y537S,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Sensitivity/Response,Breast Cancer,Palbociclib
2594,Y537S,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Breast Cancer,Palbociclib
2595,S668FS*39,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2596,L403FS*34,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2597,G579W,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2598,R658Q,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",D,Resistance,Colorectal Cancer,Regorafenib
2599,R391W,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2600,Splice Site (c.1641+2T>G),"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Resistance,Melanoma,Pembrolizumab
2601,P1175FS*5,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
2602,R214H,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Nasal Type Extranodal NK/T-cell Lymphoma,Crizotinib
2603,Loss-of-function,"[{'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",D,Sensitivity/Response,Renal Cell Carcinoma,Temsirolimus
2604,Loss-of-function,"[{'id': 521, 'name': 'Anti-VEGF Monoclonal Antibody', 'ncit_id': 'C2496', 'aliases': ['Monoclonal Antibody Anti-VEGF', 'MoAb VEGF']}]",B,Resistance,Renal Cell Carcinoma,Anti-VEGF Monoclonal Antibody
2605,MUTATION,"[{'id': 521, 'name': 'Anti-VEGF Monoclonal Antibody', 'ncit_id': 'C2496', 'aliases': ['Monoclonal Antibody Anti-VEGF', 'MoAb VEGF']}]",B,Resistance,Renal Cell Carcinoma,Anti-VEGF Monoclonal Antibody
2606,Mutation,"[{'id': 532, 'name': 'Enasidenib', 'ncit_id': 'C111573', 'aliases': ['CC-90007 Free Base', 'AG-221']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
2607,AMPLIFICATION,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",D,Sensitivity/Response,Breast Cancer,Talazoparib
2608,Fusion,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
2609,T790M,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Panitumumab+Cetuximab+Brigatinib
2610,C797S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Panitumumab+Cetuximab+Brigatinib
2611,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",B,Sensitivity/Response,Breast Cancer,Talazoparib
2612,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",B,Sensitivity/Response,Breast Cancer,Talazoparib
2613,Overexpression,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
2614,AMPLIFICATION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Liposarcoma,Palbociclib
2615,Mutation,"[{'id': 148, 'name': 'Abemaciclib', 'ncit_id': 'C97660', 'aliases': ['Verzenio', 'LY2835219', 'LY-2835219', '2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Abemaciclib
2616,Fusion,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",B,Sensitivity/Response,Lung Adenocarcinoma,Cabozantinib
2617,Fusion,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vandetanib
2618,Fusion,"[{'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vandetanib
2619,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
2620,KIF5B-RET G810A,"[{'id': 527, 'name': 'Lenvatinib', 'ncit_id': 'C95124', 'aliases': ['Multi-Kinase Inhibitor E7080', 'ER-203492-00', 'E7080', '6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lenvatinib+Ponatinib
2621,Mutation,"[{'id': 435, 'name': 'Sapanisertib', 'ncit_id': 'C90548', 'aliases': ['TAK-228', 'MLN0128', 'MLN-0128', 'INK128', 'INK-128']}, {'id': 528, 'name': 'NVP-AST487', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Thyroid Gland Carcinoma,Sapanisertib+NVP-AST487
2622,Expression,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}, {'id': 296, 'name': 'Avelumab', 'ncit_id': 'C116870', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab+Pembrolizumab+Nivolumab+Durvalumab+Avelumab
2623,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}, {'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib+Alectinib
2624,Exon 19 Deletion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Dacomitinib
2625,L858R,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
2626,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",C,Sensitivity/Response,Adrenal Carcinoma,Erdafitinib
2627,Mutation,"[{'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed+Trametinib+Docetaxel
2628,Mutation,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Atezolizumab
2629,Mutation,"[{'id': 529, 'name': 'Immune Checkpoint Inhibitor', 'ncit_id': 'C143250', 'aliases': []}]",E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Immune Checkpoint Inhibitor
2630,Mutation,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2631,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Colorectal Cancer,Binimetinib+Palbociclib
2632,G691R,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}, {'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,Infigratinib+PD173074
2633,S249C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}, {'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,Infigratinib+PD173074
2634,EXPRESSION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Sarcoma,Palbociclib
2635,p16 Expression,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Sarcoma,Palbociclib
2636,Overexpression,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 502, 'name': 'Prexasertib', 'ncit_id': 'C91392', 'aliases': ['LY2606368', '2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)-']}]",D,Sensitivity/Response,Lung Small Cell Carcinoma,Olaparib+Cisplatin+Prexasertib
2637,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",B,Sensitivity/Response,Ovarian Cancer,Talazoparib
2638,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",B,Sensitivity/Response,Ovarian Cancer,Talazoparib
2639,Expression,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2640,R248W,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2641,R175H,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2642,R273C,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2643,R273H,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2644,G245S,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2645,Y220C,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2646,M237I,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Glioblastoma,MDM2 Inhibitor AMGMDS3
2647,R158H,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2648,V157F,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2649,R249S,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2650,R280K,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2651,R280T,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2652,R158L,"[{'id': 20623, 'name': 'MDM2 Inhibitor AMGMDS3', 'ncit_id': 'C171616', 'aliases': ['Q59770979', 'AMGMDS3', '2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid']}]",D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2653,L597Q,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Skin Melanoma,Trametinib
2654,Gain-of-function,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2655,MUTATION,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",B,Sensitivity/Response,Uveal Melanoma,Cabozantinib
2656,Mutation,"[{'id': 532, 'name': 'Enasidenib', 'ncit_id': 'C111573', 'aliases': ['CC-90007 Free Base', 'AG-221']}]",A,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
2657,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Pancreatic Cancer,Trametinib
2658,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Lung Cancer,Trametinib
2659,LOSS,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Lung Cancer,Vemurafenib
2660,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Colon Cancer,Trametinib
2661,LOSS,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Colon Cancer,Vemurafenib
2662,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Melanoma,Trametinib
2663,LOSS,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2664,LOSS,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Resistance,Pancreatic Cancer,Selumetinib
2665,LOSS,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Resistance,Lung Cancer,Selumetinib
2666,Overexpression,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Pancreatic Cancer,Trametinib
2667,Overexpression,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Lung Cancer,Trametinib
2668,OVEREXPRESSION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Pancreatic Cancer,Trametinib
2669,OVEREXPRESSION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Pancreatic Cancer,Trametinib
2670,OVEREXPRESSION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Lung Cancer,Trametinib
2671,OVEREXPRESSION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Lung Cancer,Trametinib
2672,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Pancreatic Cancer,Trametinib
2673,LOSS,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2674,LOSS,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Cancer,Trametinib
2675,F858L,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Lung Cancer,Selumetinib
2676,Underexpression,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}, {'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}]",B,Sensitivity/Response,Stomach Cancer,Olaparib+Paclitaxel
2677,Mutation,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",A,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
2678,MUTATION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Everolimus
2679,DELETION,"[{'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}]",D,Resistance,Medulloblastoma,Sonidegib
2680,Amplification,"[{'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}]",D,Resistance,Medulloblastoma,Sonidegib
2681,DELETION,"[{'id': 533, 'name': 'Sonidegib', 'ncit_id': 'C82385', 'aliases': ['Smoothened Antagonist LDE225', 'Odomzo', 'LDE225', 'LDE-225', 'Erismodegib', ""(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- Methyl-4'-(trifluoromethoxy)-, Rel-""]}]",D,Sensitivity/Response,Medulloblastoma,Sonidegib
2682,Amplification,"[{'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}]",D,Sensitivity/Response,Medulloblastoma,Arsenic Trioxide
2683,Mutation,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",B,Sensitivity/Response,Breast Cancer,Neratinib
2684,Mutation,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Resistance,Renal Cell Carcinoma,Everolimus+Sunitinib
2685,Mutation,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",A,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2686,Mutation,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",A,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2687,D842V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Cancer,Imatinib Mesylate
2688,V560D,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Sensitivity/Response,Cancer,Imatinib Mesylate
2689,Overexpression,"[{'id': 510, 'name': 'JQ-1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Multiple Myeloma,JQ-1
2690,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
2691,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
2692,AMPLIFICATION,"[{'id': 540, 'name': 'HDM2 Inhibitor MK-8242', 'ncit_id': 'C116867', 'aliases': ['SCH 900242', 'MK-8242']}]",C,Sensitivity/Response,Liposarcoma,HDM2 Inhibitor MK-8242
2693,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine
2694,F354L,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 82, 'name': 'Exemestane', 'ncit_id': 'C1097', 'aliases': ['FCE-24304', 'Aromasin', '6-Methyleneandrosta-1,4-diene-3,17-dione']}]",B,Sensitivity/Response,Breast Cancer,Everolimus+Exemestane
2695,MUTATION,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Acute Promyelocytic Leukemia,Nilotinib
2696,Mutation,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Nilotinib
2697,Mutation,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Nilotinib
2698,Underexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 96, 'name': 'Vinorelbine', 'ncit_id': 'C1275', 'aliases': [""Nor-5'-Anhydrovinblastine"", 'Dihydroxydeoxynorvinkaleukoblastine', ""5'-Nor-Anhydrovinblastine"", ""3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine""]}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Vinorelbine+Gemcitabine
2699,Y646,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 541, 'name': 'JQEZ5', 'ncit_id': None, 'aliases': []}, {'id': 362, 'name': 'GSK126', 'ncit_id': None, 'aliases': []}, {'id': 542, 'name': 'UNC1999', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Melanoma,Dabrafenib+JQEZ5+GSK126+UNC1999
2700,V9 EXPRESSION,"[{'id': 329, 'name': 'Abiraterone Acetate', 'ncit_id': 'C68845', 'aliases': ['JNJ-212082', 'BR9004-1', 'BR9004', 'Zytiga', 'Yonsa', 'CB7630', 'Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-', '17-(3-Pyridyl)-5,16-androstadien-3beta-acetate']}]",E,Resistance,Prostate Cancer,Abiraterone Acetate
2701,V774_C775insHV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Cancer,Erlotinib
2702,EXPRESSION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
2703,Expression,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2704,UNDEREXPRESSION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
2705,S1088F,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",C,Sensitivity/Response,Prostate Cancer,Cisplatin
2706,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2707,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2708,V777L,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine+Trastuzumab
2709,D761N,"[{'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}]",D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2710,S784F,"[{'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}]",D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2711,G810S,"[{'id': 90, 'name': 'Multikinase Inhibitor AEE788', 'ncit_id': 'C48369', 'aliases': ['AEE788', 'AEE-788', 'AEE 788']}]",D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2712,Overexpression,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2713,OVEREXPRESSION,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}, {'id': 480, 'name': 'FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,"Dovitinib+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
2714,L1237F,"[{'id': 543, 'name': 'Checkpoint Kinase Inhibitor AZD7762', 'ncit_id': 'C66961', 'aliases': ['AZD7762']}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Sensitivity/Response,Ureter Small Cell Carcinoma,Checkpoint Kinase Inhibitor AZD7762+Irinotecan
2715,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2716,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Breast Cancer,Olaparib
2717,Underexpression,"[{'id': 544, 'name': 'VE-821', 'ncit_id': None, 'aliases': []}, {'id': 545, 'name': 'AZ20', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Osteosarcoma,VE-821+AZ20
2718,Loss-of-function,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2719,LOSS-OF-FUNCTION,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2720,Gain-of-Function,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2721,ATP1B1-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Cholangiocarcinoma,Afatinib
2722,SDC4-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
2723,A829P,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
2724,E384*,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Cholangiocarcinoma,Erlotinib
2725,EXPRESSION,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}, {'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",D,Sensitivity/Response,Lung Small Cell Carcinoma,Temozolomide+Talazoparib
2726,EXPRESSION,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}, {'id': 547, 'name': 'Niraparib', 'ncit_id': 'C80059', 'aliases': ['MK4827', 'MK-4827']}]",D,Sensitivity/Response,Ewing Sarcoma,Temozolomide+Niraparib
2727,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Sensitivity/Response,Cholangiocarcinoma,Trametinib+Dabrafenib
2728,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dabrafenib+Trametinib
2729,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dabrafenib+Trametinib
2730,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Cholangiocarcinoma,Vemurafenib
2731,V600E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",C,Sensitivity/Response,Cholangiocarcinoma,Panitumumab+Vemurafenib+Irinotecan
2732,Amplification,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",B,Resistance,Melanoma,Nilotinib
2733,Fusion,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
2734,EGFR-RAD51,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2735,OVEREXPRESSION,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Breast Angiosarcoma,Sunitinib
2736,AMPLIFICATION,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Angiosarcoma,Pazopanib
2737,Mutation,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
2738,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2739,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2740,Mutation,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",B,Sensitivity/Response,Pancreatic Cancer,Cisplatin+Oxaliplatin
2741,Mutation,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Pancreatic Cancer,Platinum Compound
2742,EXPRESSION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Head And Neck Cancer,Pembrolizumab
2743,Expression,"[{'id': 549, 'name': 'Rovalpituzumab Tesirine', 'ncit_id': 'C107678', 'aliases': ['SC16LD6.5', 'SC0002', 'Rova-T']}]",B,Sensitivity/Response,Lung Small Cell Carcinoma,Rovalpituzumab Tesirine
2744,FUS-DDIT3,"[{'id': 550, 'name': 'NVP-AEW541', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Myxoid Liposarcoma,NVP-AEW541
2745,L1678P,"[{'id': 551, 'name': 'Nirogacestat', 'ncit_id': 'C82383', 'aliases': ['PF-03084014', '(S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide']}]",C,Sensitivity/Response,Adult T-cell Leukemia,Nirogacestat
2746,L858R,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Cancer,Erlotinib
2747,Mutation,"[{'id': 688, 'name': 'Cytoreductive Surgery', 'ncit_id': 'C132068', 'aliases': ['Cytoreduction']}, {'id': 689, 'name': 'Hyperthermic Intraperitoneal Chemotherapy', 'ncit_id': 'C91835', 'aliases': ['HIPEC']}]",B,Sensitivity/Response,Peritoneal Mesothelioma,Cytoreductive Surgery+Hyperthermic Intraperitoneal Chemotherapy
2748,Amplification,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2749,Amplification,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2750,KMT2E-ASNS,"[{'id': 258, 'name': 'Asparaginase', 'ncit_id': 'C286', 'aliases': ['Spectrila', 'Serasa', 'Re-82-TAD-15', 'Paronal', 'MK-965', 'Leunase', 'Leucogen', 'Lcf-ASP', 'Laspar', 'L-Asparagine Amidohydrolase', 'L-Asparaginase', 'L-ASP', 'L-Asnase', 'Kidrolase', 'Elspar', 'Colaspase', 'Asparaginase-E.Coli', 'Asparaginase II', 'ASP-1']}]",D,Resistance,T-cell Lymphoblastic Leukemia/lymphoma,Asparaginase
2751,G12C,"[{'id': 553, 'name': 'ARS-1620', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,ARS-1620
2752,INACTIVATING MUTATION,"[{'id': 676, 'name': 'Tozasertib', 'ncit_id': 'C98053', 'aliases': ['N-(4-((4-(4-methylpiperazin-1-yl)-6-((5-methyl-1h-pyrazol-3-yl)amino)pyrimidin-2-yl)sulfanyl)phenyl)cyclopropanecarboxamide', 'Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1h-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tozasertib
2753,ALTERNATIVE TRANSCRIPT (ATI),"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}, {'id': 377, 'name': 'Apitolisib', 'ncit_id': 'C91731', 'aliases': ['RG 7422', 'GNE 390', 'GDC-0980', 'GDC 0980']}]",D,Sensitivity/Response,Malignant Mesothelioma,Olaparib+Apitolisib
2754,LOSS,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Renal Carcinoma,Olaparib
2755,Mutation,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 556, 'name': 'Veliparib', 'ncit_id': 'C60768', 'aliases': ['PARP-1 Inhibitor ABT-888', 'ABT-888', '2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine+Veliparib+Cisplatin
2756,Mutation,"[{'id': 556, 'name': 'Veliparib', 'ncit_id': 'C60768', 'aliases': ['PARP-1 Inhibitor ABT-888', 'ABT-888', '2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Pancreatic Cancer,Veliparib+Gemcitabine+Cisplatin
2757,Mutation,"[{'id': 557, 'name': 'Iniparib', 'ncit_id': 'C62526', 'aliases': ['SAR240550', 'PARP-1 Inhibitor BSI-201', 'BSI-201', '4-Iodo-3-Nitrobenzamide']}]",C,Sensitivity/Response,Pancreatic Cancer,Iniparib
2758,A763_Y764insFQEA,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2759,D770delinsGY,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2760,V769_770insASV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2761,L747_P753delinsS,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Afatinib
2762,E746_A750del,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2763,E746_A750del,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
2764,A767_V769dupASV,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2765,A763_Y764insFQEA,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Afatinib
2766,STRN-ALK,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Colon Adenocarcinoma,Ceritinib
2767,LOSS-OF-FUNCTION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Colorectal Cancer,Olaparib
2768,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Crizotinib
2769,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
2770,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Ovarian Cancer,Vemurafenib
2771,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Colorectal Cancer,Vemurafenib
2772,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib+Pertuzumab
2773,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Laryngeal Squamous Cell Carcinoma,Vemurafenib
2774,CUX1-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Sensitivity/Response,Pancreatic Cancer,Vemurafenib
2775,MUTATION,"[{'id': 190, 'name': 'Vismodegib', 'ncit_id': 'C74038', 'aliases': ['Hedgehog Antagonist GDC-0449', 'GDC-0449', 'Erivedge', '2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide']}]",B,Sensitivity/Response,Cancer,Vismodegib
2776,Mutation,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pertuzumab+Trastuzumab
2777,Amplification,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Pertuzumab+Trastuzumab
2778,Amplification,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Bladder Carcinoma,Pertuzumab+Trastuzumab
2779,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",B,Sensitivity/Response,Biliary Tract Cancer,Trastuzumab+Pertuzumab
2780,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",B,Sensitivity/Response,Salivary Gland Carcinoma,Trastuzumab+Pertuzumab
2781,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",B,Sensitivity/Response,Pancreatic Cancer,Trastuzumab+Pertuzumab
2782,LOSS,"[{'id': 560, 'name': 'Chloroquine', 'ncit_id': 'C61671', 'aliases': []}, {'id': 559, 'name': 'Pegargiminase', 'ncit_id': 'C91702', 'aliases': ['Pegylated Arginine Deiminase', 'ADI-PEG 20']}]",D,Sensitivity/Response,Sarcoma,Chloroquine+Pegargiminase
2783,LOSS,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",D,Resistance,Ovarian Cancer,Platinum Compound
2784,Mutation,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",C,Sensitivity/Response,Papillary Renal Cell Carcinoma,Everolimus
2785,Loss,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Renal Carcinoma,Sirolimus
2786,LOSS,"[{'id': 563, 'name': 'HDAC Inhibitor AR-42', 'ncit_id': 'C116850', 'aliases': ['OSU-HDAC42', 'HDAC-42', 'AR-42', '(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide']}]",D,Sensitivity/Response,Kabuki Syndrome,HDAC Inhibitor AR-42
2787,LOSS-OF-FUNCTION,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
2788,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Olaparib
2789,Mutation,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Sunitinib+Everolimus
2790,MUTATION,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Sunitinib+Everolimus
2791,ISOFORM EXPRESSION,"[{'id': 377, 'name': 'Apitolisib', 'ncit_id': 'C91731', 'aliases': ['RG 7422', 'GNE 390', 'GDC-0980', 'GDC 0980']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Malignant Pleural Mesothelioma,Apitolisib+Olaparib
2792,Overexpression,"[{'id': 681, 'name': 'Sertraline', 'ncit_id': 'C61939', 'aliases': []}]",D,Sensitivity/Response,Melanoma,Sertraline
2793,AMPLIFICATION,"[{'id': 567, 'name': 'GF109203X', 'ncit_id': None, 'aliases': []}, {'id': 566, 'name': 'Go6983', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,GF109203X+Go6983
2794,D594G,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Skin Melanoma,Sorafenib
2795,D594G,"[{'id': 568, 'name': 'U0126', 'ncit_id': None, 'aliases': []}]",D,Resistance,Skin Melanoma,U0126
2796,G469E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Skin Melanoma,Sorafenib
2797,G469E,"[{'id': 568, 'name': 'U0126', 'ncit_id': None, 'aliases': []}]",D,Resistance,Skin Melanoma,U0126
2798,L747_P753delinsS,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Pancreatic Adenocarcinoma,Erlotinib
2799,Amplification,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,JQ1
2800,Amplification,"[{'id': 569, 'name': 'Birabresib', 'ncit_id': 'C103298', 'aliases': ['OTX015', 'MK-8628', 'BRD 2/3/4 Inhibitor OTX015', '6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-']}]",D,Sensitivity/Response,Neuroblastoma,Birabresib
2801,Amplification,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}, {'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,Neuroblastoma,JQ1+Panobinostat
2802,Amplification,"[{'id': 541, 'name': 'JQEZ5', 'ncit_id': None, 'aliases': []}, {'id': 362, 'name': 'GSK126', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,JQEZ5+GSK126
2803,A702S,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2804,E709K and G719A,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2805,E709Q,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2806,Exon 18 deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2807,E709A and G719C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2808,G719S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2809,I744_K745insKIPVAI,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2810,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Vagina Sarcoma,Crizotinib
2811,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Epithelioid Inflammatory Myofibroblastic Sarcoma,Crizotinib
2812,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",A,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
2813,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib
2814,V600,"[{'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab
2815,V600,"[{'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab+Alpelisib
2816,T41A,"[{'id': 571, 'name': 'Celecoxib', 'ncit_id': 'C1728', 'aliases': ['YM 177', 'SC-58635', 'Celebrex', 'Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-', '4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide']}]",C,Sensitivity/Response,Desmoid Tumor,Celecoxib
2817,T41A,"[{'id': 572, 'name': 'Meloxicam', 'ncit_id': 'C61439', 'aliases': ['Movatec', 'Movalis', 'Mobicox', 'Mobic', 'Mobec', '4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide']}]",B,Sensitivity/Response,Desmoid Tumor,Meloxicam
2818,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Pancreatic Cancer,Larotrectinib
2819,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Cholangiocarcinoma,Larotrectinib
2820,Loss-of-function,"[{'id': 67, 'name': 'MTOR Inhibitor', 'ncit_id': 'C2201', 'aliases': []}]",C,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2821,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
2822,D1028N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
2823,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2824,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2825,T41A,[],B,Sensitivity/Response,Hepatoblastoma,
2826,S37C,[],E,Sensitivity/Response,Hepatoblastoma,
2827,G328V,"[{'id': 604, 'name': 'ALK2 Inhibitor LDN-193189', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",ALK2 Inhibitor LDN-193189
2828,Fusion,"[{'id': 575, 'name': 'Anti-HER3 Monoclonal Antibody GSK2849330', 'ncit_id': 'C111997', 'aliases': []}]",C,Sensitivity/Response,Mucinous Adenocarcinoma,Anti-HER3 Monoclonal Antibody GSK2849330
2829,MUTATION,"[{'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",C,Resistance,Breast Cancer,Ribociclib+Palbociclib
2830,STRN-NTRK2,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
2831,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",A,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2832,LMNA-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
2833,TPM3-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
2834,PDE4DIP-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
2835,SQSTM1-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2836,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Colorectal Cancer,Trametinib+Panitumumab+Dabrafenib
2837,Overexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Sensitivity/Response,Salivary Gland Cancer,Paclitaxel+Trastuzumab
2838,Overexpression,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 577, 'name': 'Zoledronic Acid', 'ncit_id': 'C1699', 'aliases': ['Zometa', 'ZOL 446', 'Reclast', 'NDC-Zoledronate', 'CGP42446A', 'CGP 42446', '[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}]",C,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab+Zoledronic Acid+Capecitabine
2839,Y220C,"[{'id': 59, 'name': 'Bortezomib', 'ncit_id': 'C1851', 'aliases': ['Velcade', 'PS341', 'PS-341', 'MLN341', 'LDP 341', '[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid']}]",C,Sensitivity/Response,Breast Cancer,Bortezomib
2840,L869R,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",C,Sensitivity/Response,Breast Cancer,Neratinib
2841,T798I,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",C,Resistance,Breast Cancer,Neratinib
2842,A750T,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2843,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
2844,V600K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
2845,V600,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
2846,L858R,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2847,Exon 19 Deletion,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2848,Rare Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2849,BCR-ABL T315A,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2850,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate
2851,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2852,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate+Nilotinib
2853,BCR-ABL T315I,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
2854,BCR-ABL T315I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2855,BCR-ABL T315I,"[{'id': 580, 'name': 'Omacetaxine Mepesuccinate', 'ncit_id': 'C1127', 'aliases': ['Synribo', 'Homoharringtonine', 'HHT', 'CGX-635', 'Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)', 'Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)', 'Ceflatonin']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Omacetaxine Mepesuccinate
2856,BCR-ABL Y253H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2857,H1047R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Breast Cancer,Lapatinib
2858,H1047R,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Breast Cancer,Trastuzumab
2859,H1047R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
2860,H1047R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Breast Cancer,Lapatinib+Dactolisib
2861,E545K,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib
2862,BCR-ABL F317V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2863,E545K,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
2864,BCR-ABL L248R,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2865,E545K,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab+Lapatinib
2866,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2867,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2868,BCR-ABL V299L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2869,BCR-ABL F317I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2870,BCR-ABL F317S,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2871,BCR-ABL Q252H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2872,BCR-ABL T315I,"[{'id': 580, 'name': 'Omacetaxine Mepesuccinate', 'ncit_id': 'C1127', 'aliases': ['Synribo', 'Homoharringtonine', 'HHT', 'CGX-635', 'Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)', 'Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)', 'Ceflatonin']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Omacetaxine Mepesuccinate
2873,BCR-ABL E255K,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2874,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2875,BCR-ABL T315I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2876,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Nilotinib
2877,BCR-ABL L248V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2878,BCR-ABL Y253H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2879,BCR-ABL F311L,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2880,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2881,BCR-ABL H396P,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2882,BCR-ABL V299L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate
2883,BCR-ABL M244V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2884,BCR-ABL L248R,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2885,BCR-ABL G250E,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2886,BCR-ABL Q252H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2887,BCR-ABL D276G,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2888,BCR-ABL V299L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2889,BCR-ABL F311I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2890,BCR-ABL F311V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2891,BCR-ABL F317C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2892,BCR-ABL F317I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2893,BCR-ABL F317L,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2894,BCR-ABL F317V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2895,BCR-ABL M351T,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2896,BCR-ABL E355G,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2897,BCR-ABL F359V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2898,BCR-ABL V379I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2899,BCR-ABL H396R,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2900,Q79K,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Melanoma,Dabrafenib
2901,OVEREXPRESSION,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2902,V600E/K and Amplification,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2903,Mutation,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2904,Mutation,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2905,OVEREXPRESSION,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2906,BCR-ABL G250E,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
2907,R172I,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
2908,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2909,Loss,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2910,WILD TYPE,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Melanoma,Vemurafenib
2911,Fusion,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Pancreatic Adenocarcinoma,Afatinib
2912,BCR-ABL Q252H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2913,Amplification,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2914,BCR-ABL L384M,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2915,BCR-ABL E255V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2916,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2917,BCR-ABL Y253H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2918,BCR-ABL L248V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2919,BCR-ABL L248V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2920,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2921,BCR-ABL E255K,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2922,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2923,BCR-ABL T315I,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate+Dasatinib
2924,G12/G13,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2925,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2926,Mutation,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",B,Resistance,Colorectal Cancer,Oxaliplatin
2927,Mutation,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Resistance,Colorectal Cancer,Irinotecan
2928,Mutation,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Resistance,Colorectal Cancer,Bevacizumab
2929,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2930,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",B,Resistance,Chronic Myeloid Leukemia,Dasatinib
2931,G13V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2932,G12S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2933,Loss,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
2934,G12D,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2935,Amplification,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
2936,T790M,"[{'id': 586, 'name': 'Naquotinib', 'ncit_id': 'C115110', 'aliases': ['ASP8273', '2-Pyrazinecarboxamide, 6-Ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}, {'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Non-small Cell Carcinoma,Naquotinib+Mitogen-Activated Protein Kinase Kinase Inhibitor+Osimertinib
2937,G12A,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2938,G13D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
2939,G12V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2940,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
2941,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
2942,Y35N,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Resistance,Kidney Cancer,Sirolimus
2943,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Ovarian Cancer,Rucaparib
2944,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Ovarian Cancer,Rucaparib
2945,Mutation,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2946,G12/G13,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2947,UNDEREXPRESSION,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",C,Sensitivity/Response,Cancer,Tazemetostat
2948,UNDEREXPRESSION,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",C,Sensitivity/Response,Cancer,Tazemetostat
2949,Mutation,"[{'id': 379, 'name': 'Aspirin', 'ncit_id': 'C287', 'aliases': ['Measurin', 'Extren', 'Entericin', 'Empirin', 'Ecotrin', 'Aspergum', 'ASA', 'Acetylsalicylic Acid', '2-(Acetyloxy)benzoic Acid']}]",B,Sensitivity/Response,Colorectal Cancer,Aspirin
2950,R351W,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Imatinib
2951,Exon 11 Mutation,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2952,EWSR1-NR4A3,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,Sunitinib
2953,UNDEREXPRESSION,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2954,T618I,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",D,Sensitivity/Response,Chronic Neutrophilic Leukemia,Ruxolitinib
2955,T618I,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,Chronic Neutrophilic Leukemia,Ruxolitinib
2956,56_61QKQKVG>R,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Langerhans-cell Histiocytosis,Trametinib
2957,C121S and G128D,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Resistance,Langerhans-cell Histiocytosis,Trametinib
2958,NTRK1-TRIM63,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",E,Sensitivity/Response,Melanoma,Larotrectinib
2959,NTRK1-DDR2,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",E,Sensitivity/Response,Melanoma,Larotrectinib
2960,NTRK1-GON4L,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",E,Sensitivity/Response,Melanoma,Larotrectinib
2961,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Hematologic Cancer,Larotrectinib
2962,ETV6-NTRK2,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Larotrectinib
2963,AMPLIFICATION,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
2964,AMPLIFICATION,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Stomach Cancer,Dasatinib
2965,LOSS-OF-FUNCTION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",D,Sensitivity/Response,Ovarian Cancer,Atezolizumab+Pembrolizumab+Nivolumab
2966,intron 10 rearrangement,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2967,intron 9 rearrangement,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2968,D594K,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",B,Resistance,Colorectal Cancer,Irinotecan
2969,D594K,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",B,Resistance,Colorectal Cancer,Oxaliplatin
2970,S249C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2971,V443L,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Resistance,Transitional Cell Carcinoma,Infigratinib
2972,V443M,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Resistance,Transitional Cell Carcinoma,Infigratinib
2973,V496V,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Resistance,Transitional Cell Carcinoma,Infigratinib
2974,V555M,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}, {'id': 591, 'name': 'AZ12908010', 'ncit_id': None, 'aliases': []}, {'id': 36, 'name': 'PD173074', 'ncit_id': None, 'aliases': []}]",D,Resistance,Myeloid Neoplasm,FGFR Inhibitor AZD4547+AZ12908010+PD173074
2975,FGFR3-TACC3,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2976,R248C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2977,Y373C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2978,Y375C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2979,G380R,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2980,G370C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2981,F386L,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2982,N78S (c.233A>G),"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Von Hippel-Lindau Disease,Sunitinib
2983,Underexpression,"[{'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Platinum Compound
2984,Underexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cisplatin+Gemcitabine
2985,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
2986,Underexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cisplatin
2987,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 103, 'name': 'Platinum Compound', 'ncit_id': 'C1450', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Platinum Compound
2988,OVEREXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 656, 'name': 'Nedaplatin', 'ncit_id': 'C61099', 'aliases': ['NDP', 'Cis-Diammine(glucolato)platinum', 'CDGP', '254-S', ""(Glycolato-O,O')diammineplatinum(II)""]}]",B,Resistance,Lung Non-small Cell Carcinoma,Gemcitabine+Nedaplatin
2989,Underexpression,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
2990,UNDEREXPRESSION,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine
2991,R132,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dasatinib
2992,Mutation,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Resistance,Lung Adenocarcinoma,Nivolumab+Pembrolizumab+Atezolizumab
2993,E102_I103delEI,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Langerhans-cell Histiocytosis,Trametinib
2994,LOSS-OF-FUNCTION,"[{'id': 596, 'name': 'Lysine', 'ncit_id': 'C29171', 'aliases': []}]",B,Resistance,Colorectal Cancer,Lysine
2995,Mutation,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",B,Sensitivity/Response,Endometrial Cancer,Fulvestrant+Dovitinib
2996,Mutation,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab
2997,Mutation,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Resistance,Lung Non-small Cell Carcinoma,Afatinib+Gefitinib
2998,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2999,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Breast Secretory Carcinoma,Larotrectinib
3000,LOSS-OF-FUNCTION,"[{'id': 375, 'name': 'Letrozole', 'ncit_id': 'C1527', 'aliases': ['Femara', 'CGS 20267', ""4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile""]}, {'id': 598, 'name': 'Anastrozole', 'ncit_id': 'C1607', 'aliases': ['ZD-1033', 'ICI-D1033', 'ICI D1033', 'Arimidex', 'Anastrazole', ""Alpha,alpha,alpha', Alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile"", ""2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)""]}, {'id': 82, 'name': 'Exemestane', 'ncit_id': 'C1097', 'aliases': ['FCE-24304', 'Aromasin', '6-Methyleneandrosta-1,4-diene-3,17-dione']}]",B,Resistance,Breast Cancer,Letrozole+Anastrozole+Exemestane
3001,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",B,Sensitivity/Response,Solid Tumor,Larotrectinib
3002,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",A,Sensitivity/Response,Solid Tumor,Larotrectinib
3003,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",B,Sensitivity/Response,Sarcoma,Larotrectinib
3004,AMPLIFICATION,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",D,Sensitivity/Response,Melanoma,Binimetinib
3005,Amplification,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Gastric Adenocarcinoma,Cetuximab
3006,Amplification,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",D,Sensitivity/Response,Esophageal Carcinoma,Ibrutinib
3007,Amplification,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",D,Sensitivity/Response,Esophageal Cancer,Ibrutinib
3008,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3009,LOSS-OF-FUNCTION,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Sunitinib+Crizotinib
3010,V600,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3011,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3012,V600K,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3013,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3014,V600K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3015,KIF5B-RET,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Sensitivity/Response,Lung Cancer,Selpercatinib
3016,Fusion,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",D,Sensitivity/Response,Cancer,Selpercatinib
3017,M918T,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3018,V804M,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3019,Y646F,"[{'id': 541, 'name': 'JQEZ5', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Skin Melanoma,JQEZ5
3020,OVEREXPRESSION,"[{'id': 603, 'name': 'Leuprolide', 'ncit_id': 'C62042', 'aliases': ['Leuprorelin', '6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)', '6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)']}, {'id': 78, 'name': 'Bicalutamide', 'ncit_id': 'C1599', 'aliases': ['N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide', 'ICI 176334', 'ICI 176,334', 'Cosudex', 'Casodex', '4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline', ""4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide"", '(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide']}]",B,Sensitivity/Response,Salivary Gland Cancer,Leuprolide+Bicalutamide
3021,V7 EXPRESSION,"[{'id': 329, 'name': 'Abiraterone Acetate', 'ncit_id': 'C68845', 'aliases': ['JNJ-212082', 'BR9004-1', 'BR9004', 'Zytiga', 'Yonsa', 'CB7630', 'Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-', '17-(3-Pyridyl)-5,16-androstadien-3beta-acetate']}]",C,Resistance,Salivary Gland Cancer,Abiraterone Acetate
3022,D816V,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",E,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
3023,D816H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Resistance,Acute Myeloid Leukemia,Imatinib Mesylate
3024,N822K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Imatinib Mesylate
3025,Promoter Mutation,"[{'id': 606, 'name': 'Iodine I-131', 'ncit_id': 'C1639', 'aliases': ['Iodotrope', 'Iodotope', 'Iodine 131', 'Iodide, I-131', 'Iodide I-131', 'I-131', 'I 131', 'Bound Iodide I-131', '131-Iodine']}]",B,Resistance,Thyroid Gland Carcinoma,Iodine I-131
3026,V600K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3027,V600,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",B,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
3028,ETV6-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3029,BCR-ABL F359V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
3030,BCR-ABL E255V,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
3031,Overexpression,"[{'id': 607, 'name': 'Ganitumab', 'ncit_id': 'C71531', 'aliases': []}]",D,Sensitivity/Response,Ovarian Cancer,Ganitumab
3032,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Trametinib+Dabrafenib
3033,EBF1-PDGFRB,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3034,C475V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3035,BCR-ABL F317L,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3036,BCR-ABL N336S,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3037,BCR-ABL E453A,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3038,BCR-ABL L387F,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3039,BCR-ABL V299L,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3040,BCR-ABL Q300R,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3041,BCR-ABL F359I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3042,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3043,BCR-ABL E255V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3044,BCR-ABL F486S,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3045,BCR-ABL H396R,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3046,BCR-ABL M351T,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3047,BCR-ABL T315I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3048,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3049,BCR-ABL Y253H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3050,BCR-ABL G250E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3051,BCR-ABL M244V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3052,BCR-ABL F359V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3053,AGGF1-PDGFRB C843G,"[{'id': 608, 'name': 'CHZ868', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,CHZ868
3054,Overexpression,"[{'id': 607, 'name': 'Ganitumab', 'ncit_id': 'C71531', 'aliases': []}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Pancreatic Adenocarcinoma,Ganitumab+Gemcitabine
3055,Overexpression,"[{'id': 609, 'name': 'Tarextumab', 'ncit_id': 'C95719', 'aliases': ['OMP-59R5', 'OMP 59R5', 'MoAb OMP-59R5']}]",D,Sensitivity/Response,Pancreatic Cancer,Tarextumab
3056,Overexpression,"[{'id': 609, 'name': 'Tarextumab', 'ncit_id': 'C95719', 'aliases': ['OMP-59R5', 'OMP 59R5', 'MoAb OMP-59R5']}]",D,Sensitivity/Response,Rectum Cancer,Tarextumab
3057,GOLGA5-JAK2,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3058,PAX3-FOXO1,"[{'id': 610, 'name': 'BET Inhibitor', 'ncit_id': 'C128462', 'aliases': ['BET Bromodomain Inhibitor']}]",D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,BET Inhibitor
3059,Overexpression,"[{'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Sensitivity/Response,Neuroblastoma,Dinaciclib
3060,Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Glioblastoma,Bevacizumab
3061,Overexpression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Breast Cancer,Lapatinib
3062,Overexpression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Sensitivity/Response,Breast Cancer,Lapatinib
3063,OVEREXPRESSION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,Olaparib
3064,BRD4-NUTM1,"[{'id': 569, 'name': 'Birabresib', 'ncit_id': 'C103298', 'aliases': ['OTX015', 'MK-8628', 'BRD 2/3/4 Inhibitor OTX015', '6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-']}]",C,Sensitivity/Response,NUT Midline Carcinoma,Birabresib
3065,FIP1L1-PDGFRA T674I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
3066,F694L,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Ruxolitinib
3067,Mutation,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
3068,EBF1-PDGFRB,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3069,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
3070,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3071,BCR-ABL V379I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3072,BCR-ABL A397P,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3073,BCR-ABL F359C,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3074,BCR-ABL E355G,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3075,BCR-ABL M351T,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3076,BCR-ABL T315I,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3077,BCR-ABL E255K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3078,BCR-ABL Y253H,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3079,BCR-ABL G250E,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3080,BCR-ABL M244V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3081,BCR-ABL F359V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3082,BCR-ABL L248V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3083,BCR-ABL F317L,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3084,BCR-ABL E459K,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3085,Wildtype,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 531, 'name': 'Leucovorin', 'ncit_id': 'C71631', 'aliases': ['Folinic Acid', '5-Formyltetrahydrofolate']}]",B,Sensitivity/Response,Colorectal Cancer,Oxaliplatin+Fluorouracil+Panitumumab+Leucovorin
3086,Fusion,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
3087,Expression,"[{'id': 615, 'name': 'Abexinostat', 'ncit_id': 'C68920', 'aliases': ['PCI-24781', 'HDAC Inhibitor PCI-24781', 'CRA-024781', '3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide', '2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)-']}, {'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Abexinostat+Pazopanib
3088,ITD,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3089,Overexpression,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Gastroesophageal Junction Adenocarcinoma,Trastuzumab
3090,Overexpression,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Stomach Cancer,Trastuzumab
3091,Fusion,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selpercatinib
3092,KIF5B-RET,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Lung Cancer,Selpercatinib
3093,V804M,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3094,Fusion,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Selpercatinib
3095,Mutation,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3096,AMPLIFICATION,"[{'id': 617, 'name': 'Dual IGF-1R/InsR Inhibitor BMS-754807', 'ncit_id': 'C74043', 'aliases': ['BMS-754807']}]",D,Sensitivity/Response,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3097,G13D,"[{'id': 617, 'name': 'Dual IGF-1R/InsR Inhibitor BMS-754807', 'ncit_id': 'C74043', 'aliases': ['BMS-754807']}]",D,Resistance,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3098,V600E,"[{'id': 617, 'name': 'Dual IGF-1R/InsR Inhibitor BMS-754807', 'ncit_id': 'C74043', 'aliases': ['BMS-754807']}]",D,Resistance,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3099,Overexpression,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",B,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab+Docetaxel
3100,I462K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3101,I462R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3102,S464L,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3103,S464T,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3104,G465R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3105,G465E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3106,G465V,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3107,K467N,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3108,K467T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3109,K489Q,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3110,K489E,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3111,I491K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3112,I491R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3113,S492R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3114,S492C,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3115,V441G,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3116,V441D,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3117,V441F,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",E,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3118,S442R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3119,S442I,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3120,F404I,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3121,F404V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3122,T415M,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3123,Amplification,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Colorectal Cancer,Sorafenib
3124,Amplification,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3125,EBF1-PDGFRB,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,Imatinib
3126,EBF1-PDGFRB,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dasatinib+Imatinib
3127,ATF7IP-PDGFRB,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dasatinib
3128,Overexpression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,Crizotinib
3129,OVEREXPRESSION,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,Ponatinib
3130,OVEREXPRESSION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Resistance,Alveolar Rhabdomyosarcoma,Palbociclib+Ribociclib
3131,AMPLIFICATION,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Angiosarcoma,Pazopanib
3132,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
3133,MUTATION,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",B,Sensitivity/Response,Melanoma,Nilotinib
3134,LOSS,"[{'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}, {'id': 148, 'name': 'Abemaciclib', 'ncit_id': 'C97660', 'aliases': ['Verzenio', 'LY2835219', 'LY-2835219', '2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)']}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Ovarian Small Cell Carcinoma,Ribociclib+Abemaciclib+Palbociclib
3135,LOSS,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}, {'id': 148, 'name': 'Abemaciclib', 'ncit_id': 'C97660', 'aliases': ['Verzenio', 'LY2835219', 'LY-2835219', '2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Palbociclib+Abemaciclib
3136,R248Q,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}, {'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}]",D,Resistance,Ovarian Cancer,Paclitaxel+Doxorubicin+Etoposide
3137,A146T,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
3138,Q61P,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
3139,G12S,"[{'id': 620, 'name': 'MUC1-targeted Peptide GO-203-2C', 'ncit_id': 'C95722', 'aliases': ['GO-203-2C']}]",D,Resistance,Lung Non-small Cell Carcinoma,MUC1-targeted Peptide GO-203-2C
3140,Activating Mutation,"[{'id': 621, 'name': 'Salirasib', 'ncit_id': 'C71146', 'aliases': ['S-Farnesylthiosalicylic Acid', '2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic Acid']}]",B,Sensitivity/Response,Pancreatic Cancer,Salirasib
3141,G12D,"[{'id': 382, 'name': 'Phosphatidylinositide 3-Kinase Inhibitor', 'ncit_id': 'C2152', 'aliases': []}]",D,Sensitivity/Response,Pancreatic Cancer,Phosphatidylinositide 3-Kinase Inhibitor
3142,Activating Mutation,"[{'id': 622, 'name': 'Inhibitor', 'ncit_id': 'C154898', 'aliases': []}]",D,Sensitivity/Response,Pancreatic Cancer,Inhibitor
3143,G12,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",D,Resistance,Pancreatic Cancer,Mitogen-Activated Protein Kinase Kinase Inhibitor
3144,Activating Mutation,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",D,Sensitivity/Response,Pancreatic Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3145,Mutation,"[{'id': 623, 'name': 'Sulindac', 'ncit_id': 'C850', 'aliases': ['Sulreuma', 'Sulinol', 'Sulindac Sulfoxide', 'Sudac', 'Reumyl', 'Reumofil', 'Novo-Sundac', 'MK-231', 'Imbaral', 'Clisundac', 'Clinoril', 'Citireuma', 'Cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic Acid', 'Artribid', 'Arthrocine', 'Apo-Sulin', 'Algocetil', 'Aflodac', '(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic Acid']}, {'id': 571, 'name': 'Celecoxib', 'ncit_id': 'C1728', 'aliases': ['YM 177', 'SC-58635', 'Celebrex', 'Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-', '4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide']}, {'id': 379, 'name': 'Aspirin', 'ncit_id': 'C287', 'aliases': ['Measurin', 'Extren', 'Entericin', 'Empirin', 'Ecotrin', 'Aspergum', 'ASA', 'Acetylsalicylic Acid', '2-(Acetyloxy)benzoic Acid']}]",B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Sulindac+Celecoxib+Aspirin
3146,Amplification,"[{'id': 623, 'name': 'Sulindac', 'ncit_id': 'C850', 'aliases': ['Sulreuma', 'Sulinol', 'Sulindac Sulfoxide', 'Sudac', 'Reumyl', 'Reumofil', 'Novo-Sundac', 'MK-231', 'Imbaral', 'Clisundac', 'Clinoril', 'Citireuma', 'Cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic Acid', 'Artribid', 'Arthrocine', 'Apo-Sulin', 'Algocetil', 'Aflodac', '(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic Acid']}, {'id': 624, 'name': 'Ibuprofen', 'ncit_id': 'C561', 'aliases': ['P-Isobutylhydratropic Acid', 'Motrin', 'Benzeneacetic Acid, Alpha-methyl-4-(2-methylpropyl)-', 'Advil', '(.+ -.)-p-Isobutylhydratropic Acid']}, {'id': 379, 'name': 'Aspirin', 'ncit_id': 'C287', 'aliases': ['Measurin', 'Extren', 'Entericin', 'Empirin', 'Ecotrin', 'Aspergum', 'ASA', 'Acetylsalicylic Acid', '2-(Acetyloxy)benzoic Acid']}]",B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Sulindac+Ibuprofen+Aspirin
3147,Mutation,"[{'id': 379, 'name': 'Aspirin', 'ncit_id': 'C287', 'aliases': ['Measurin', 'Extren', 'Entericin', 'Empirin', 'Ecotrin', 'Aspergum', 'ASA', 'Acetylsalicylic Acid', '2-(Acetyloxy)benzoic Acid']}]",B,Sensitivity/Response,Colorectal Cancer,Aspirin
3148,M541L,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",E,Sensitivity/Response,Colon Signet Ring Adenocarcinoma,Imatinib
3149,ATF7IP-PDGFRB,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 626, 'name': 'Rebastinib', 'ncit_id': 'C152162', 'aliases': ['DCC-2036']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Nilotinib+Imatinib+Rebastinib+Dasatinib+Bafetinib+Ponatinib
3150,KIAA1549-BRAF,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3151,FAM131B-BRAF,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3152,KIAA1549-BRAF,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3153,Activating Mutation,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3154,A775_G776insYVMA,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3155,KIAA1549-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}]",D,Adverse Response,Childhood Low-grade Glioma,Vemurafenib+PLX4720
3156,Overexpression,"[{'id': 622, 'name': 'Inhibitor', 'ncit_id': 'C154898', 'aliases': []}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Inhibitor
3157,NUP214-ABL1,"[{'id': 398, 'name': 'Vincristine', 'ncit_id': 'C933', 'aliases': ['Vincrystine', 'VCR', 'LEUROCRISTINE', '22-Oxovincaleukoblastine']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 8063, 'name': 'Dexamethasone', 'ncit_id': 'C422', 'aliases': ['Hemady', 'Dxevo', 'ZoDex', 'Visumetazone', 'TaperDex', 'Spersadex', 'Orgadrone', 'Mymethasone', 'Millicorten', 'Methylfluorprednisolone', 'Loverine', 'Lokalison-F', 'Hexadrol', 'Hexadecadrol', 'Gammacorten', 'Fortecortin', 'Fluorodelta', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Dinormon', 'Dexone', 'Dexinoral', 'Dexapos', 'Dexamonozon', 'Dexamethasonum', 'Dexamethasone Intensol', 'Dexameth', 'Dexamecortin', 'Dexalocal', 'Dexafluorene', 'Dexafarma', 'Dexacortin', 'Dexacortal', 'Dexa-sine', 'Dexa-Scheroson', 'Dexa-Rhinosan', 'Dexa-Mamallet', 'Desameton', 'Desamethasone', 'Deronil', 'Deltafluorene', 'Dekacort', 'Dectancyl', 'Decasone R.p.', 'Decameth', 'Decalix', 'Decadron DP', 'Decadron', 'Decadrol', 'Decacort', 'Cortisumman', 'Cortidexason', 'Baycuten N', 'Baycuten', 'Baycadron', 'Auxiloson', 'Auricularum', 'Anemul Mono', 'Amplidermis', 'Alin Oftalmico', 'Alin Depot', 'Alin', 'Alba-Dex', 'Aknichthol Dexa', 'Adexone', 'Aacidexam', '9Alpha-fluoro-16alpha-methylprednisolone', '9alpha-Fluoro-16alpha- Methylprednisolone', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Vincristine+Dasatinib+Dexamethasone
3158,F232C,"[{'id': 630, 'name': 'JAK Inhibitor I', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,JAK Inhibitor I
3159,Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Stomach Cancer,Bevacizumab
3160,Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Ovarian Cancer,Bevacizumab+Erlotinib
3161,SNX2-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3162,Overexpression,"[{'id': 631, 'name': 'Adavosertib', 'ncit_id': 'C91725', 'aliases': ['MK1775', 'MK-1775', 'AZD1775', 'AZD-1775', '2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one']}]",D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",Adavosertib
3163,Overexpression,"[{'id': 631, 'name': 'Adavosertib', 'ncit_id': 'C91725', 'aliases': ['MK1775', 'MK-1775', 'AZD1775', 'AZD-1775', '2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one']}]",D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",Adavosertib
3164,G284R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",C,Sensitivity/Response,Breast Cancer,Lapatinib+Trastuzumab
3165,BCR-ABL E255V,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3166,Amplification,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Breast Cancer,Pazopanib
3167,Mutation,"[{'id': 496, 'name': 'Anti-PD-L1 Monoclonal Antibody', 'ncit_id': 'C128057', 'aliases': []}, {'id': 632, 'name': 'CTLA-4 Inhibitor', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Anti-PD-L1 Monoclonal Antibody+CTLA-4 Inhibitor
3168,RCSD1-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3169,RCSD1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3170,Fusion,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3171,Fusion,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3172,D579del,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Sensitivity/Response,Sinonasal Undifferentiated Carcinoma,Imatinib Mesylate
3173,SNX2-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,Imatinib
3174,SSBP2-JAK2,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3175,V600E,"[{'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab+Binimetinib
3176,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3177,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3178,Mutation,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3179,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Biliary Tract Cancer,Dabrafenib+Trametinib
3180,Loss,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Neurofibroma,Trametinib
3181,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Plexiform Neurofibroma,Selumetinib
3182,G595R,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",B,Resistance,Solid Tumor,Larotrectinib
3183,G623R,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Resistance,Solid Tumor,Larotrectinib
3184,G595R,"[{'id': 637, 'name': 'Selitrectinib', 'ncit_id': 'C138160', 'aliases': ['TRK Inhibitor LOXO-195', 'BAY 2731954', 'LOXO195', 'LOXO-195', 'LOXO 195', '(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one']}]",C,Sensitivity/Response,Solid Tumor,Selitrectinib
3185,G623R,"[{'id': 637, 'name': 'Selitrectinib', 'ncit_id': 'C138160', 'aliases': ['TRK Inhibitor LOXO-195', 'BAY 2731954', 'LOXO195', 'LOXO-195', 'LOXO 195', '(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one']}]",C,Sensitivity/Response,Solid Tumor,Selitrectinib
3186,EXON 14 SKIPPING MUTATION,"[{'id': 638, 'name': 'Tepotinib', 'ncit_id': 'C88314', 'aliases': ['EMD1214063', 'EMD-1214063', 'EMD 1214063', 'Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tepotinib
3187,Exon 20 Insertion,"[{'id': 639, 'name': 'TAK-788', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAK-788
3188,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Ovarian Cancer,Olaparib
3189,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Ovarian Cancer,Olaparib
3190,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Ovarian Cancer,Olaparib
3191,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Ovarian Cancer,Olaparib
3192,Mutation,"[{'id': 454, 'name': 'Ivosidenib', 'ncit_id': 'C114383', 'aliases': ['Tibsovo', 'AG-120']}]",A,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
3193,Mutation,"[{'id': 532, 'name': 'Enasidenib', 'ncit_id': 'C111573', 'aliases': ['CC-90007 Free Base', 'AG-221']}]",A,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
3194,Loss-of-function,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",A,Sensitivity/Response,Tuberous Sclerosis,Everolimus
3195,LOSS-OF-FUNCTION,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",A,Sensitivity/Response,Tuberous Sclerosis,Everolimus
3196,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3197,Mutation,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3198,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3199,Fusion,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
3200,Fusion,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3201,V600,"[{'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}, {'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",A,Sensitivity/Response,Melanoma,Encorafenib+Binimetinib
3202,V555_V559DEL,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
3203,FOXP1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3204,MUTATION,"[{'id': 642, 'name': 'SU11274', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3205,Q294E,"[{'id': 642, 'name': 'SU11274', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3206,S80N and H94Y,"[{'id': 642, 'name': 'SU11274', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3207,V391I,"[{'id': 642, 'name': 'SU11274', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3208,W802*,"[{'id': 642, 'name': 'SU11274', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3209,LOSS-OF-FUNCTION,"[{'id': 365, 'name': 'Ipilimumab', 'ncit_id': 'C2654', 'aliases': []}]",B,Sensitivity/Response,Renal Cell Carcinoma,Ipilimumab
3210,Amplification,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Pertuzumab+Trastuzumab
3211,Promoter Methylation,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}, {'id': 397, 'name': 'Lomustine', 'ncit_id': 'C617', 'aliases': ['WR-139017', 'RB-1509', 'Prava', ""N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea"", 'Lucostine', 'Lucostin', 'Lomustinum', 'Lomeblastin', 'Gleostine', 'Citostal', 'Chloroethylcyclohexylnitrosourea', 'Chloroethylcyclo- Hexylnitrosourea', 'CeeNU', 'Cecenu', 'CCNU', 'Belustine', 'Belustin', '1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-', '1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea']}]",A,Sensitivity/Response,Glioblastoma,Temozolomide+Lomustine
3212,DEK-AFF2,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Head And Neck Cancer,Pembrolizumab
3213,R248C,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3214,S249C,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3215,G370C,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3216,Y373C,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3217,KIF5B-MET,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3218,G12R,"[{'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",C,Sensitivity/Response,Histiocytosis-Lymphadenopathy Plus Syndrome,Cobimetinib
3219,KIAA1549-BRAF,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 83, 'name': 'Temsirolimus', 'ncit_id': 'C1844', 'aliases': ['Torisel', 'Rapamycin Analog CCI-779', 'Rapamycin Analog', 'Cell Cycle Inhibitor 779', 'CCI-779 Rapamycin Analog', 'CCI-779', '42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin']}]",C,Sensitivity/Response,Spindle Cell Sarcoma,Sorafenib+Bevacizumab+Temsirolimus
3220,Mutation,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3221,EGFR-RAD51,"[{'id': 645, 'name': 'Icotinib', 'ncit_id': 'C138996', 'aliases': ['BPI-2009', '(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Icotinib
3222,E542K,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3223,E545X,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}, {'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",A,Sensitivity/Response,Breast Cancer,Alpelisib+Fulvestrant
3224,Mutation,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3225,H1047X,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3226,Fusion,"[{'id': 646, 'name': 'Futibatinib', 'ncit_id': 'C114283', 'aliases': ['2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-', 'TAS-120']}]",C,Sensitivity/Response,Cholangiocarcinoma,Futibatinib
3227,T1977K,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Sirolimus
3228,C1483F,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Sirolimus
3229,F1888L,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Sirolimus
3230,S2215F,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Sirolimus
3231,L2230V,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Sirolimus
3232,LOSS-OF-FUNCTION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Liver Cancer,Sorafenib
3233,Fusion,"[{'id': 648, 'name': 'Derazantinib', 'ncit_id': 'C104267', 'aliases': ['ARQ-087', 'ARQ 087']}]",B,Sensitivity/Response,Cholangiocarcinoma,Derazantinib
3234,OVEREXPRESSION,"[{'id': 650, 'name': 'Carfilzomib', 'ncit_id': 'C52196', 'aliases': ['PR-171', 'Kyprolis', '(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide']}]",D,Sensitivity/Response,Colorectal Cancer,Carfilzomib
3235,ｍRNA expression low,"[{'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}, {'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",B,Sensitivity/Response,Breast Cancer,Fulvestrant+Palbociclib
3236,Q61H,"[{'id': 365, 'name': 'Ipilimumab', 'ncit_id': 'C2654', 'aliases': []}]",B,Sensitivity/Response,Melanoma,Ipilimumab
3237,V600,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
3238,D820E,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Thymic Carcinoma,Sorafenib
3239,V559G,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3240,Y553N,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3241,V560DEL,"[{'id': 537, 'name': 'Imatinib Mesylate', 'ncit_id': 'C1687', 'aliases': ['STI571', 'STI-571', 'STI 571', 'Glivec', 'Gleevec', 'CGP57148B', 'CGP 57148', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate']}]",C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3242,P577_D579DEL,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Thymic Carcinoma,Sorafenib
3243,Mutation,"[{'id': 44, 'name': 'Dacomitinib', 'ncit_id': 'C53398', 'aliases': ['Vizimpro', 'PF-299804', 'PF-00299804-03', 'PF-00299804', 'EGFR Inhibitor PF-00299804', '(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
3244,DELETION,"[{'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}, {'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}, {'id': 2, 'name': 'Daunorubicin', 'ncit_id': 'C62091', 'aliases': ['RUBOMYCIN C', 'Rubidomycin', 'Leukaemomycin C', 'L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-', 'DNR', 'Daunorrubicina', 'DAUNOMYCIN', '5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-', '(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 651, 'name': 'Fludarabine', 'ncit_id': 'C1094', 'aliases': ['Fluradosa', '9-Beta-D-arabinofuranosyl-2-fluoroadenine', '9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine', '2-Fluorovidarabine', '2-Fluoro-9-beta-arabinofuranosyladenine']}]",B,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine+Methotrexate+Daunorubicin+Imatinib+Fludarabine
3245,R832L,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
3246,R832L,"[{'id': 145, 'name': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor', 'ncit_id': 'C2167', 'aliases': []}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
3247,ITD,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3248,ITD,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Leukemia,Sorafenib
3249,ITD,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Leukemia,Sunitinib
3250,FIP1L1-PDGFRA,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
3251,FIP1L1-PDGFRA,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib+Sorafenib
3252,N822K,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3253,FGFR1OP2-FGFR1,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3254,FIP1L1-PDGFRA,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3255,ITD,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Leukemia,Sunitinib+Sorafenib
3256,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Pancreatic Adenocarcinoma,Olaparib
3257,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Pancreatic Adenocarcinoma,Olaparib
3258,Overexpression,"[{'id': 81, 'name': 'Paclitaxel', 'ncit_id': 'C1411', 'aliases': ['Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol', 'Asotax', 'Anzatax', '[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester', '5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine']}, {'id': 93, 'name': 'Carboplatin', 'ncit_id': 'C1282', 'aliases': ['Ribocarbo', 'Platinwas', 'Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)', 'Paraplatine', 'Paraplatin AQ', 'Paraplatin', 'Paraplat', 'Novoplatinum', 'Nealorin', 'JM-8', 'Ercar', 'Displata', 'Cis-diammine(cyclobutanedicarboxylato)platinum II', 'Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum', 'Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)', 'CBDCA', 'Carbotec', 'Carbosol', 'Carbosin', 'Carboplatinum', 'Carboplatino', 'Carboplatin Hexal', 'Carboplat', 'Blastocarb', '1,1-cyclobutanedicarboxylic Acid Platinum Complex', ""(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum""]}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",B,Sensitivity/Response,Endometrial Serous Adenocarcinoma,Paclitaxel+Carboplatin+Trastuzumab
3259,G12C,"[{'id': 654, 'name': 'Sotorasib', 'ncit_id': 'C154287', 'aliases': ['Lumakras', 'AMG510', 'AMG-510', 'AMG 510']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3260,M766Q,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Osimertinib
3261,M766Q,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
3262,M766Q,"[{'id': 655, 'name': 'Poziotinib', 'ncit_id': 'C98838', 'aliases': ['HM781-36', 'NOV120101', 'HM781-36B']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Poziotinib
3263,A502_Y503insAY,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
3264,V560G,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib+Regorafenib+Imatinib
3265,V560G,"[{'id': 27, 'name': 'Regorafenib', 'ncit_id': 'C78204', 'aliases': ['Stivarga', 'BAY 73-4506', '4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib+Imatinib+Ponatinib
3266,V560G,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",E,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
3267,K642E,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Ponatinib
3268,KIAA1549-BRAF,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Childhood Pilocytic Astrocytoma,Vemurafenib+Sorafenib
3269,N822K,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3270,D816H,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3271,D816G,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3272,D820A,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3273,D820G,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3274,N822K,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib+Imatinib
3275,A829P,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib+Imatinib
3276,T670I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
3277,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
3278,TPM3-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Spindle Cell Sarcoma,Larotrectinib
3279,PDE4DIP-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Sarcoma,Larotrectinib
3280,Mutation,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3281,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3282,Fusion,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3283,MUTATION,"[{'id': 435, 'name': 'Sapanisertib', 'ncit_id': 'C90548', 'aliases': ['TAK-228', 'MLN0128', 'MLN-0128', 'INK128', 'INK-128']}]",B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Sapanisertib
3284,Overexpression,"[{'id': 664, 'name': 'Patritumab Deruxtecan', 'ncit_id': 'C136987', 'aliases': ['Anti-HER3 Antibody-drug Conjugate U3 1402', 'U3-1402a', 'U3-1402', 'U3 1402']}]",B,Sensitivity/Response,Breast Cancer,Patritumab Deruxtecan
3285,EML6::ALK e1-e20 and FBXO11::ALK e1-e20,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
3286,R273H,"[{'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}, {'id': 68, 'name': 'Doxorubicin', 'ncit_id': 'C456', 'aliases': ['Hydroxyldaunorubicin', 'Hydroxyl Daunorubicin', 'Hydroxydaunomycin', 'Adriablastin', '14-Hydroxydaunomycin', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione', '(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione']}]",D,Resistance,Osteosarcoma,Methotrexate+Doxorubicin
3287,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3288,LOSS-OF-FUNCTION,"[{'id': 382, 'name': 'Phosphatidylinositide 3-Kinase Inhibitor', 'ncit_id': 'C2152', 'aliases': []}]",D,Sensitivity/Response,Cancer,Phosphatidylinositide 3-Kinase Inhibitor
3289,MUTATION,"[{'id': 435, 'name': 'Sapanisertib', 'ncit_id': 'C90548', 'aliases': ['TAK-228', 'MLN0128', 'MLN-0128', 'INK128', 'INK-128']}]",B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Sapanisertib
3290,Mutation,"[{'id': 454, 'name': 'Ivosidenib', 'ncit_id': 'C114383', 'aliases': ['Tibsovo', 'AG-120']}]",B,Sensitivity/Response,Cholangiocarcinoma,Ivosidenib
3291,R132,"[{'id': 667, 'name': 'Mutant IDH1 Inhibitor DS-1001', 'ncit_id': 'C148134', 'aliases': ['Mutant Isocitrate Dehydrogenase Type 1 Inhibitor DS-1001', 'DS-1001b', 'DS-1001', 'DS 1001']}]",B,Sensitivity/Response,Glioma,Mutant IDH1 Inhibitor DS-1001
3292,Mutation,"[{'id': 669, 'name': 'Belvarafenib', 'ncit_id': 'C121646', 'aliases': ['HM95573']}]",B,Sensitivity/Response,Melanoma,Belvarafenib
3293,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Cholangiocarcinoma,Dabrafenib+Trametinib
3294,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Sensitivity/Response,Ovarian Cancer,Dabrafenib+Trametinib
3295,G12C,"[{'id': 654, 'name': 'Sotorasib', 'ncit_id': 'C154287', 'aliases': ['Lumakras', 'AMG510', 'AMG-510', 'AMG 510']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3296,ATM,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3297,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3298,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3299,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Breast Cancer,Rucaparib
3300,LOSS,"[{'id': 670, 'name': 'Elimusertib', 'ncit_id': 'C146807', 'aliases': ['ATR Kinase Inhibitor BAY1895344', 'BAY1895344', 'BAY-1895344', 'BAY 1895344', 'ATR Inhibitor BAY1895344']}]",B,Sensitivity/Response,Solid Tumor,Elimusertib
3301,D816V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Cancer,Dasatinib+Imatinib
3302,NRG1 FUSIONS,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Pancreatic Cancer,Afatinib
3303,E545,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}, {'id': 54, 'name': 'Fulvestrant', 'ncit_id': 'C1379', 'aliases': ['ZD9238', 'ICI 182780', 'ICI 182,780', 'Faslodex(ICI 182,780)', 'Faslodex', '7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol']}]",A,Sensitivity/Response,Breast Cancer,Alpelisib+Fulvestrant
3304,MUTATION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",C,Sensitivity/Response,Colorectal Cancer,Pembrolizumab
3305,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3306,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3307,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3308,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Prostate Cancer,Olaparib
3309,D842V,"[{'id': 671, 'name': 'Avapritinib', 'ncit_id': 'C123827', 'aliases': ['CS3007', 'AYVAKIT', '(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine', 'PDGFR Alpha/KIT Mutant-specific Inhibitor BLU-285', 'BLU-285']}]",B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Avapritinib
3310,CCDC6-RET,"[{'id': 672, 'name': 'Agerafenib', 'ncit_id': 'C107245', 'aliases': ['RXDX-105', 'CEP-32496', 'AC013773', '1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride']}]",C,Sensitivity/Response,Colorectal Cancer,Agerafenib
3311,CAD-ALK,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Colorectal Cancer,Entrectinib
3312,GOPC-ROS1,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Glioblastoma,Lorlatinib
3313,V600E,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3314,KIAA1549-BRAF,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3315,Mutation,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",B,Sensitivity/Response,Childhood Low-grade Glioma,Selumetinib
3316,Amplification,"[{'id': 674, 'name': 'Lucitanib', 'ncit_id': 'C95726', 'aliases': ['E-3810', 'AL3810', '1-Naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-']}]",B,Sensitivity/Response,Breast Cancer,Lucitanib
3317,SLC3A2-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3318,CD74-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3319,SLC3A2-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
3320,ATP1B1-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Afatinib
3321,APP-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Afatinib
3322,CD74-NRG1,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3323,SLC3A2-NRG1,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 675, 'name': 'Lumretuzumab', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Mucinous Adenocarcinoma,Erlotinib+Lumretuzumab
3324,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",A,Sensitivity/Response,Solid Tumor,Larotrectinib
3325,R1004G,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Head And Neck Cancer,Crizotinib
3326,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3327,Exon 14 Mutation,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3328,N549H,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
3329,N549H,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
3330,V561M,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
3331,V561M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3332,D842V,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
3333,KIF5B-RET V804L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3334,V804M,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3335,R849W,"[{'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Resistance,Chronic Myeloid Leukemia,Bosutinib
3336,Overexpression,"[{'id': 687, 'name': 'FGFR4 Inhibitor H3B-6527', 'ncit_id': 'C128862', 'aliases': ['H3B6527', 'H3B-6527', 'H3B 6527', 'Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527']}]",D,Sensitivity/Response,Hepatocellular Carcinoma,FGFR4 Inhibitor H3B-6527
3337,Overexpression,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Hepatocellular Carcinoma,Sorafenib
3338,OVEREXPRESSION,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Lung Adenocarcinoma,Erlotinib
3339,OVEREXPRESSION,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,FGFR Inhibitor AZD4547+Erlotinib
3340,ITD N676K,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",C,Resistance,Acute Myeloid Leukemia,Midostaurin
3341,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3342,Fusion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",C,Sensitivity/Response,Pancreatic Adenocarcinoma,Erlotinib+Pertuzumab
3343,Fusion,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
3344,LOSS-OF-FUNCTION,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Pembrolizumab+Nivolumab
3345,LOSS-OF-FUNCTION,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Atezolizumab+Durvalumab
3346,CD74-ROS1 G2032R,"[{'id': 690, 'name': 'DS-6501b', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,DS-6501b
3347,AMPLIFICATION,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3348,Mutation,"[{'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}, {'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",B,Sensitivity/Response,Solid Tumor,Vorinostat+Pazopanib
3349,Fusion,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Ceritinib
3350,Fusion,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Ceritinib
3351,G466V,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Irinotecan
3352,L525R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Solid Tumor,Cetuximab
3353,N486_P490del,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,Mitogen-Activated Protein Kinase Kinase Inhibitor
3354,Mutation,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Urinary Bladder Cancer,Cisplatin+Gemcitabine
3355,G12C,"[{'id': 693, 'name': 'KRAS G12C Inhibitor MRTX849', 'ncit_id': 'C157493', 'aliases': ['MRTX849', 'MRTX-849', 'MRTX 849']}]",D,Sensitivity/Response,Solid Tumor,KRAS G12C Inhibitor MRTX849
3356,D594E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3357,Class 3 Mutations,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3358,V211D,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",C,Resistance,Colorectal Cancer,Binimetinib+Panitumumab
3359,V211D,"[{'id': 694, 'name': 'MAP855', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,MAP855
3360,Fusion,"[{'id': 695, 'name': 'EPZ004777', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Acute Biphenotypic Leukemia,EPZ004777
3361,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Langerhans Cell Sarcoma,Vemurafenib
3362,LOSS-OF-FUNCTION,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Sensitivity/Response,Renal Cell Carcinoma,Nivolumab
3363,Exon 19 Deletion,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Resistance,Lung Non-small Cell Carcinoma,Pembrolizumab+Nivolumab
3364,Exon 19 Deletion,"[{'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}, {'id': 296, 'name': 'Avelumab', 'ncit_id': 'C116870', 'aliases': []}]",B,Resistance,Lung Non-small Cell Carcinoma,Durvalumab+Atezolizumab+Avelumab
3365,gBRCAm,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
3366,Fusion,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3367,EML4-ALK G1202R and L1196M,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Lorlatinib
3368,EML4-ALK G1202R and L1196M,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}, {'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}, {'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Cancer,Lorlatinib+Ceritinib+Brigatinib+Alectinib+Crizotinib
3369,ALK Fusion G1202R,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",D,Sensitivity/Response,Cancer,Lorlatinib
3370,EML4-ALK L1196M and L1198F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
3371,EML4-ALK G1202R and L1198F,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}, {'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}, {'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",D,Resistance,Cancer,Lorlatinib+Brigatinib+Ceritinib+Alectinib
3372,FRAMESHIFT MUTATION,"[{'id': 289, 'name': 'PD1 Inhibitor', 'ncit_id': 'C124946', 'aliases': []}]",C,Sensitivity/Response,Uveal Melanoma,PD1 Inhibitor
3373,EML4-ALK L1196M,"[{'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}, {'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}, {'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}, {'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",D,Sensitivity/Response,Cancer,Brigatinib+Alectinib+Lorlatinib+Ceritinib
3374,EML4-ALK L1196M,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Cancer,Crizotinib
3375,EML4-ALK G1202del,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Resistance,Lung Non-small Cell Carcinoma,Ceritinib
3376,low expression,"[{'id': 696, 'name': 'Akt/ERK Inhibitor ONC201', 'ncit_id': 'C113792', 'aliases': ['TIC10', 'ONC201']}]",B,Sensitivity/Response,Glioblastoma,Akt/ERK Inhibitor ONC201
3377,K28M,"[{'id': 696, 'name': 'Akt/ERK Inhibitor ONC201', 'ncit_id': 'C113792', 'aliases': ['TIC10', 'ONC201']}]",B,Sensitivity/Response,Glioma,Akt/ERK Inhibitor ONC201
3378,K27M,"[{'id': 696, 'name': 'Akt/ERK Inhibitor ONC201', 'ncit_id': 'C113792', 'aliases': ['TIC10', 'ONC201']}]",B,Sensitivity/Response,Glioma,Akt/ERK Inhibitor ONC201
3379,EML4-ALK L1198F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
3380,G697R,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}, {'id': 35, 'name': 'SU5614', 'ncit_id': None, 'aliases': []}, {'id': 698, 'name': 'K 252a', 'ncit_id': 'C1382', 'aliases': ['SF 2370', 'Protein Kinase Inhibitor K252a', 'K252A', 'K-252a', 'Antibiotic SF 2370', 'Antibiotic K 252A', ""9,1-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic Acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, Methyl Ester, (9-alpha,10-beta,12-alpha)-""]}]",D,Resistance,Acute Myeloid Leukemia,Midostaurin+SU5614+K 252a
3381,EML4::ALK C1156Y-L1198F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
3382,Exon 20 Insertion,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3383,V600E,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}, {'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}]",B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Binimetinib+Encorafenib
3384,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Cancer,Crizotinib
3385,V600R,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}]",B,Sensitivity/Response,Melanoma,BRAF Inhibitor
3386,V600D,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}]",C,Sensitivity/Response,Melanoma,BRAF Inhibitor
3387,L597,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}]",C,Sensitivity/Response,Melanoma,BRAF Inhibitor
3388,V600R,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3389,V600D,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",C,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3390,V600_K601>E,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",C,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3391,V600M,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3392,L597,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3393,V601E,"[{'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}, {'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}]",B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3394,G469,"[{'id': 110, 'name': 'Mitogen-Activated Protein Kinase Kinase Inhibitor', 'ncit_id': 'C69145', 'aliases': []}, {'id': 699, 'name': 'BRAF Inhibitor', 'ncit_id': 'C155322', 'aliases': ['B-RAF Inhibitor']}]",B,Sensitivity/Response,Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+BRAF Inhibitor
3395,Overexpression,"[{'id': 700, 'name': 'Fisogatinib', 'ncit_id': 'C123826', 'aliases': ['N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide', 'CS3008', 'CS-3008', 'CS 3008', 'BLU554', 'BLU 554', '2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-', 'Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554', 'BLU-554']}]",B,Sensitivity/Response,Hepatocellular Carcinoma,Fisogatinib
3396,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",C,Sensitivity/Response,Cholangiocarcinoma,Trastuzumab+Pertuzumab
3397,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3398,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3399,R683G,"[{'id': 469, 'name': 'Sirolimus', 'ncit_id': 'C1212', 'aliases': []}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Sirolimus
3400,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3401,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3402,Alternative Transcript (ATI),"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Cancer,Crizotinib
3403,Amplification,"[{'id': 4287, 'name': 'Trastuzumab Deruxtecan', 'ncit_id': 'C152716', 'aliases': []}]",B,Sensitivity/Response,Stomach Cancer,Trastuzumab Deruxtecan
3404,Amplification,"[{'id': 4287, 'name': 'Trastuzumab Deruxtecan', 'ncit_id': 'C152716', 'aliases': []}]",B,Sensitivity/Response,Breast Cancer,Trastuzumab Deruxtecan
3405,Fusion,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Pancreatic Cancer,Larotrectinib
3406,Mutation,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 156, 'name': 'Pemetrexed', 'ncit_id': 'C61614', 'aliases': ['Pemfexy', 'Multitargeted Antifolate', 'MTA', 'L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Pemetrexed
3407,Expression,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3408,Expression,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
3409,SNX2-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,B-lymphoblastic Leukemia/lymphoma,Dasatinib+Imatinib
3410,D594H,"[{'id': 1413, 'name': 'Enfortumab Vedotin', 'ncit_id': 'C114500', 'aliases': ['Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E', 'AGS-22M6E', 'Padcev', 'Enfortumab Vedotin-ejfv', 'ASG-22CE', 'Anti-Nectin 4 ADC ASG-22CE', 'AGS 22ME']}]",D,Sensitivity/Response,Cancer,Enfortumab Vedotin
3411,V60E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3412,G128V,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3413,V154I,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3414,P124S,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3415,P124L,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3416,C125S,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3417,V35M,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3418,L46F,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3419,N126D,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3420,Amplificatioin,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3421,P29S,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Resistance,Melanoma,Vemurafenib+Dabrafenib
3422,mutation,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3423,C125S,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Melanoma,Dabrafenib+Trametinib
3424,Amplification,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Melanoma,Dabrafenib+Trametinib
3425,Q61K,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",B,Resistance,Melanoma,Dabrafenib+Trametinib
3426,Loss,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Resistance,Melanoma,Dabrafenib+Vemurafenib
3427,Exon 20 Insertion,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trastuzumab Emtansine
3428,G2032R,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3429,D2033N,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Cancer,Crizotinib
3430,S1986F,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3431,G2032R,"[{'id': 2818, 'name': 'Repotrectinib', 'ncit_id': 'C133821', 'aliases': ['TPX-0005', 'Multikinase Inhibitor TPX-0005', 'Multi-kinase Inhibitor TPX-0005', 'ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Repotrectinib
3432,G623E,"[{'id': 2818, 'name': 'Repotrectinib', 'ncit_id': 'C133821', 'aliases': ['TPX-0005', 'Multikinase Inhibitor TPX-0005', 'Multi-kinase Inhibitor TPX-0005', 'ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005']}]",C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,Repotrectinib
3433,S1986Y/F,"[{'id': 241, 'name': 'Lorlatinib', 'ncit_id': 'C113655', 'aliases': ['PF-06463922', 'Lorbrena', '7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', '2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3434,R2033N,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
3435,D2033N,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
3436,K57N,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",C,Resistance,Melanoma,Selumetinib
3437,M918T,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Cabozantinib
3438,K3326*,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}, {'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",C,Sensitivity/Response,Glioblastoma,Olaparib+Temozolomide
3439,Mutation,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3440,Amplification,"[{'id': 425, 'name': 'Savolitinib', 'ncit_id': 'C104732', 'aliases': ['Volitinib', 'HMPL-504', 'AZD6094', 'AZD 6094']}]",B,Sensitivity/Response,Stomach Cancer,Savolitinib
3441,N486_P490del,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Pancreatic Cancer,Trametinib
3442,H123Q,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Pancreatic Cancer,Trametinib
3443,G132D,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Pancreatic Adenocarcinoma,Trametinib
3444,G132S,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Resistance,Pancreatic Adenocarcinoma,Trametinib
3445,AKAP9-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Congenital Melanocytic Nevus,Trametinib
3446,D594G,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Cancer,Trametinib
3447,V600E,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Dabrafenib
3448,V600E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Trametinib+Dabrafenib
3449,NRF1-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Trametinib
3450,BCR-ABL T315V,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3451,BCR-ABL V299L,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3452,BCR-ABL T315A,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3453,BCR-ABL E279K,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3454,BCR-ABL F317R,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
3455,BCR-ABL L248R F359I,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
3456,BCR-ABL L248R,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}]",D,Resistance,Chronic Myeloid Leukemia,Axitinib
3457,BCR-ABL T315I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Acute Lymphoblastic Leukemia,Imatinib+Dasatinib+Nilotinib
3458,BCR-ABL T315I,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Nilotinib+Imatinib
3459,BCR-ABL E255K V299L,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib+Dasatinib
3460,RCSD1-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3461,RCSD1-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3462,Amplification,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}]",D,Sensitivity/Response,Glioblastoma,Talazoparib
3463,EXON 11-19 DELETION,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 531, 'name': 'Leucovorin', 'ncit_id': 'C71631', 'aliases': ['Folinic Acid', '5-Formyltetrahydrofolate']}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Fluorouracil+Leucovorin
3464,Overexpression,"[{'id': 59, 'name': 'Bortezomib', 'ncit_id': 'C1851', 'aliases': ['Velcade', 'PS341', 'PS-341', 'MLN341', 'LDP 341', '[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid']}]",C,Sensitivity/Response,Multiple Myeloma,Bortezomib
3465,Amplification,"[{'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",B,Sensitivity/Response,Cancer,Ribociclib
3466,Overexpression,"[{'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Ribociclib
3467,Amplification,"[{'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Sensitivity/Response,Ovarian Cancer,Dinaciclib
3468,Overexpression,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Resistance,Ovarian Cancer,Palbociclib
3469,MET-ATXN7L1,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3470,LOSS-OF-FUNCTION,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 7387, 'name': 'Azathioprine', 'ncit_id': 'C290', 'aliases': ['AZTP', 'AZA', '6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine']}]",B,Adverse Response,Childhood Acute Lymphocytic Leukemia,Mercaptopurine+Thioguanine+Azathioprine
3471,EXON 14 SKIPPING MUTATION,"[{'id': 300, 'name': 'Capmatinib', 'ncit_id': 'C90564', 'aliases': ['INCB28060', 'INCB028060', 'INCB 28060', 'INC280', 'INC-280', '2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3472,EXON 14 SKIPPING MUTATION,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Histiocytic And Dendritic Cell Cancer,Crizotinib
3473,EXON 14 SKIPPING MUTATION,"[{'id': 300, 'name': 'Capmatinib', 'ncit_id': 'C90564', 'aliases': ['INCB28060', 'INCB028060', 'INCB 28060', 'INC280', 'INC-280', '2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide']}]",D,Sensitivity/Response,Cancer,Capmatinib
3474,EXPRESSION,"[{'id': 8063, 'name': 'Dexamethasone', 'ncit_id': 'C422', 'aliases': ['Hemady', 'Dxevo', 'ZoDex', 'Visumetazone', 'TaperDex', 'Spersadex', 'Orgadrone', 'Mymethasone', 'Millicorten', 'Methylfluorprednisolone', 'Loverine', 'Lokalison-F', 'Hexadrol', 'Hexadecadrol', 'Gammacorten', 'Fortecortin', 'Fluorodelta', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Dinormon', 'Dexone', 'Dexinoral', 'Dexapos', 'Dexamonozon', 'Dexamethasonum', 'Dexamethasone Intensol', 'Dexameth', 'Dexamecortin', 'Dexalocal', 'Dexafluorene', 'Dexafarma', 'Dexacortin', 'Dexacortal', 'Dexa-sine', 'Dexa-Scheroson', 'Dexa-Rhinosan', 'Dexa-Mamallet', 'Desameton', 'Desamethasone', 'Deronil', 'Deltafluorene', 'Dekacort', 'Dectancyl', 'Decasone R.p.', 'Decameth', 'Decalix', 'Decadron DP', 'Decadron', 'Decadrol', 'Decacort', 'Cortisumman', 'Cortidexason', 'Baycuten N', 'Baycuten', 'Baycadron', 'Auxiloson', 'Auricularum', 'Anemul Mono', 'Amplidermis', 'Alin Oftalmico', 'Alin Depot', 'Alin', 'Alba-Dex', 'Aknichthol Dexa', 'Adexone', 'Aacidexam', '9Alpha-fluoro-16alpha-methylprednisolone', '9alpha-Fluoro-16alpha- Methylprednisolone', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3475,Amplification,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Sensitivity/Response,Ovarian Cancer,Cisplatin+Dinaciclib
3476,OVEREXPRESSION,"[{'id': 429, 'name': 'Palbociclib', 'ncit_id': 'C49176', 'aliases': ['Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-', 'PD-0332991', 'PD 991', 'PD 332991', 'PD 0332991', 'Ibrance', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one']}]",D,Sensitivity/Response,Glioblastoma Proneural Subtype,Palbociclib
3477,EXPRESSION,"[{'id': 8063, 'name': 'Dexamethasone', 'ncit_id': 'C422', 'aliases': ['Hemady', 'Dxevo', 'ZoDex', 'Visumetazone', 'TaperDex', 'Spersadex', 'Orgadrone', 'Mymethasone', 'Millicorten', 'Methylfluorprednisolone', 'Loverine', 'Lokalison-F', 'Hexadrol', 'Hexadecadrol', 'Gammacorten', 'Fortecortin', 'Fluorodelta', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Dinormon', 'Dexone', 'Dexinoral', 'Dexapos', 'Dexamonozon', 'Dexamethasonum', 'Dexamethasone Intensol', 'Dexameth', 'Dexamecortin', 'Dexalocal', 'Dexafluorene', 'Dexafarma', 'Dexacortin', 'Dexacortal', 'Dexa-sine', 'Dexa-Scheroson', 'Dexa-Rhinosan', 'Dexa-Mamallet', 'Desameton', 'Desamethasone', 'Deronil', 'Deltafluorene', 'Dekacort', 'Dectancyl', 'Decasone R.p.', 'Decameth', 'Decalix', 'Decadron DP', 'Decadron', 'Decadrol', 'Decacort', 'Cortisumman', 'Cortidexason', 'Baycuten N', 'Baycuten', 'Baycadron', 'Auxiloson', 'Auricularum', 'Anemul Mono', 'Amplidermis', 'Alin Oftalmico', 'Alin Depot', 'Alin', 'Alba-Dex', 'Aknichthol Dexa', 'Adexone', 'Aacidexam', '9Alpha-fluoro-16alpha-methylprednisolone', '9alpha-Fluoro-16alpha- Methylprednisolone', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3478,Amplification,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
3479,Overexpression,"[{'id': 360, 'name': 'Radiation Therapy', 'ncit_id': 'C15313', 'aliases': ['ENERGY_TYPE', 'Radiation Therapy, NOS', 'Therapy, Radiation', 'RT', 'RADIOTHERAPY', 'Radiotherapeutics', 'RADIATION', 'Irradiation', 'Irradiated', 'Irradiate', 'Cancer Radiotherapy']}, {'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}]",D,Sensitivity/Response,Glioma,Radiation Therapy+Gefitinib
3480,Overexpression,"[{'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pertuzumab
3481,Overexpression,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Resistance,Colorectal Cancer,Cetuximab
3482,Overexpression,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Lapatinib+Trastuzumab
3483,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Colorectal Cancer,Afatinib
3484,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Stomach Cancer,Afatinib
3485,Exon 18 Mutation,"[{'id': 671, 'name': 'Avapritinib', 'ncit_id': 'C123827', 'aliases': ['CS3007', 'AYVAKIT', '(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine', 'PDGFR Alpha/KIT Mutant-specific Inhibitor BLU-285', 'BLU-285']}]",A,Sensitivity/Response,Gastrointestinal Stromal Tumor,Avapritinib
3486,Amplification,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
3487,Amplification,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Adenosquamous Lung Carcinoma,Pazopanib
3488,R367Q,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",C,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3489,R238W,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3490,S445F,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3491,Rearrangement,[],D,Sensitivity/Response,Acute Biphenotypic Leukemia,
3492,BCR-ABL D363G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3493,BCR-ABL E255V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3494,BCR-ABL E98G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3495,BCR-ABL L384M,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3496,BCR-ABL M244V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3497,BCR-ABL L364I,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3498,BCR-ABL V186A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3499,BCR-ABL Y253H,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3500,Overexpression,"[{'id': 1261, 'name': 'Rogaratinib', 'ncit_id': 'C112205', 'aliases': ['BAY-1163877', '4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one', 'BAY1163877']}]",D,Sensitivity/Response,Colon Cancer,Rogaratinib
3501,Overexpression,"[{'id': 1261, 'name': 'Rogaratinib', 'ncit_id': 'C112205', 'aliases': ['BAY-1163877', '4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one', 'BAY1163877']}, {'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Sensitivity/Response,Lung Cancer,Rogaratinib+Docetaxel
3502,Overexpression,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",D,Sensitivity/Response,Colorectal Cancer,Erdafitinib
3503,P253R,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Pazopanib
3504,S249C,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Pazopanib
3505,Amplification,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3506,AMPLIFICATION,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3507,BCR-ABL,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}, {'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib+Bafetinib+Nilotinib
3508,BCR-ABL F317L,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Dasatinib+Imatinib
3509,Exon 14 Mutation,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3510,BCR-ABL M351T,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
3511,BCR-ABL T315A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Cancer,Imatinib+Dasatinib
3512,BCR-ABL F317V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Resistance,Cancer,Dasatinib
3513,BCR-ABL H396P,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
3514,BCR-ABL Y253F,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Imatinib
3515,BCR-ABL Q252H,"[{'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Bafetinib+Imatinib
3516,BCR-ABL M244V,"[{'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Cancer,Bafetinib+Imatinib
3517,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Esophageal Carcinoma,Cisplatin
3518,OVEREXPRESSION,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",C,Sensitivity/Response,Sarcoma,Ruxolitinib
3519,BCR-ABL G250E,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 625, 'name': 'Bafetinib', 'ncit_id': 'C62516', 'aliases': ['NS-187', 'INNO-406', 'Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406', 'CNS-9', ""Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-""]}]",D,Resistance,Cancer,Imatinib+Bafetinib
3520,OVEREXPRESSION,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",B,Sensitivity/Response,Neuroendocrine Tumor,Pazopanib
3521,Amplification,"[{'id': 457, 'name': 'Trastuzumab Emtansine', 'ncit_id': 'C82492', 'aliases': ['Trastuzumab-MCC-DM1 Immunoconjugate', 'Trastuzumab-MCC-DM1 Antibody-Drug Conjugate', 'Trastuzumab-MCC-DM1', 'Trastuzumab-DM1', 'T-DM1', 'RO5304020', 'PRO132365', 'Kadcyla', ""Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"", 'ADO-TRASTUZUMAB EMTANSINE', 'Ado Trastuzumab Emtansine']}]",B,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab Emtansine
3522,G719X,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3523,L861Q,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3524,S768I,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3525,Y1021H,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
3526,G469E,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Breast Ductal Carcinoma,Trametinib
3527,R367Q,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood Acute Lymphocytic Leukemia,Mercaptopurine+Thioguanine
3528,EML4-ALK L1196M,"[{'id': 856, 'name': 'Ensartinib', 'ncit_id': 'C102754', 'aliases': ['X-396', '6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3529,Expression,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Glioblastoma,Crizotinib
3530,OVEREXPRESSION,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Resistance,Breast Cancer,Olaparib
3531,OVEREXPRESSION,"[{'id': 6356, 'name': 'Trabectedin', 'ncit_id': 'C1691', 'aliases': ['Yondelis', ""Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-Octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-"", 'ET-743', 'Ecteinascidin 743', 'Ecteinascidin']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Sarcoma,Trabectedin+Olaparib
3532,Overexpression,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib+Crizotinib
3533,V559D,"[{'id': 19829, 'name': 'CHMFL-KIT-031', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Gastrointestinal Stromal Tumor,CHMFL-KIT-031
3534,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3535,Amplification,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Gastric Adenocarcinoma,Cabozantinib
3536,OVEREXPRESSION,"[{'id': 13, 'name': 'Nilotinib', 'ncit_id': 'C48375', 'aliases': ['AMN 107 Base Form', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Nilotinib
3537,D183H,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3538,T303S,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3539,L191F,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3540,D183E,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3541,K176N,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3542,G174E,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3543,N144S,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3544,N114D,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3545,S103I,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3546,S103N,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3547,S103T,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3548,A190V,"[{'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3549,A190T,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3550,N144S,"[{'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine
3551,L191F,"[{'id': 173, 'name': 'Cytarabine', 'ncit_id': 'C408', 'aliases': ['WR-28453', 'Udicil', 'U-19920', 'U 19920', 'Tarabine PFS', 'Starasid', 'Erpalfa', 'Cytosine-beta-arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine Arabinoside', 'Cytosar-U', 'Cytosar', 'Cytarbel', 'Cytarabinum', 'CHX-3311', 'Beta-Cytosine Arabinoside', 'Aracytine', 'Aracytin', 'Aracytidine', 'Arabinosylcytosine', 'Arabinofuranosylcytosine', 'Arabine', 'ARA-cell', 'Ara-C', 'Alexan', '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '1.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '.beta.-Cytosine Arabinoside']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine
3552,S103T,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 19112, 'name': 'Lometrexol', 'ncit_id': 'C979', 'aliases': ['Pyrido[2,3-d]pyrimidine, L-glutamic Acid Derivative (9CI)', 'L-Glutamic Acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-', 'L-Glutamic Acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-', '6R-5,10-Dideazatetrahydrofolate', '(6R)-DDATHF']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Lometrexol
3553,A190T,"[{'id': 19112, 'name': 'Lometrexol', 'ncit_id': 'C979', 'aliases': ['Pyrido[2,3-d]pyrimidine, L-glutamic Acid Derivative (9CI)', 'L-Glutamic Acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-', 'L-Glutamic Acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-', '6R-5,10-Dideazatetrahydrofolate', '(6R)-DDATHF']}, {'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Lometrexol+Mercaptopurine
3554,EWSR1-ATF1,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",B,Sensitivity/Response,Clear Cell Sarcoma,Crizotinib
3555,Overexpression,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Cabozantinib
3556,REARRANGEMENT,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3557,Overexpression,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,High Grade Glioma,Dasatinib
3558,BCR-ABL S438C,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Resistance,Chronic Myeloid Leukemia,Dasatinib
3559,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 8631, 'name': 'Picoplatin', 'ncit_id': 'C48416', 'aliases': ['ZD0473', 'Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)-', 'NX-473', 'JM473', 'Cis-Amminedichloro (2-Methylpyridine) Platinum (II)', 'AMD473']}]",D,Resistance,Ovarian Cancer,Cisplatin+Picoplatin
3560,Overexpression,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,FGFR Inhibitor AZD4547
3561,Amplification,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",D,Sensitivity/Response,Stomach Cancer,Erdafitinib
3562,Amplification,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",D,Sensitivity/Response,Lung Cancer,Erdafitinib
3563,Overexpression,"[{'id': 12707, 'name': 'Bazedoxifene', 'ncit_id': 'C73598', 'aliases': ['WAY 140424', 'TSE-424', '1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-']}]",D,Resistance,Rhabdomyosarcoma,Bazedoxifene
3564,S646F,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",D,Sensitivity/Response,Acute Lymphoblastic Leukemia,Ruxolitinib
3565,H1112L,"[{'id': 638, 'name': 'Tepotinib', 'ncit_id': 'C88314', 'aliases': ['EMD1214063', 'EMD-1214063', 'EMD 1214063', 'Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-']}]",D,Sensitivity/Response,Cancer,Tepotinib
3566,MUTATION,"[{'id': 308, 'name': 'Metformin', 'ncit_id': 'C61612', 'aliases': ['N,N-Dimethylimidodicarbonimidic Diamide', 'N,N-dimethylbiguanide', '1,1-Dimethylbiguanide']}, {'id': 117, 'name': 'Vandetanib', 'ncit_id': 'C2737', 'aliases': ['ZD6474', 'ZD-6474', 'Zactima', 'Caprelsa', 'AZD6474']}]",B,Sensitivity/Response,Hereditary Renal Cell Carcinoma,Metformin+Vandetanib
3567,Fusion,"[{'id': 648, 'name': 'Derazantinib', 'ncit_id': 'C104267', 'aliases': ['ARQ-087', 'ARQ 087']}]",D,Sensitivity/Response,Cholangiocarcinoma,Derazantinib
3568,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3569,Mutation,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",B,Resistance,Glioblastoma,Temozolomide
3570,M237I,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",D,Resistance,Glioblastoma,Temozolomide
3571,R273H,"[{'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}]",D,Resistance,Glioblastoma,Temozolomide
3572,Overexpression,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",B,Sensitivity/Response,Hepatocellular Carcinoma,Sunitinib
3573,Overexpression,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Rhabdomyosarcoma,Sunitinib
3574,Amplification,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Lung Squamous Cell Carcinoma,Imatinib+Sunitinib
3575,BCR-PDGFRA,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Imatinib
3576,COL1A1-PDGFB,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Sunitinib
3577,Overexpression,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Sunitinib
3578,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3579,ETV6-NTRK3,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Entrectinib
3580,E542K,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Resistance,Breast Cancer,PI-103
3581,E545K,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Resistance,Breast Cancer,PI-103
3582,H1047L,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,PI-103
3583,H1047R,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,PI-103
3584,K111N,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
3585,Loss,"[{'id': 19830, 'name': 'PI-103', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
3586,E542K,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3587,E542K,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3588,E545K,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3589,E545K,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3590,H1047L,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3591,K111N,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3592,Loss,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Resistance,Breast Cancer,PI3Ka/Di
3593,Loss,"[{'id': 19832, 'name': 'PI3Ka/Di', 'ncit_id': None, 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3594,C797S,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 318, 'name': 'Brigatinib', 'ncit_id': 'C98831', 'aliases': ['AP26113', 'AP-26113', 'AP 26113', 'Alunbrig', '5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine', '(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cetuximab+Brigatinib
3595,V600E,"[{'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Thyroid Gland Cancer,PLX4720+Ponatinib
3596,V600,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",B,Sensitivity/Response,Childhood Low-grade Glioma,Dabrafenib
3597,G328V,"[{'id': 15211, 'name': 'MEK-1/MEKK-1 Inhibitor E6201', 'ncit_id': 'C79848', 'aliases': ['E6201']}]",D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",MEK-1/MEKK-1 Inhibitor E6201
3598,V600E,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Thyroid Gland Cancer,Ponatinib+PLX4720
3599,TPM3-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Larotrectinib
3600,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Trastuzumab
3601,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}]",A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Capecitabine
3602,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Neratinib
3603,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}]",B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Capecitabine
3604,L718V and L718Q,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Resistance,Lung Adenocarcinoma,Osimertinib
3605,L858R,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
3606,L755S,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",C,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Capecitabine+Neratinib
3607,P29S,"[{'id': 30, 'name': 'PLX4720', 'ncit_id': None, 'aliases': []}]",D,Resistance,Skin Melanoma,PLX4720
3608,C797S,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Adenocarcinoma,Osimertinib
3609,L718Q,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Adenocarcinoma,Osimertinib
3610,L718V,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Adenocarcinoma,Osimertinib
3611,S249C,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Transitional Cell Carcinoma,Ponatinib
3612,Amplification,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Stomach Cancer,Ponatinib
3613,Amplification,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Stomach Cancer,Ponatinib
3614,V955I,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",C,Resistance,Colorectal Cancer,Cetuximab
3615,G12C,"[{'id': 654, 'name': 'Sotorasib', 'ncit_id': 'C154287', 'aliases': ['Lumakras', 'AMG510', 'AMG-510', 'AMG 510']}]",B,Sensitivity/Response,Cancer,Sotorasib
3616,L718V,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Cancer,Erlotinib
3617,C797S,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Cancer,Afatinib
3618,L718Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Cancer,Afatinib
3619,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
3620,Amplification,"[{'id': 52, 'name': 'Neratinib', 'ncit_id': 'C49094', 'aliases': ['PB-272', 'PB 272', 'HKI-272', 'HKI 272', '2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-', '(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
3621,L718V,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Cancer,Afatinib
3622,L718Q,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Resistance,Cancer,Erlotinib
3623,C797S,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Cancer,Erlotinib
3624,R238W,"[{'id': 86, 'name': 'Mercaptopurine', 'ncit_id': 'C195', 'aliases': ['WR-2785', 'U-4748', 'Purinethol', 'Purinethiol', 'Purine-6-thiol, Monohydrate', 'Purine-6-thiol Monohydrate', 'Purine-6-thiol (8CI)', 'Purine, 6-mercapto-', 'Purimethol', 'Puri-Nethol', 'NCI-C04886', 'Mern', 'Mercapurin', 'Mercaptopurinum', 'Mercapto-6-purine', 'Mercaptina', 'Mercaleukin', 'Mercaleukim', 'Leupurin', 'Leukerin', 'Ismipur', 'Flocofil', 'BW 57-323H', 'Azathiopurine', 'Alti-Mercaptopurine', '7-Mercapto-1,3,4,6-tetrazaindene', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', '6-Thioxopurine', '6-Thiopurine', '6-Purinethiol', '6-MP', '6-Mercaptopurine Monohydrate', '6-Mercaptopurine', '6 Thiopurine', '6 Thiohypoxanthine', '6 MP', '3H-Purine-6-thiol', '1,7-Dihydro-6H-purine-6-thione Monohydrate', '1,7-Dihydro-6H-purine-6-thione']}, {'id': 87, 'name': 'Thioguanine', 'ncit_id': 'C876', 'aliases': ['X 27', 'WR-1141', 'Wellcome U3B', 'Tioguanine', 'Tioguanin', 'Thioguanine Hydrate', 'Thioguanine Hemihydrate', 'Tabloid', 'Lanvis', 'BW 5071', '6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)', '6-Thioguanine', '6-TG', '6-Mercaptoguanine', '6-Mercapto-2-aminopurine', '6-Amino-2-mercaptopurine', '6 Thioguanine', '6 Mercaptoguanine', '2-Mercapto-6-aminopurine', '2-Aminopurine-6-thiol Hemihydrate', '2-Aminopurine-6-thiol', '2-Aminopurine-6(1H)-thione', '2-Aminopurin-6-thiol', '2-Amino-6-purinethiol', '2-Amino-6-mercaptopurine', '2-Amino-1,7-dihydro-6H-purine-6-thione', '2-Amino 6MP']}]",D,Resistance,Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3625,C797G,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Adenocarcinoma,Osimertinib
3626,L792H,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Resistance,Lung Adenocarcinoma,Osimertinib
3627,C797S,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib+Erlotinib
3628,L718Q,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib+Erlotinib
3629,Overexpression,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",D,Resistance,Colorectal Cancer,Oxaliplatin
3630,Expression,"[{'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",D,Resistance,Colon Cancer,Oxaliplatin
3631,BCR-ABL S417Y,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3632,BCR-ABL E355G,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3633,BCR-ABL F486S,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3634,BCR-ABL E459K,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3635,Double Ph,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3636,P-Loop Mutation,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3637,D835Y,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Cancer,Gilteritinib
3638,D835Y,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3639,OVEREXPRESSION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
3640,OVEREXPRESSION,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
3641,E545K,"[{'id': 5509, 'name': 'Radiation Ionizing Radiotherapy', 'ncit_id': 'C15846', 'aliases': ['Radiation']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Cervical Cancer,Radiation Ionizing Radiotherapy+Cisplatin
3642,OVEREXPRESSION,"[{'id': 8063, 'name': 'Dexamethasone', 'ncit_id': 'C422', 'aliases': ['Hemady', 'Dxevo', 'ZoDex', 'Visumetazone', 'TaperDex', 'Spersadex', 'Orgadrone', 'Mymethasone', 'Millicorten', 'Methylfluorprednisolone', 'Loverine', 'Lokalison-F', 'Hexadrol', 'Hexadecadrol', 'Gammacorten', 'Fortecortin', 'Fluorodelta', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Dinormon', 'Dexone', 'Dexinoral', 'Dexapos', 'Dexamonozon', 'Dexamethasonum', 'Dexamethasone Intensol', 'Dexameth', 'Dexamecortin', 'Dexalocal', 'Dexafluorene', 'Dexafarma', 'Dexacortin', 'Dexacortal', 'Dexa-sine', 'Dexa-Scheroson', 'Dexa-Rhinosan', 'Dexa-Mamallet', 'Desameton', 'Desamethasone', 'Deronil', 'Deltafluorene', 'Dekacort', 'Dectancyl', 'Decasone R.p.', 'Decameth', 'Decalix', 'Decadron DP', 'Decadron', 'Decadrol', 'Decacort', 'Cortisumman', 'Cortidexason', 'Baycuten N', 'Baycuten', 'Baycadron', 'Auxiloson', 'Auricularum', 'Anemul Mono', 'Amplidermis', 'Alin Oftalmico', 'Alin Depot', 'Alin', 'Alba-Dex', 'Aknichthol Dexa', 'Adexone', 'Aacidexam', '9Alpha-fluoro-16alpha-methylprednisolone', '9alpha-Fluoro-16alpha- Methylprednisolone', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3643,OVEREXPRESSION,"[{'id': 8063, 'name': 'Dexamethasone', 'ncit_id': 'C422', 'aliases': ['Hemady', 'Dxevo', 'ZoDex', 'Visumetazone', 'TaperDex', 'Spersadex', 'Orgadrone', 'Mymethasone', 'Millicorten', 'Methylfluorprednisolone', 'Loverine', 'Lokalison-F', 'Hexadrol', 'Hexadecadrol', 'Gammacorten', 'Fortecortin', 'Fluorodelta', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Dinormon', 'Dexone', 'Dexinoral', 'Dexapos', 'Dexamonozon', 'Dexamethasonum', 'Dexamethasone Intensol', 'Dexameth', 'Dexamecortin', 'Dexalocal', 'Dexafluorene', 'Dexafarma', 'Dexacortin', 'Dexacortal', 'Dexa-sine', 'Dexa-Scheroson', 'Dexa-Rhinosan', 'Dexa-Mamallet', 'Desameton', 'Desamethasone', 'Deronil', 'Deltafluorene', 'Dekacort', 'Dectancyl', 'Decasone R.p.', 'Decameth', 'Decalix', 'Decadron DP', 'Decadron', 'Decadrol', 'Decacort', 'Cortisumman', 'Cortidexason', 'Baycuten N', 'Baycuten', 'Baycadron', 'Auxiloson', 'Auricularum', 'Anemul Mono', 'Amplidermis', 'Alin Oftalmico', 'Alin Depot', 'Alin', 'Alba-Dex', 'Aknichthol Dexa', 'Adexone', 'Aacidexam', '9Alpha-fluoro-16alpha-methylprednisolone', '9alpha-Fluoro-16alpha- Methylprednisolone', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione']}, {'id': 381, 'name': 'Ribociclib', 'ncit_id': 'C95701', 'aliases': ['LEE011', 'LEE-011', 'Kisqali', '7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide']}]",D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3644,Expression,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Sensitivity/Response,Glioblastoma,Pexidartinib
3645,Expression,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}, {'id': 6473, 'name': 'Vatalanib', 'ncit_id': 'C1868', 'aliases': ['ZK-232934', 'PTK787/ZK 222584', 'PTK787', 'N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine', 'CGP-79787', 'CGP 79787']}]",D,Sensitivity/Response,Glioblastoma,Pexidartinib+Vatalanib
3646,Expression,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}, {'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",D,Sensitivity/Response,Glioblastoma,Pexidartinib+Dovitinib
3647,Fusion,"[{'id': 1975, 'name': 'Pemigatinib', 'ncit_id': 'C121553', 'aliases': ['Pemazyre', 'INCB054828', ""2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-""]}]",B,Sensitivity/Response,Cholangiolocellular Carcinoma,Pemigatinib
3648,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3649,DELETION (p.K227_T233del),"[{'id': 11808, 'name': 'Tamibarotene', 'ncit_id': 'C71025', 'aliases': ['Z-208', 'TOS-80T', 'TM-411', 'SY-1425', 'Retinobenzoic Acid', 'N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic Acid', 'INNO-507', 'Benzoic Acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-Tetramethyl-2-naphthalenyl)amino)carbonyl)-', 'Am80', 'Am-80', '4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)']}, {'id': 265, 'name': 'Tretinoin', 'ncit_id': 'C900', 'aliases': ['Vitinoin', 'Vitamin A Acid, All-trans-', 'Vitamin A Acid', 'Vesanoid', 'Tretinoinum', 'Trans-Retinoic Acid', 'Trans Vitamin A Acid', 'Trans Retinoic Acid', 'Stieva-A Forte', 'Stieva-A', 'Ro 5488', 'Retisol-A', 'Retinoic Acid', 'Retin-A-Micro', 'Retin-A MICRO', 'Retin-A', 'Renova', 'Eudyna', 'Epi-Aberel', 'Dermairol', 'Cordes Vas', 'Beta-Retinoic Acid', 'Avita', 'ATRA', 'All-trans-Vitamin A Acid', 'All-trans-Retinoic Acid', 'All-trans Vitamin A Acid', 'All-trans Retinoic Acid', 'All Trans-Retinoic Acid', 'Aknoten', 'Airol', 'Aberel', '2,4,6,8-Nonatetraenoic Acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-', '(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid']}]",C,Resistance,Acute Promyelocytic Leukemia,Tamibarotene+Tretinoin
3650,Mutation,"[{'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}, {'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Resistance,Glioblastoma,Pembrolizumab+Nivolumab
3651,PML-RARA A216V,"[{'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}]",B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3652,PML-RARA S214L,"[{'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}]",B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3653,PML-RARA A216T,"[{'id': 47, 'name': 'Arsenic Trioxide', 'ncit_id': 'C1005', 'aliases': ['White Arsenic', 'Trisenox', 'ATO', 'Arsenous Oxide', 'Arsenous Acid Anhydride', 'Arsenous Acid', 'Arsenic Sesquioxide', 'Arsenic (III) Oxide']}]",B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3654,E545K,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3655,E545K,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Lapatinib+Trastuzumab
3656,H1047R,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3657,G101A,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3658,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3659,F104S,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3660,F104L,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3661,R107_R110dup,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3662,A113G,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3663,L119V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3664,VIII,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Glioblastoma,Afatinib
3665,VIII,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}]",D,Sensitivity/Response,Glioblastoma,Afatinib+Pacritinib
3666,G810,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Lung Non-small Cell Carcinoma,Selpercatinib
3667,G810,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Thyroid Gland Medullary Carcinoma,Selpercatinib
3668,G598V,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Glioblastoma,Afatinib+Osimertinib+Erlotinib
3669,G598V,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}, {'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}]",D,Sensitivity/Response,Glioblastoma,Afatinib+Pacritinib
3670,G598V,"[{'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Glioblastoma,Pacritinib+Erlotinib
3671,EBF1-PDGFRB,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Chemotherapy+Imatinib
3672,G598V,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}]",D,Sensitivity/Response,Glioblastoma,Lapatinib+Pacritinib
3673,Amplification,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3674,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib
3675,Amplification,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib
3676,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
3677,Amplification,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Lapatinib
3678,Amplification,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Trastuzumab
3679,Amplification,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Trastuzumab+Lapatinib
3680,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3681,Loss,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib
3682,Loss,"[{'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Resistance,Her2-receptor Positive Breast Cancer,Dactolisib
3683,Loss,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
3684,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib+Lapatinib
3685,R248C,"[{'id': 436, 'name': 'Erdafitinib', 'ncit_id': 'C103273', 'aliases': ['JNJ-42756493', 'Balversa', '1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-']}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3686,Mutation,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
3687,Loss,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 343, 'name': 'Dactolisib', 'ncit_id': 'C74072', 'aliases': ['NVPBEZ235', 'BEZ235', 'Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-']}]",D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3688,G598V,"[{'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}, {'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",D,Sensitivity/Response,Glioblastoma,Pacritinib+Osimertinib
3689,Y693,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3690,Expression,"[{'id': 5876, 'name': '3-Dimensional Conformal Radiation Therapy', 'ncit_id': 'C16035', 'aliases': ['3D Conformal', 'Radiation, 3D Conformal', 'Radiation Conformal Therapy', 'Conformal Therapy', '3D-CRT', '3D CRT', '3D CONFORMAL RADIATION THERAPY', '3-dimensional Radiation Therapy']}, {'id': 11, 'name': 'Temozolomide', 'ncit_id': 'C1244', 'aliases': ['TMZ', 'Temomedac', 'Temodar', 'Temodal', 'Temcad', 'SCH 52365', 'RP-46161', 'Methazolastone', 'M And B 39831', 'M & B 39831', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', '8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one', '3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide']}, {'id': 188, 'name': 'Nimotuzumab', 'ncit_id': 'C2733', 'aliases': []}]",B,Sensitivity/Response,Glioblastoma,3-Dimensional Conformal Radiation Therapy+Temozolomide+Nimotuzumab
3691,PML-RARA,"[{'id': 6433, 'name': 'Gemtuzumab Ozogamicin', 'ncit_id': 'C1806', 'aliases': ['WAY-CMA-676', 'Mylotarg', 'HP67.6-Calicheamicin', 'Gemtuzumab', 'CMA-676', 'CDP-771', 'Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody']}]",B,Sensitivity/Response,Acute Promyelocytic Leukemia,Gemtuzumab Ozogamicin
3692,Mutation,"[{'id': 308, 'name': 'Metformin', 'ncit_id': 'C61612', 'aliases': ['N,N-Dimethylimidodicarbonimidic Diamide', 'N,N-dimethylbiguanide', '1,1-Dimethylbiguanide']}]",B,Sensitivity/Response,Colorectal Cancer,Metformin
3693,D103Y,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3694,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3695,V156D,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3696,R129L,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3697,A113G,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3698,R107_R110dup,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3699,D103V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3700,D103E,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3701,D103Y,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3702,A393E,"[{'id': 19834, 'name': 'AZD-4547', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Transitional Cell Carcinoma,AZD-4547
3703,S249C,"[{'id': 19834, 'name': 'AZD-4547', 'ncit_id': None, 'aliases': []}]",C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,AZD-4547
3704,R248C,"[{'id': 433, 'name': 'Infigratinib', 'ncit_id': 'C88302', 'aliases': ['BGJ398', 'BGJ-398', '3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea']}]",B,Sensitivity/Response,Bladder Carcinoma,Infigratinib
3705,R248C,"[{'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}]",C,Sensitivity/Response,Transitional Cell Carcinoma,Dovitinib
3706,R248C,"[{'id': 19835, 'name': 'R3Mab', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Solid Tumor,R3Mab
3707,LOSS,"[{'id': 19836, 'name': 'EPZ011989', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Malignant Pleural Mesothelioma,EPZ011989
3708,D835,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3709,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3710,D103E,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3711,Y842C,"[{'id': 1629, 'name': 'FLT3/ABL/Aurora Kinase Inhibitor KW-2449', 'ncit_id': 'C116858', 'aliases': ['KW-2449']}]",D,Resistance,Acute Myeloid Leukemia,FLT3/ABL/Aurora Kinase Inhibitor KW-2449
3712,Y842C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3713,Y842C,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Acute Myeloid Leukemia,Sunitinib
3714,Y842C,"[{'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib
3715,Y842C,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3716,F691L,"[{'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}]",D,Resistance,Acute Myeloid Leukemia,Lestaurtinib
3717,F691L,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",D,Resistance,Acute Myeloid Leukemia,Midostaurin
3718,D835I,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3719,D816V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
3720,D816V,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
3721,D816V,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
3722,H1047R,"[{'id': 43, 'name': 'Akt Inhibitor MK2206', 'ncit_id': 'C90581', 'aliases': ['MK-2206 FREE BASE', 'MK2206', 'MK-2206', 'MK 2206', '1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-']}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Sensitivity/Response,Colorectal Cancer,Akt Inhibitor MK2206+Vemurafenib
3723,Fusion,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 342, 'name': 'Cobimetinib', 'ncit_id': 'C68923', 'aliases': ['XL518', 'MEK Inhibitor GDC-0973', 'GDC-0973', 'Cotellic']}]",C,Sensitivity/Response,Melanoma,Trametinib+Cobimetinib
3724,F104I,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Resistance,Follicular Lymphoma,Venetoclax
3725,F104I,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",D,Resistance,Follicular Lymphoma,Venetoclax
3726,TRUNCATING MUTATIONS AND DELETERIOUS SUBSTITUTIONS,"[{'id': 8934, 'name': 'Therapeutic Glucocorticoid', 'ncit_id': 'C521', 'aliases': ['Glucocorticoid']}]",D,Resistance,Acute Lymphoblastic Leukemia,Therapeutic Glucocorticoid
3727,Oncogenic Mutations (loss of function alterations),"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Prostate Carcinoma,Olaparib
3728,Oncogenic Mutations (loss of function alterations),"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Prostate Carcinoma,Olaparib
3729,V600E,"[{'id': 101, 'name': 'Irinotecan', 'ncit_id': 'C62040', 'aliases': [""[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"", '7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin', ""(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"", ""(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione""]}, {'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
3730,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}, {'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Vemurafenib+Erlotinib
3731,BCR-ABL Y253F,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Resistance,Chronic Myeloid Leukemia,Imatinib
3732,ITD & TKD MUTATIONS,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3733,D835H,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3734,D835V,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3735,IGH-CRLF2,"[{'id': 386, 'name': 'Ruxolitinib', 'ncit_id': 'C77888', 'aliases': ['Oral JAK Inhibitor INCB18424', 'Jakafi', 'INCB18424', 'INCB-18424', '(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile']}]",D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3736,E545K,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3737,H1047R,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3738,C420R,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3739,K111N,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3740,F691L,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3741,MUTATION,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",B,Sensitivity/Response,Core Binding Factor Acute Myeloid Leukemia,Dasatinib
3742,A203T,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}, {'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",D,Sensitivity/Response,Myelofibrosis,Entrectinib+Larotrectinib
3743,R458G,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}, {'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Atypical Chronic Myeloid Leukemia,Larotrectinib+Entrectinib
3744,V411L,[],C,Sensitivity/Response,Colorectal Cancer,
3745,S249C,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Transitional Cell Carcinoma,Cisplatin
3746,V600E,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}, {'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",B,Resistance,Colorectal Cancer,Bevacizumab+Oxaliplatin+Capecitabine+Cetuximab
3747,Y842C,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Resistance,Acute Myeloid Leukemia,Quizartinib
3748,Fusion,"[{'id': 17, 'name': 'Alectinib', 'ncit_id': 'C101790', 'aliases': ['RO5424802', 'RG7853', 'CH5424802', 'Alecensa', 'AF802', 'AF-802', '5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3749,F691L,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Pexidartinib
3750,M664I,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3751,ITD & D839G,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3752,K663Q,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
3753,D839A,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3754,D839N,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3755,D839H,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3756,F691L,"[{'id': 447, 'name': 'Pexidartinib', 'ncit_id': 'C88303', 'aliases': ['CML-261', 'PLX3397', '3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Pexidartinib
3757,Loss,"[{'id': 361, 'name': 'Ipatasertib', 'ncit_id': 'C91072', 'aliases': ['RG-7440', 'GDC-0068', '(2S)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one']}]",B,Sensitivity/Response,Prostate Cancer,Ipatasertib
3758,R201H,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Appendix Cancer,Trametinib
3759,Mutation,"[{'id': 32, 'name': 'Capecitabine', 'ncit_id': 'C1794', 'aliases': ['Xeloda', 'Ro 09-1978/000', ""5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine""]}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",B,Resistance,Her2-receptor Positive Breast Cancer,Capecitabine+Lapatinib
3760,Mutation,"[{'id': 485, 'name': 'Binimetinib', 'ncit_id': 'C84865', 'aliases': ['Mektovi', 'MEK162', 'ARRY-438162', 'ARRY-162']}]",B,Sensitivity/Response,Ovary Serous Adenocarcinoma,Binimetinib
3761,S249C,[],D,Sensitivity/Response,Urinary Bladder Cancer,
3762,D594N,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3763,EML4-ALK C1156Y,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3764,G101V,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3765,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",A,Sensitivity/Response,Prostate Cancer,Olaparib
3766,F691L,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Resistance,Acute Myeloid Leukemia,Quizartinib
3767,F691L,"[{'id': 157, 'name': 'Sunitinib', 'ncit_id': 'C71622', 'aliases': ['1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-']}]",D,Resistance,Acute Myeloid Leukemia,Sunitinib
3768,F691L,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3769,F691L,"[{'id': 1629, 'name': 'FLT3/ABL/Aurora Kinase Inhibitor KW-2449', 'ncit_id': 'C116858', 'aliases': ['KW-2449']}]",D,Resistance,Acute Myeloid Leukemia,FLT3/ABL/Aurora Kinase Inhibitor KW-2449
3770,EXON 14 SKIPPING MUTATION,"[{'id': 300, 'name': 'Capmatinib', 'ncit_id': 'C90564', 'aliases': ['INCB28060', 'INCB028060', 'INCB 28060', 'INC280', 'INC-280', '2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3771,EXON 14 SKIPPING MUTATION,"[{'id': 638, 'name': 'Tepotinib', 'ncit_id': 'C88314', 'aliases': ['EMD1214063', 'EMD-1214063', 'EMD 1214063', 'Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tepotinib
3772,Amplification,"[{'id': 300, 'name': 'Capmatinib', 'ncit_id': 'C90564', 'aliases': ['INCB28060', 'INCB028060', 'INCB 28060', 'INC280', 'INC-280', '2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3773,Fusion,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selpercatinib
3774,Mutation,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3775,Fusion,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",B,Sensitivity/Response,Thyroid Gland Cancer,Selpercatinib
3776,Mutation,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Venetoclax
3777,Mutation,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Venetoclax
3778,N841I,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3779,EML4-ALK C1156Y,"[{'id': 856, 'name': 'Ensartinib', 'ncit_id': 'C102754', 'aliases': ['X-396', '6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3780,EML4-ALK G1269A,"[{'id': 856, 'name': 'Ensartinib', 'ncit_id': 'C102754', 'aliases': ['X-396', '6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3781,SQSTM1-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
3782,LMNA::NTRK1 e2-e10,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Crizotinib
3783,Y373C,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Sensitivity/Response,Transitional Cell Carcinoma,Erlotinib
3784,EML4::ALK e6-e19 G1269A and Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3785,V658A,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Melanoma,Imatinib
3786,V658A,"[{'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}]",D,Sensitivity/Response,Melanoma,Crenolanib
3787,G12V,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3788,RBPMS-MET,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",C,Sensitivity/Response,Congenital Fibrosarcoma,Cabozantinib
3789,ITD&F691(I/L),"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3790,ITD & D835(V/Y/F/H),"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Resistance,Acute Myeloid Leukemia,Ponatinib
3791,ITD & Y842C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib+Ponatinib
3792,ITD & D839G,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Quizartinib
3793,ITD & D839G,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Ponatinib+Sorafenib
3794,G697S,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3795,LMNA::NTRK1 e11-e10,"[{'id': 426, 'name': 'Entrectinib', 'ncit_id': 'C114984', 'aliases': ['RXDX101', 'RXDX-101', 'RXDX 101', 'Rozlytrek', 'N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide']}]",C,Sensitivity/Response,Colorectal Cancer,Entrectinib
3796,LMNA::NTRK1 e2-e10,"[{'id': 4885, 'name': 'TRK Inhibitor', 'ncit_id': 'C155765', 'aliases': ['Tropomyosin-related-kinase Inhibitor']}]",C,Sensitivity/Response,Sarcomatoid Carcinoma,TRK Inhibitor
3797,G636C,"[{'id': 2075, 'name': 'FGFR Inhibitor ASP5878', 'ncit_id': 'C122719', 'aliases': ['ASP5878']}]",D,Sensitivity/Response,Stomach Cancer,FGFR Inhibitor ASP5878
3798,N535K,"[{'id': 480, 'name': 'FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Rhabdomyosarcoma,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
3799,V550E,"[{'id': 480, 'name': 'FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Rhabdomyosarcoma,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
3800,ITD and co-mutations,"[{'id': 199, 'name': 'Chemotherapy', 'ncit_id': 'C15632', 'aliases': ['Chemotherapy, Cancer, General', 'Chemotherapy (NOS)', 'Chemo']}]",B,Resistance,Acute Myeloid Leukemia,Chemotherapy
3801,ITD D651G,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3802,ITD  N676D,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3803,ITD I687F,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3804,ITD & Y842C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3805,ITD & TKD MUTATIONS,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib
3806,Fusion,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3807,ETV6-NTRK3,"[{'id': 422, 'name': 'Methotrexate', 'ncit_id': 'C642', 'aliases': ['WR-19039', 'Trixilem', 'Trexeron', 'Tremetex', 'Texate', 'Rheumatrex', 'Novatrex', 'N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid', 'MTX', 'Mexate-AQ', 'Mexate', 'Metrotex', 'Metotrexato', 'Methotrexatum', 'Methotrexate Methylaminopterin', 'Methotrexate LPF', 'Methoblastin', 'Metex', 'Medsatrexate', 'Maxtrex', 'Lumexon', 'Ledertrexate', 'Lantarel', 'Folex PFS', 'Folex', 'Fauldexato', 'Farmitrexat', 'Emthexate', 'Emthexat', 'Emtexate', 'CL-14377', 'CL 14377', 'Brimexate', 'Amethopterin', 'Alpha-Methopterin', 'Abitrexate', '4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid', '4-Amino-10-methylfolic Acid']}, {'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}, {'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Methotrexate+Larotrectinib+Etoposide
3808,G810C,"[{'id': 2709, 'name': 'Pralsetinib', 'ncit_id': 'C132295', 'aliases': ['Gavreto', '(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide', 'RET Inhibitor BLUE-667', 'BLU667', 'BLU-667']}, {'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Cancer,Pralsetinib+Selpercatinib
3809,G810S,"[{'id': 2709, 'name': 'Pralsetinib', 'ncit_id': 'C132295', 'aliases': ['Gavreto', '(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide', 'RET Inhibitor BLUE-667', 'BLU667', 'BLU-667']}, {'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3810,Y806C,"[{'id': 2709, 'name': 'Pralsetinib', 'ncit_id': 'C132295', 'aliases': ['Gavreto', '(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide', 'RET Inhibitor BLUE-667', 'BLU667', 'BLU-667']}, {'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3811,Y806N,"[{'id': 2709, 'name': 'Pralsetinib', 'ncit_id': 'C132295', 'aliases': ['Gavreto', '(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide', 'RET Inhibitor BLUE-667', 'BLU667', 'BLU-667']}, {'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}]",C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3812,V738A,"[{'id': 601, 'name': 'Selpercatinib', 'ncit_id': 'C134987', 'aliases': ['WHO 10967', 'Retevmo', '6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril', 'RET Inhibitor LOXO-292', 'RET Kinase Inhibitor LOXO-292', 'LOXO-292']}, {'id': 2709, 'name': 'Pralsetinib', 'ncit_id': 'C132295', 'aliases': ['Gavreto', '(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide', 'RET Inhibitor BLUE-667', 'BLU667', 'BLU-667']}]",D,Resistance,Cancer,Selpercatinib+Pralsetinib
3813,ITD,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3814,ITD,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3815,ETV6-NTRK3,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3816,Mutation,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Ovary Serous Adenocarcinoma,Trametinib
3817,Q61K,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Ovary Serous Adenocarcinoma,Trametinib
3818,Y842C,"[{'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3819,KIAA1549-BRAF,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}]",D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3820,KIAA1549-BRAF,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Trametinib
3821,R167Q (c.500G>A),"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",C,Sensitivity/Response,Von Hippel-Lindau Disease,Pazopanib
3822,V600E,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}]",D,Resistance,Diffuse Large B-cell Lymphoma,Venetoclax
3823,N505I,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Sensitivity/Response,Skin Melanoma,Sorafenib+Imatinib
3824,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Lung Adenocarcinoma,Cisplatin
3825,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}, {'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,Lung Adenocarcinoma,Cisplatin+Panobinostat
3826,Loss-of-function,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Prostate Cancer,Olaparib+Dasatinib
3827,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Prostate Cancer,Talazoparib+Dasatinib
3828,Loss-of-function,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Sensitivity/Response,Prostate Cancer,Dasatinib+Cisplatin
3829,Loss-of-function,"[{'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}, {'id': 520, 'name': 'Bosutinib', 'ncit_id': 'C60809', 'aliases': ['SKI-606', 'SKI 606', 'Bosulif', '4-Anilinobenzo(g)quinoline-3-carbonitrile', '4-Anilino-3-quinolinecarbonitrile', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile']}]",D,Sensitivity/Response,Prostate Cancer,Talazoparib+Bosutinib
3830,Overexpression,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Ovarian Cancer,Cisplatin
3831,Mutation,"[{'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Cabozantinib
3832,Overexpression,"[{'id': 547, 'name': 'Niraparib', 'ncit_id': 'C80059', 'aliases': ['MK4827', 'MK-4827']}, {'id': 168, 'name': 'Talazoparib', 'ncit_id': 'C95733', 'aliases': ['BMN-673', 'BMN 673']}, {'id': 556, 'name': 'Veliparib', 'ncit_id': 'C60768', 'aliases': ['PARP-1 Inhibitor ABT-888', 'ABT-888', '2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide']}, {'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",D,Sensitivity/Response,Neuroblastoma,Niraparib+Talazoparib+Veliparib+Olaparib
3833,E17K,"[{'id': 112, 'name': 'Capivasertib', 'ncit_id': 'C102564', 'aliases': ['AZD5363']}]",B,Sensitivity/Response,Cancer,Capivasertib
3834,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}, {'id': 138, 'name': 'Pembrolizumab', 'ncit_id': 'C106432', 'aliases': ['SCH 900475', 'MK-3475', 'Lambrolizumab', 'Keytruda', ""Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide""]}]",B,Sensitivity/Response,Melanoma,Nivolumab+Pembrolizumab
3835,Expression,"[{'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
3836,Expression,"[{'id': 137, 'name': 'Nivolumab', 'ncit_id': 'C68814', 'aliases': ['Nivolumab Biosimilar CMAB819', 'CMAB819', 'Opdivo', 'ONO-4538', 'NIVO', 'MDX-1106', 'BMS-936558']}]",B,Sensitivity/Response,Nasopharynx Carcinoma,Nivolumab
3837,V600E,"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
3838,Mutation,"[{'id': 42, 'name': 'Olaparib', 'ncit_id': 'C71721', 'aliases': ['PARP Inhibitor AZD2281', 'Lynparza', 'KU-0059436', 'AZD2281', 'AZD-2281', 'AZD 2281']}]",B,Sensitivity/Response,Breast Cancer,Olaparib
3839,Fusion,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",C,Sensitivity/Response,Melanoma,Trametinib
3840,G697S,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",D,Reduced Sensitivity,Acute Myeloid Leukemia,Gilteritinib
3841,AMPLIFICATION,"[{'id': 489, 'name': 'MDM2 Inhibitor KRT-232', 'ncit_id': 'C116624', 'aliases': ['KRT232', 'KRT-232', 'KRT 232', '(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid', 'AMG-232', 'AMG 232']}, {'id': 491, 'name': 'RG7112', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Glioblastoma,MDM2 Inhibitor KRT-232+RG7112
3842,Overexpression,"[{'id': 14, 'name': 'Gefitinib', 'ncit_id': 'C1855', 'aliases': ['ZD1839', 'ZD 1839', 'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine', 'Iressa', ""4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline""]}, {'id': 430, 'name': 'Linsitinib', 'ncit_id': 'C70982', 'aliases': ['OSI-906AA', 'OSI-906', 'IGF-1R Inhibitor OSI-906', 'Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, Cis-', 'Cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol']}, {'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",D,Sensitivity/Response,Salivary Gland Adenoid Cystic Carcinoma,Gefitinib+Linsitinib+Crizotinib
3843,ITD,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 4738, 'name': 'Hematopoietic Cell Transplantation', 'ncit_id': 'C15431', 'aliases': ['Hematopoietic Stem Cell Infusion', 'Stem Cell Transplantation', 'Stem Cell Transplant', 'HSCT', 'Hematopoietic Stem Cell Transplantation', 'HCT']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib+Hematopoietic Cell Transplantation
3844,ITD,"[{'id': 4738, 'name': 'Hematopoietic Cell Transplantation', 'ncit_id': 'C15431', 'aliases': ['Hematopoietic Stem Cell Infusion', 'Stem Cell Transplantation', 'Stem Cell Transplant', 'HSCT', 'Hematopoietic Stem Cell Transplantation', 'HCT']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Hematopoietic Cell Transplantation+Sorafenib
3845,ITD & Y842C,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 832, 'name': 'Selinexor', 'ncit_id': 'C102546', 'aliases': ['ATG-010', 'Xpovio', 'SINE KPT-330', 'Selective Inhibitor Of Nuclear Export KPT-330', 'KPT-330', 'CRM1 Nuclear Export Inhibitor KPT-330', '2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)-']}]",D,Resistance,Acute Myeloid Leukemia,Sorafenib+Selinexor
3846,ITD & Y842C,"[{'id': 2982, 'name': 'FLT3 Inhibitor FF-10101 Succinate', 'ncit_id': 'C137988', 'aliases': ['FF10101 Succinate', 'FF-10101-01', 'FF-10101 Succinate']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,FLT3 Inhibitor FF-10101 Succinate
3847,BCR-ABL G250E,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Cancer,Dasatinib
3848,BCR-ABL H396P,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Cancer,Dasatinib
3849,Amplification,"[{'id': 20818, 'name': 'JNJ38877605', 'ncit_id': None, 'aliases': []}, {'id': 20817, 'name': 'PHA-665752', 'ncit_id': None, 'aliases': []}]",D,Resistance,Lung Non-small Cell Carcinoma,JNJ38877605+PHA-665752
3850,G12V,"[{'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",D,Resistance,Head And Neck Squamous Cell Carcinoma,Alpelisib
3851,K383fs,"[{'id': 166, 'name': '7-Ethyl-10-Hydroxycamptothecin', 'ncit_id': 'C61618', 'aliases': ['SN-38', 'SN 38', '7-Ethyl-10-hydroxy-20(S)-camptothecin']}, {'id': 237, 'name': 'Oxaliplatin', 'ncit_id': 'C1181', 'aliases': ['Trans-l Diaminocyclohexane Oxalatoplatinum', 'Trans-l DACH Oxalatoplatinum', 'SR-96669', 'RP-54780', 'RP 54780', 'Oxalatoplatinum', 'Oxalatoplatin', 'Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)', 'Oxalato (1R,2R-cyclohexanediamine)platinum(II)', 'JM-83', 'Eloxatine', 'ELOXATIN', 'Diaminocyclohexane Oxalatoplatinum', 'DACPLAT', 'Dacotin', 'Aiheng', 'Ai Heng', ""[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"", ""[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"", '1-OHP']}]",D,Sensitivity/Response,Colon Carcinoma,7-Ethyl-10-Hydroxycamptothecin+Oxaliplatin
3852,AMPLIFICATION,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Hepatocellular Carcinoma,Sorafenib
3853,Overexpression,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",C,Sensitivity/Response,Papillary Renal Cell Carcinoma,Sorafenib
3854,Overexpression,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}, {'id': 362, 'name': 'GSK126', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroblastoma,Tazemetostat+GSK126
3855,Amplification,"[{'id': 12, 'name': 'Crizotinib', 'ncit_id': 'C74061', 'aliases': ['Xalkori', 'PF-2341066', 'PF-02341066', 'MET Tyrosine Kinase Inhibitor PF-02341066', '2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-', '(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine']}]",C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3856,Overexpression,"[{'id': 315, 'name': 'Mocetinostat', 'ncit_id': 'C62521', 'aliases': ['N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide', 'MGCD0103', 'MG-0103', 'Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-']}]",D,Sensitivity/Response,Breast Cancer,Mocetinostat
3857,G12C,"[{'id': 63, 'name': 'Selumetinib', 'ncit_id': 'C66939', 'aliases': ['MEK Inhibitor AZD6244', 'AZD6244', 'ARRY-142886']}, {'id': 21397, 'name': 'ERK1/2 Inhibitor ATG-017', 'ncit_id': 'C176765', 'aliases': ['AZD0364', 'AZD-0364', 'AZD 0364', 'ATG017', 'ATG-017', 'ATG 017']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+ERK1/2 Inhibitor ATG-017
3858,SFPQ-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}, {'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib+Dasatinib
3859,RCSD1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3860,RCSD1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3861,RCSD1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3862,RCSD1-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3863,RCSD1-ABL1,"[{'id': 629, 'name': 'Tyrosine Kinase Inhibitor', 'ncit_id': 'C1967', 'aliases': []}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Tyrosine Kinase Inhibitor
3864,ETV6-ABL1,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3865,RANBP2-ABL1,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3866,RCSD1-ABL1,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Ponatinib
3867,RCSD1-ABL1,"[{'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Ponatinib
3868,ITD,"[{'id': 15052, 'name': 'Pacritinib', 'ncit_id': 'C78837', 'aliases': ['SB1518', 'SB-1518', 'SB 1518', 'Oral JAK2 Inhibitor SB1518']}]",B,Sensitivity/Response,Acute Myeloid Leukemia,Pacritinib
3869,A767_V769dupASV,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3870,N771_P772insL,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3871,Exon 20 Insertion,"[{'id': 15, 'name': 'Erlotinib', 'ncit_id': 'C65530', 'aliases': []}]",B,Resistance,Lung Adenocarcinoma,Erlotinib
3872,D770_N771insG,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3873,S768_D770dup,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3874,A763_Y764insFQEA,"[{'id': 187, 'name': 'Osimertinib', 'ncit_id': 'C116377', 'aliases': ['Tagrisso', 'Mereletinib', 'AZD9291', 'AZD-9291', '2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-']}]",C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3875,FGFR3-TACC3,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,FGFR Inhibitor AZD4547
3876,Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Breast Cancer,Bevacizumab
3877,Overexpression,"[{'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}, {'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}, {'id': 679, 'name': 'Trichostatin A', 'ncit_id': 'C1261', 'aliases': []}]",B,Resistance,Breast Cancer,Panobinostat+Vorinostat+Trichostatin A
3878,Overexpression,"[{'id': 631, 'name': 'Adavosertib', 'ncit_id': 'C91725', 'aliases': ['MK1775', 'MK-1775', 'AZD1775', 'AZD-1775', '2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one']}]",D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Adavosertib
3879,Overexpression,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",D,Resistance,Colorectal Cancer,Bevacizumab
3880,Deletion,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Sensitivity/Response,Cancer,Fluorouracil+Cisplatin
3881,FGFR3-TACC3,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",C,Sensitivity/Response,Cervical Squamous Cell Carcinoma,FGFR Inhibitor AZD4547
3882,FGFR3-TACC3,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",C,Sensitivity/Response,Diffuse Astrocytoma,FGFR Inhibitor AZD4547
3883,BAG4-FGFR1,"[{'id': 452, 'name': 'FGFR Inhibitor AZD4547', 'ncit_id': 'C88272', 'aliases': ['AZD4547']}]",C,Sensitivity/Response,Carcinoma,FGFR Inhibitor AZD4547
3884,Loss-of-function,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Neuroendocrine Tumor,JQ1
3885,Expression,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Ibrutinib
3886,Expression,"[{'id': 227, 'name': 'Ibrutinib', 'ncit_id': 'C81934', 'aliases': ['PCI-32765', 'Imbruvica', 'CRA-032765', 'BTK Inhibitor PCI-32765', '2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-']}]",D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Ibrutinib
3887,overexpression of VEGF165b,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",D,Adverse Response,Colorectal Cancer,Bevacizumab
3888,overexpression of VEGF-Axxxa,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Breast Cancer,Bevacizumab
3889,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3890,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",C,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3891,Mutation,"[{'id': 431, 'name': 'Rucaparib', 'ncit_id': 'C137800', 'aliases': ['8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one', '6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-']}]",B,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3892,low ratio of VEGF165b/VEGFtotal,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Colorectal Cancer,Bevacizumab
3893,Overexpression of VEGF121,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Bevacizumab
3894,Overexpression of VEGF121 and VEGF110,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Stomach Cancer,Bevacizumab
3895,Overexpression of VEGF121 and VEGF110,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Breast Cancer,Bevacizumab
3896,Overexpression of VEGF121 and VEGF110,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Breast Cancer,Bevacizumab
3897,Overexpression of VEGF121 and VEGF110,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Breast Cancer,Bevacizumab
3898,Q575Δ,"[{'id': 641, 'name': 'Gilteritinib', 'ncit_id': 'C116722', 'aliases': ['Xospata', 'ASP2215', 'ASP-2215', '6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide']}]",C,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3899,Q575Δ,"[{'id': 6556, 'name': 'Tyrphostin AG 1295', 'ncit_id': 'C2031', 'aliases': ['AG 1295', '6,7-Dimethyl-2-phenylquinoxaline']}, {'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Tyrphostin AG 1295+Midostaurin+Sorafenib+Lestaurtinib
3900,Y572Δ,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}, {'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}, {'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}, {'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Quizartinib+Lestaurtinib+Crenolanib+Midostaurin+Sorafenib+Ponatinib
3901,E573Δ,"[{'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}, {'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}, {'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}, {'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib+Midostaurin+Crenolanib+Ponatinib+Quizartinib+Lestaurtinib
3902,S574Δ,"[{'id': 260, 'name': 'Lestaurtinib', 'ncit_id': 'C48402', 'aliases': ['SPM-924', 'KT-5555', 'CEP-701', ""9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-""]}, {'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}, {'id': 21, 'name': 'Crenolanib', 'ncit_id': 'C64639', 'aliases': ['PDGFR Inhibitor CP-868596', 'CP-868596', 'CP-868,596', '[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine', '4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-']}, {'id': 323, 'name': 'Midostaurin', 'ncit_id': 'C1872', 'aliases': ['Rydapt', 'PKC412', 'PKC-412', 'N-Benzoylstaurosporine', 'N-Benzoyl-Staurosporine', 'CGP41251', 'CGP 41251']}, {'id': 55, 'name': 'Ponatinib', 'ncit_id': 'C95777', 'aliases': ['Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'AP24534', 'AP-24534']}, {'id': 6, 'name': 'Sorafenib', 'ncit_id': 'C61948', 'aliases': ['Bay-439006', 'BAY 43-9006', 'BA4 43 9006']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib+Quizartinib+Crenolanib+Midostaurin+Ponatinib+Sorafenib
3903,Overexpression,"[{'id': 21466, 'name': 'CAN508', 'ncit_id': None, 'aliases': []}, {'id': 335, 'name': 'Alvocidib', 'ncit_id': 'C74940', 'aliases': ['Flavopiridol', 'Alvocidib Freebase', '(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one']}]",D,Sensitivity/Response,Esophageal Cancer,CAN508+Alvocidib
3904,Overexpression,"[{'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Sensitivity/Response,Hepatocellular Carcinoma,Dinaciclib
3905,Overexpression,"[{'id': 574, 'name': 'Venetoclax', 'ncit_id': 'C103147', 'aliases': ['Venclyxto', 'Venclexta', 'RG7601', 'GDC-0199', 'ABT199', 'ABT-199', 'ABT-0199', '4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide']}, {'id': 410, 'name': 'Dinaciclib', 'ncit_id': 'C78854', 'aliases': ['SCH 727965', 'MK-7965', 'CDK Inhibitor SCH 727965', '2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- A]pyrimidin-5-yl]-, (2S)-']}]",D,Resistance,Lymphoma,Venetoclax+Dinaciclib
3906,EXPRESSION,"[{'id': 29, 'name': 'Mirdametinib', 'ncit_id': 'C52195', 'aliases': ['PD 901', 'MEK Inhibitor PD0325901', 'PD0325901', 'PD-0325901']}, {'id': 569, 'name': 'Birabresib', 'ncit_id': 'C103298', 'aliases': ['OTX015', 'MK-8628', 'BRD 2/3/4 Inhibitor OTX015', '6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-']}]",D,Sensitivity/Response,Melanoma,Mirdametinib+Birabresib
3907,OVEREXPRESSION,[],D,Sensitivity/Response,Melanoma,
3908,OVEREXPRESSION,"[{'id': 306, 'name': 'JQ1', 'ncit_id': None, 'aliases': []}]",D,Sensitivity/Response,Childhood Medulloblastoma,JQ1
3909,OVEREXPRESSION,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}, {'id': 451, 'name': 'Verteporfin', 'ncit_id': 'C1014', 'aliases': []}]",D,Sensitivity/Response,Esophageal Cancer,Docetaxel+Verteporfin
3910,R1032Q,"[{'id': 519, 'name': 'Axitinib', 'ncit_id': 'C38718', 'aliases': ['N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide', 'Inlyta', 'AG013736', 'AG-013736']}, {'id': 228, 'name': 'Dovitinib', 'ncit_id': 'C76199', 'aliases': []}, {'id': 527, 'name': 'Lenvatinib', 'ncit_id': 'C95124', 'aliases': ['Multi-Kinase Inhibitor E7080', 'ER-203492-00', 'E7080', '6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-']}, {'id': 144, 'name': 'Cabozantinib', 'ncit_id': 'C52200', 'aliases': [""N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"", ""1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-""]}]",D,Sensitivity/Response,Colorectal Cancer,Axitinib+Dovitinib+Lenvatinib+Cabozantinib
3911,low ratio of VEGF165b/VEGFtotal,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Sensitivity/Response,Colorectal Cancer,Bevacizumab
3912,MEF2D-CSF1R,"[{'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Panobinostat
3913,MEF2D-CSF1R,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3914,Y646H,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Tazemetostat
3915,CD4v8-v10 and CD44v3-v10,"[{'id': 240, 'name': 'RG7356', 'ncit_id': None, 'aliases': []}]",B,Resistance,Cancer,RG7356
3916,I1171T,"[{'id': 159, 'name': 'Ceritinib', 'ncit_id': 'C115112', 'aliases': ['Zykadia', 'LDK378', 'LDK 378', '2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-']}]",C,Sensitivity/Response,Neuroblastoma,Ceritinib
3917,CD44v6,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Ovarian Cancer,Cisplatin
3918,CD44v6,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Stomach Cancer,Cisplatin
3919,G12C,"[{'id': 654, 'name': 'Sotorasib', 'ncit_id': 'C154287', 'aliases': ['Lumakras', 'AMG510', 'AMG-510', 'AMG 510']}]",A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3920,CD44v8-10,"[{'id': 73, 'name': 'Docetaxel', 'ncit_id': 'C1526', 'aliases': ['Taxotere Injection Concentrate', 'Taxotere', 'RP56976', 'N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol', 'Docecad', '[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester']}]",D,Reduced Sensitivity,Prostate Cancer,Docetaxel
3921,CD44v6,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Resistance,Stomach Cancer,Cisplatin
3922,CD44v6,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",B,Resistance,Cervical Cancer,Cisplatin
3923,E1799K,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",D,Sensitivity/Response,Megalencephaly,Everolimus
3924,E1799K,"[{'id': 41, 'name': 'Everolimus', 'ncit_id': 'C48387', 'aliases': ['Zortress', 'Votubia', 'RAD001', 'RAD 001', 'Certican', 'Afinitor', '42-O-(2-Hydroxy)ethyl Rapamycin', '(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone']}]",D,Sensitivity/Response,Focal Cortical Dysplasia,Everolimus
3925,Overexpression of VEGF121,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}]",B,Resistance,Glioblastoma,Bevacizumab
3926,Overexpression of AR-V9,"[{'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}]",B,Resistance,Prostate Cancer,Abiraterone
3927,G469V,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3928,G596C,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
3929,G469S,"[{'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}, {'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}]",D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
3930,V7 EXPRESSION,"[{'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}, {'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}]",B,Resistance,Prostate Cancer,Abiraterone+Enzalutamide
3931,V7 EXPRESSION,"[{'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}, {'id': 17080, 'name': 'Galeterone', 'ncit_id': 'C84866', 'aliases': ['VN/124-1', 'VN/124', 'TOK-001', 'Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001', 'Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-']}]",B,Sensitivity/Response,Prostate Cancer,Enzalutamide+Galeterone
3932,V7 EXPRESSION,"[{'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}, {'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}]",B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
3933,V7 EXPRESSION,"[{'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}]",B,Resistance,Prostate Cancer,Enzalutamide
3934,V7 EXPRESSION,"[{'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}, {'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}]",B,Resistance,Prostate Cancer,Abiraterone+Enzalutamide
3935,P447_L455del,"[{'id': 375, 'name': 'Letrozole', 'ncit_id': 'C1527', 'aliases': ['Femara', 'CGS 20267', ""4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile""]}, {'id': 570, 'name': 'Alpelisib', 'ncit_id': 'C94214', 'aliases': ['Piqray', 'Phosphoinositide 3-kinase Inhibitor BYL719', 'BYL719']}]",C,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Letrozole+Alpelisib
3936,V7 EXPRESSION,"[{'id': 163, 'name': 'Enzalutamide', 'ncit_id': 'C71744', 'aliases': ['Xtandi', 'MDV3100', 'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-', 'ASP9785']}, {'id': 164, 'name': 'Abiraterone', 'ncit_id': 'C77333', 'aliases': ['CB 7598', '17-(3-Pyridyl)androsta-5,16-dien-3beta-ol']}]",B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
3937,V567es expression,"[{'id': 167, 'name': 'Taxane Compound', 'ncit_id': 'C1490', 'aliases': []}]",B,Resistance,Prostate Cancer,Taxane Compound
3938,E114K,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",D,Sensitivity/Response,Cancer,Cetuximab+Panitumumab
3939,LMNA-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Solid Tumor,Larotrectinib
3940,TPR-NTRK1,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Sensitivity/Response,Solid Tumor,Larotrectinib
3941,F617L,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Resistance,Gastrointestinal Stromal Tumor,Larotrectinib
3942,G595R and G667S,"[{'id': 573, 'name': 'Larotrectinib', 'ncit_id': 'C115977', 'aliases': ['LOXO-101', 'LOXO 101', 'ARRY 470', '3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide', '1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-']}]",C,Resistance,Solid Tumor,Larotrectinib
3943,R165Q,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3944,KRAS4A,"[{'id': 3806, 'name': 'Rigosertib', 'ncit_id': 'C152216', 'aliases': ['ON 01910', 'N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) Phenyl)glycine', 'Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) Methyl)phenyl)-']}, {'id': 23380, 'name': 'KG5', 'ncit_id': None, 'aliases': []}]",D,Resistance,Pancreatic Cancer,Rigosertib+KG5
3945,KRAS4A underexpression,"[{'id': 3806, 'name': 'Rigosertib', 'ncit_id': 'C152216', 'aliases': ['ON 01910', 'N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) Phenyl)glycine', 'Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) Methyl)phenyl)-']}, {'id': 23381, 'name': 'RG5', 'ncit_id': None, 'aliases': []}]",D,Resistance,Pancreatic Cancer,Rigosertib+RG5
3946,TNC-L,"[{'id': 85, 'name': 'Gemcitabine', 'ncit_id': 'C66876', 'aliases': ['Difluorodeoxycytidine', 'DFdCyd', 'DFdC', ""2'Deoxy-2',2'-Difluorocytidine"", '1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose']}]",D,Resistance,Pancreatic Cancer,Gemcitabine
3947,underexpression beta-1,"[{'id': 82, 'name': 'Exemestane', 'ncit_id': 'C1097', 'aliases': ['FCE-24304', 'Aromasin', '6-Methyleneandrosta-1,4-diene-3,17-dione']}, {'id': 53, 'name': 'Tamoxifen', 'ncit_id': 'C62078', 'aliases': ['1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene']}]",B,Sensitivity/Response,Breast Cancer,Exemestane+Tamoxifen
3948,LGR5FL,"[{'id': 420, 'name': 'Fluorouracil', 'ncit_id': 'C505', 'aliases': ['Ro-2-9757', 'Ro 2-9757', 'Ribofluor', 'Fluroblastin', 'Fluril', 'Fluracil', 'Fluracedyl', 'Flurablastin', 'Fluouracil', 'Fluoro Uracil', 'Carac', 'Adrucil', 'AccuSite', '5FU', '5-FU', '5-Fluracil', '5-Fluorouracil', '5-Fluoro-2,4(1H,3H)-pyrimidinedione', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', '5 FU', '5 Fluorouracilum', '5 Fluorouracil', '2,4-Dioxo-5-fluoropyrimidine']}]",D,Resistance,Colorectal Cancer,Fluorouracil
3949,EDB,"[{'id': 4783, 'name': 'Daromun', 'ncit_id': 'C154627', 'aliases': ['L19IL2/L19TNF', 'L19-IL2/L19-TNF-alpha', 'L19-IL2 And L19-TNF-alpha', 'Darleukin/Fibromun', 'Darleukin And Fibromun']}]",B,Sensitivity/Response,Melanoma,Daromun
3950,EDB,"[{'id': 25, 'name': 'Dacarbazine', 'ncit_id': 'C411', 'aliases': ['WR-139007', 'Imidazole Carboxamide Dimethyltriazeno', 'Imidazole Carboxamide', 'Fauldetic', 'DTIC-Dome', 'DTIC', 'Dimethyl-triazeno-imidazole-carboximide', 'Dimethyl-triazeno-imidazole Carboxamide', 'Dimethyl Triazeno Imidazole Carboxamide', 'Dimethyl Triazeno Imidazol Carboxamide', 'Dimethyl (triazeno) Imidazolecarboxamide', 'DIC', 'Detimedac', 'Deticene', 'Dakarbazin', 'Dacatic', 'Dacarbazine - DTIC', 'Dacarbazina Almirall', 'Dacarbazina', 'Biocarbazine', 'Asercit', '5-(Dimethyltriazeno)imidazole-4-carboxamide', '5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide', '5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide', '4-(Dimethyltriazeno)imidazole-5-carboxamide', '1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-']}, {'id': 23382, 'name': 'L19IL2', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Melanoma,Dacarbazine+L19IL2
3951,EDB,"[{'id': 23382, 'name': 'L19IL2', 'ncit_id': None, 'aliases': []}]",B,Sensitivity/Response,Melanoma,L19IL2
3952,Overexpression,"[{'id': 363, 'name': 'Alisertib', 'ncit_id': 'C71717', 'aliases': ['MLN8237', 'MLN-8237', 'Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy-', 'Aurora A Kinase Inhibitor MLN8237']}, {'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Sensitivity/Response,Esophagus Adenocarcinoma,Alisertib+Cisplatin
3953,A232V,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 1559, 'name': 'Duligotuzumab', 'ncit_id': 'C116628', 'aliases': ['RG 7597', 'MEHD7945A', 'MEHD-7945A', 'MEHD 7945A', 'Duligotumab']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Cancer,Trastuzumab+Pertuzumab+Duligotuzumab+Lapatinib
3954,MUTATION,"[{'id': 663, 'name': 'Tipifarnib', 'ncit_id': 'C1703', 'aliases': ['Zarnestra', 'R115777', '(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone']}]",B,Sensitivity/Response,Bladder Urothelial Carcinoma,Tipifarnib
3955,MUTATION,"[{'id': 663, 'name': 'Tipifarnib', 'ncit_id': 'C1703', 'aliases': ['Zarnestra', 'R115777', '(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone']}]",B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Tipifarnib
3956,TOP2A/90,"[{'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}]",D,Resistance,Leukemia,Etoposide
3957,TOP2A/90,"[{'id': 829, 'name': 'MVT Regimen', 'ncit_id': 'C10254', 'aliases': ['MVT', 'Mitoxantrone/VePesid/Thiotepa', 'Mitoxantrone/Etoposide/Thiotepa Regimen', 'Mitoxantrone/Etoposide/Thiotepa', 'Mitoxantrone-Etoposide-Thiotepa', 'Etoposide/Mitoxantrone/Thiotepa', 'DHAD/TSPA/VP-16']}, {'id': 23383, 'name': ""4'-(9-acridinylamino)methanesulfon-m-anisidide"", 'ncit_id': None, 'aliases': []}, {'id': 500, 'name': 'Etoposide', 'ncit_id': 'C491', 'aliases': ['VP16', 'VP-16-213', 'VP-16', 'VP 16-213', 'VP 16', 'Vepesid', 'Toposar', 'Lastet', 'EPEG', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', ""9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"", ""4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]""]}, {'id': 18854, 'name': 'DVP Regmen', 'ncit_id': 'C9656', 'aliases': ['DVP', 'DNR/PRED/VCR', 'Daunorubicin/Vincristine/Prednisone Regimen', 'Daunorubicin/Vincristine/Prednisone', 'Daunorubicin/Prednisone/Vincristine', 'Daunorubicin-Vincristine-Prednisone']}, {'id': 7022, 'name': 'Pixantrone', 'ncit_id': 'C26663', 'aliases': ['6,9-Bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione']}]",D,Resistance,Leukemia,MVT Regimen+4'-(9-acridinylamino)methanesulfon-m-anisidide+Etoposide+DVP Regmen+Pixantrone
3958,delta11q,"[{'id': 326, 'name': 'Cisplatin', 'ncit_id': 'C376', 'aliases': ['Platosin', 'Platistin', 'Platiran', 'Platinum, Diaminedichloro-, Cis- (8CI)', 'Platinum Diamminodichloride', 'Platinum', 'Platinoxan', 'Platinol-AQ VHA Plus', 'Platinol-AQ', 'Platinol- AQ', 'Platinol', 'Platinex', 'Platiblastin-S', 'Platiblastin', 'Platamine', 'Plastistil', 'Placis', ""Peyrone's Salt"", ""Peyrone's Chloride"", 'Neoplatin', 'Metaplatin', 'Lederplatin', 'DDP', 'Cysplatyna', 'Citosin', 'Citoplatino', 'Cisplatyl', 'Cisplatinum', 'Cisplatina', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Cis-platinum II', 'Cis-platinum', 'Cis-platinous Diamine Dichloride', 'Cis-dichloroammine Platinum (II)', 'Cis-diamminedichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Cis-diamminedichloridoplatinum', 'Cis-diammine-dichloroplatinum', 'CDDP', 'Briplatin', 'Blastolem', 'Abiplatin', '(SP-4-2)-Diamminedichloroplatinum']}]",D,Reduced Sensitivity,Breast Cancer,Cisplatin
3959,R222C,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3960,S492R,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab
3961,P596L,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3962,K708R,"[{'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}, {'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3963,G719S,"[{'id': 28, 'name': 'Panitumumab', 'ncit_id': 'C1857', 'aliases': []}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3964,V104M,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 1559, 'name': 'Duligotuzumab', 'ncit_id': 'C116628', 'aliases': ['RG 7597', 'MEHD7945A', 'MEHD-7945A', 'MEHD 7945A', 'Duligotumab']}]",D,Sensitivity/Response,Cancer,Lapatinib+Trastuzumab+Pertuzumab+Duligotuzumab
3965,P262H,"[{'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 1559, 'name': 'Duligotuzumab', 'ncit_id': 'C116628', 'aliases': ['RG 7597', 'MEHD7945A', 'MEHD-7945A', 'MEHD 7945A', 'Duligotumab']}]",D,Sensitivity/Response,Cancer,Trastuzumab+Pertuzumab+Lapatinib+Duligotuzumab
3966,G1109C,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Afatinib
3967,L861Q,"[{'id': 146, 'name': 'Afatinib', 'ncit_id': 'C66940', 'aliases': ['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']}]",D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Afatinib
3968,G284R,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}, {'id': 1559, 'name': 'Duligotuzumab', 'ncit_id': 'C116628', 'aliases': ['RG 7597', 'MEHD7945A', 'MEHD-7945A', 'MEHD 7945A', 'Duligotumab']}, {'id': 247, 'name': 'Pertuzumab', 'ncit_id': 'C38692', 'aliases': ['Pertuzumab Biosimilar HS627', 'HS627', 'RO4368451', 'RhuMAb2C4', 'Perjeta', 'Omnitarg', 'Monoclonal Antibody 2C4', 'MoAb 2C4', 'Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer', '2C4 Antibody', '2C4']}, {'id': 84, 'name': 'Trastuzumab', 'ncit_id': 'C1647', 'aliases': []}]",D,Sensitivity/Response,Cancer,Lapatinib+Duligotuzumab+Pertuzumab+Trastuzumab
3969,v242,"[{'id': 427, 'name': 'Durvalumab', 'ncit_id': 'C103194', 'aliases': ['MEDI4736', 'MEDI-4736', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'Imfinzi']}, {'id': 296, 'name': 'Avelumab', 'ncit_id': 'C116870', 'aliases': []}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",E,Resistance,Lung Non-small Cell Carcinoma,Durvalumab+Avelumab+Atezolizumab
3970,V777L,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",D,Sensitivity/Response,Cancer,Lapatinib
3971,Alternative splicing,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",D,Resistance,Chronic Myeloid Leukemia,Imatinib
3972,"delta-ex2, delta-ex5-6","[{'id': 860, 'name': 'Tisagenlecleucel', 'ncit_id': 'C102758', 'aliases': ['Tisagenlecleucel-T', 'Kymriah', 'CTL019 T-cells', 'CTL019', 'CART19', 'CART-19']}]",D,Resistance,B-lymphoblastic Leukemia/lymphoma,Tisagenlecleucel
3973,DELETION POLYMORPHISM,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",B,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
3974,p61BRAF(V600E),"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",D,Resistance,Melanoma,Vemurafenib
3975,p61BRAF(V600E),"[{'id': 4, 'name': 'Vemurafenib', 'ncit_id': 'C64768', 'aliases': ['Zelboraf', 'RO 5185426', 'RG7204', 'RG 7204', 'PLX4032', 'PLX-4032', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'BRAF (V600E) Kinase Inhibitor RO5185426', '1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-']}]",C,Resistance,Melanoma,Vemurafenib
3976,,"[{'id': 411, 'name': 'Tazemetostat', 'ncit_id': 'C107506', 'aliases': [""N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"", ""N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide"", 'EPZ6438', 'EPZ-6438', 'E7438']}]",B,Sensitivity/Response,Follicular Lymphoma,Tazemetostat
3977,F691L,"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",A,Resistance,Acute Myeloid Leukemia,Quizartinib
3978,F691L,"[{'id': 12837, 'name': 'Tirbanibulin', 'ncit_id': 'C74077', 'aliases': ['2-Pyridineacetamide, 5-(4-(2-(4-Morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-', 'KX2-391', 'KX01']}]",D,Sensitivity/Response,Acute Myeloid Leukemia,Tirbanibulin
3979,Overexpression,"[{'id': 19064, 'name': 'Multi-subtype Natural Human Leukocyte Interferon Alpha', 'ncit_id': 'C97509', 'aliases': ['Multisubtype Natural Human Interferon Alpha', 'Multiferon']}]",A,Resistance,Melanoma,Multi-subtype Natural Human Leukocyte Interferon Alpha
3980,Amplification,"[{'id': 45, 'name': 'Lapatinib', 'ncit_id': 'C26653', 'aliases': ['GW572016', 'GW2016', 'GW 2016', 'GSK572016']}]",A,Sensitivity/Response,Childhood Ependymoma,Lapatinib
3981,ITD&F691(I/L),"[{'id': 505, 'name': 'Quizartinib', 'ncit_id': 'C68936', 'aliases': [""N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"", 'AC220', 'AC010220', 'AC-220', '(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide']}]",D,Resistance,Acute Myeloid Leukemia,Quizartinib
3982,T599dup,"[{'id': 19, 'name': 'Trametinib', 'ncit_id': 'C77908', 'aliases': ['N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide', 'Mekinist', 'MEK Inhibitor GSK1120212', 'JTP-74057', 'GSK1120212']}, {'id': 22, 'name': 'Dabrafenib', 'ncit_id': 'C82386', 'aliases': ['GSK2118436', 'GSK-2118436A', 'GSK-2118436', 'BRAF Inhibitor GSK2118436', 'Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-']}]",C,Sensitivity/Response,Ganglioglioma,Trametinib+Dabrafenib
3983,ZC3HAV1-ABL2,"[{'id': 5, 'name': 'Imatinib', 'ncit_id': 'C62035', 'aliases': ['4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}]",C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3984,EWSR1-NR4A3,"[{'id': 56, 'name': 'Pazopanib', 'ncit_id': 'C74547', 'aliases': ['GW786034', 'Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-']}]",B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,Pazopanib
3985,V600E,"[{'id': 483, 'name': 'Encorafenib', 'ncit_id': 'C98283', 'aliases': ['LGX818', 'LGX-818', 'LGX 818', 'Braftovi']}, {'id': 16, 'name': 'Cetuximab', 'ncit_id': 'C1723', 'aliases': []}]",A,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab
3986,EXPRESSION,"[{'id': 489, 'name': 'MDM2 Inhibitor KRT-232', 'ncit_id': 'C116624', 'aliases': ['KRT232', 'KRT-232', 'KRT 232', '(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid', 'AMG-232', 'AMG 232']}]",D,Sensitivity/Response,Ovarian Cancer,MDM2 Inhibitor KRT-232
3987,High expression,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Stomach Cancer,Dasatinib
3988,Overexpression,"[{'id': 20, 'name': 'Dasatinib', 'ncit_id': 'C38713', 'aliases': ['Sprycel', 'Dasatinib Monohydrate', 'Dasatinib Hydrate', 'BMS-354825', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate']}]",D,Sensitivity/Response,Head And Neck Carcinoma,Dasatinib
3989,Overexpression,"[{'id': 563, 'name': 'HDAC Inhibitor AR-42', 'ncit_id': 'C116850', 'aliases': ['OSU-HDAC42', 'HDAC-42', 'AR-42', '(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide']}]",D,Sensitivity/Response,Esophageal Cancer,HDAC Inhibitor AR-42
3990,Overexpression,"[{'id': 679, 'name': 'Trichostatin A', 'ncit_id': 'C1261', 'aliases': []}, {'id': 678, 'name': 'Vorinostat', 'ncit_id': 'C1796', 'aliases': ['Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Suberanilohydroxamic Acid', 'SAHA', ""N-Hydroxy-N'-phenyloctanediamide"", 'MSK-390', 'L-001079038']}, {'id': 445, 'name': 'Panobinostat', 'ncit_id': 'C66948', 'aliases': ['LBH589', 'Farydak', 'Faridak', '(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide']}]",D,Sensitivity/Response,Esophageal Cancer,Trichostatin A+Vorinostat+Panobinostat
3991,V600E and Amplification,"[{'id': 33, 'name': 'Bevacizumab', 'ncit_id': 'C2039', 'aliases': ['MYL-1402O', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar ABP 215', 'ABP 215', 'Zirabev', 'Mvasi', 'Bevacizumab-bvzr', 'Bevacizumab-awwb', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar GB-222', 'SCT501', 'RhuMab-VEGF', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer', 'HD204', 'BP102 Biosimilar', 'BP102', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Awwb', 'Avastin', 'Anti-VEGF RhuMAb', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF']}, {'id': 261, 'name': 'Atezolizumab', 'ncit_id': 'C106250', 'aliases': ['Tecentriq', 'RO5541267', 'RG7446', 'MPDL328OA', 'MPDL3280A', 'MPDL-3280A', 'MPDL 328OA', 'MPDL 3280A', 'Immunoglobulin G1, Anti-(human CD Antigen Cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide With Human Monoclonal MPDL3280A Kappa-chain, Dimer']}]",B,Sensitivity/Response,Epithelial Ovarian Cancer,Bevacizumab+Atezolizumab
